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ABSTRACT OF THE DISSERTATION 
 
Design and Synthesis of 
Multifunctional Mesoporous Silica Nanoparticles 
for Drug Delivery and Bioimaging Applications 
 
by 
 
Wei Chen 
Doctor of Philosophy in Chemistry 
University of California, Los Angeles, 2019 
Professor Jeffrey I. Zink, Chair 
 
 
Multifunctional mesoporous silica nanoparticles (MSNs) have aroused much attention during 
the past decades for drug delivery and bioimaging applications because of their intrinsic properties 
including extremely high surface area, large pore volume, tunable pore diameter, easy surface 
modification, and high biocompatibility. Even though MSNs have these preeminent properties, 
rendering this unique nanostructure a promising nanocarrier for biomedical applications, several 
hurdles still challenge the fields of drug delivery and bioimaging when using MSNs as the 
nanocarries: (i) high loading and high release amounts of water-insoluble drugs delivered to the 
site of diseases; (ii) precise control of the dosage of drugs delivered to the site of diseases using 
non-invasive external stimuli; and (iii) construction of MSNs-based shortwave infrared optical 
 iii 
imaging contrast agents as an innovative tool for bioimaging and cancer diagnostics. Therefore, 
this dissertation primarily focuses on the development of innovative strategies that solve these 
unmet needs and that advance the research in the field of biomedical applications using MSNs as 
the nanocarriers. 
In this dissertation, first of all, we review the research work, which mainly focuses on the 
design and synthesis of multifunctional MSNs and nanomachines for biomedical applications in 
Accounts of Chemical Research. A wide variety of nanomachines responsive to the different 
stimuli (pH, redox, enzyme, heat, light, and/or magnetic field) are discussed in this Account. 
Additionally, we develop a facile strategy for MSNs delivery and release of the water-insoluble 
drug clofazimine (CFZ), which is used to treat multidrug-resistant tuberculosis. The strategy 
employs a companion molecule as a chaperone to improve both the loading of CFZ into the pores 
of MSNs and its subsequent release, thus enabling both high loading and high release of this water-
insoluble drug by MSNs. In vitro treatment of macrophages infected with Mycobacterium 
tuberculosis with the optimized CFZ-loaded MSNs killed the bacteria in the cells in a dose-
dependent manner. These studies demonstrate a highly efficient method for loading nanoparticles 
with water-insoluble drug molecules and the efficacy of the nanoparticles in delivering drugs into 
eukaryotic cells in aqueous media. Additionally, we used a noninvasive alternating magnetic field 
(AMF) to stimulate and control the dosage of drug release from MSNs. Noninvasive stimuli-
responsive drug delivery using AMF in conjunction with superparamagnetic nanoparticles also 
offers the potential for the spatial and temporal control of drug release. In vitro studies showed that 
the death of pancreatic cancer cells treated by drug-loaded nanoparticles was controlled by 
 iv 
different lengths of AMF exposure time due to different amounts of drug released from the carriers. 
Finally, to develop a new shortwave infrared (SWIR) optical imaging contrast agent which has a 
higher tissue penetration depth, we demonstrate that J-aggregates of near infrared (NIR) 
fluorophore IR-140 can be prepared inside hollow mesoporous silica nanoparticles (HMSNs) to 
result in nanomaterials that absorb and emit SWIR light. The use of J-aggregates stabilized in 
HMSNs as SWIR imaging agents has the potential to overcome the stability, toxicity, and 
brightness challenges of contrast agents for this compelling region of the electromagnetic spectrum. 
Collectively, in this dissertation, we explore and develop innovative strategies to load and deliver 
high amounts of water-insoluble drugs; control the dosage of anticancer drugs released from MSNs 
triggered by an AMF; and establish a new SWIR optical imaging contrast agent based on the 
superior carriers – MSNs. 
  
 v 
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Chapter 1 
Introduction 
This introduction consists of two parts. First, in section 1, I introduce and give an overview 
of the research work in each of the chapters of my dissertation. In section 2, I provide a background 
to the field taken from a review article we published in Accounts of Chemical Research. 
1.1 Introduction of the research work of this dissertation 
Mesoporous silica nanoparticles (MSNs) were first reported in the patent literature in 1971.1  
Yet MSNs did not get much attention until Mobil Oil Corporation synthesized mesoporous silica 
materials from aluminosilicate gels using a liquid crystal template mechanism in 1992; the 
materials are now known as Mobil Crystalline Materials (MCM-41).2 Among the widespread 
applications, biology and medicine-related research using MSNs as the nanocarriers has aroused 
much attention because MSNs possess preeminent properties including extremely high surface 
area, large pore volume, tunable pore size, easy surface functionalization, and high 
biocompatibility.3–11 The high surface area and large pore volume make MSNs serve as superior 
nanocarriers to carry large amounts of drugs or biomolecule cargos.12–16 The easy surface 
functionalization allows MSNs to be tailored and possess a variety of surface chemistries for their 
specific applications, e.g. cell targeting.10,11,17–19 Of particular importance, their low toxicity 
enables MSNs to be used as practical nanocarriers to achieve a variety of biomedical applications. 
Among the biomedical applications, of particular interest to us are (1) high loading and high release 
amounts of water-insoluble drugs delivered to the site of diseases; (2) precise control of the drug 
or cargo molecules released from the MSNs triggered by external stimuli; (3) construction of 
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MSNs-based shortwave infrared optical imaging contrast agents as an innovative tool for 
bioimaging and cancer diagnostics; and (4) the development of nanosensors to detect molecules 
of interest. The introduction to the following chapters, which mainly focus on the biomedical 
applications of MSNs, are presented in the following paragraphs. 
In Chapter 2, we developed a facile “chaperone-assisted” delivery strategy which improves 
the loading of clofazimine (CFZ), an antibiotic used to treat tuberculosis, and delivers a large 
amount of CFZ with MSNs into an aqueous environment.6 We found that acetophenone (AP) is 
the most promising chaperone among nine candidate molecules tested. Then, we compared the 
efficacy of AP and DMSO as nonaqueous solvents for CFZ loading and release. Next, we 
measured the effect of the CFZ loading concentration on CFZ release and AP release and 
determined the optimized CFZ loading concentration. The effect of the location of AP relative to 
MSNs on CFZ was also explored. Finally, using the optimized AP/CFZ-loaded MSNs, we 
investigated the antibacterial effect of this hydrotropy-based delivery strategy on intracellular M. 
tuberculosis to further validate their potential use in medicine and biomedical research. To the best 
of our knowledge, this is the first work to demonstrate an appropriate chaperone for CFZ and to 
apply the strategy to the construction of nanoparticles with enhanced CFZ loading and release 
efficiency. 
In Chapter 3, monodispersed manganese- and cobalt-doped iron oxide (MnFe2O4@CoFe2O4) 
nanoparticles with a high magnetization (105 emu/g) and high specific loss power (1510.8 W/g) 
were synthesized.20 The high magnetization of these superparamagnetic nanoparticles provides 
efficient magnetic heating under an alternating magnetic field (AMF), thus holding great promise 
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for magnetic heating-triggered drug delivery. To increase the amount of drug over that available 
using the nanoparticles themselves, we synthesized mesoporous silica shell “containers” around 
the magnetic core, forming a spherical core@shell structure 55 nm in diameter. The spatial, 
temporal, and dose control of drug release was achieved using a thermo-responsive gatekeeper 
containing a thermo-labile molecule 4,4′-azobis(4-cyanovaleric acid) and a host guest 
complexation formed by adamantylamine and β-cyclodextrin. Most importantly, in this study we 
demonstrated externally controlled dosage of fluorescein or doxorubicin (DOX) by controlling the 
AMF exposure time. Multiple sequential exposures of AMF allow cargo release in a step-wise 
manner. In vitro studies show that the drug-delivery system is biocompatible. DOX-loaded 
nanoparticles did not cause a decrease in cell viability in the absence of AMF stimulation, but the 
viabilities of the pancreatic cancer cells decreased by 28%, 37%, and 53% as the AMF exposure 
time increased from 2, to 5, to 10 min. Taken together, the thermo-responsive drug delivery 
actuated by AMF offers the potential of becoming an emerging chemotherapy that noninvasively 
and precisely controls the dosage of drugs, avoiding the risk generated when overheating the 
surroundings. 
In Chapter 4, we have presented J-aggregation as an approach to prepare biocompatible, 
shortwave infrared (SWIR) imaging contrast agents and demonstrated this concept by stabilizing 
J-aggregates of the near infrared (NIR) fluorophore IR-140 inside hollow mesoporous silica 
nanoparticles (HMSNs).21 The J-aggregates inside polyethylene glycol conjugated HMSNs 
(HMSNs-PEG) are stable for multiple weeks in phosphate-buffered saline and enable high 
resolution imaging in vivo with 980 nm excitation. The bathochromically-shifted absorption and 
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emission and small Stokes shifts of the IR-140 J-aggregate allow imaging with 980 nm excitation 
and 1000–1700 nm acquisition, providing high resolution in vivo images. Collectively, the use of 
J-aggregates stabilized in HMSNs-PEG as SWIR imaging agents has the potential to overcome 
the stability, toxicity, and brightness challenges of contrast agents for this compelling region of the 
electromagnetic spectrum. 
In Chapter 5, we developed multifunctional nanoparticles with designed selectivity using 
hollow mesoporous silica nanoparticles, ship-in-a-bottle synthesis of a crystalline solid-state 
detector, and protection of the crystal by acid-responsive nanogates.22 The system demonstrated 
the inverse application of the usual trapping of contents by the gate followed by their release. 
Instead, the gate protected the contents followed by selective exposure. Crystallization of 
[Pt(tpy)Cl](PF6) (tpy = 2,2':6',2"-terpyridine) inside the cavity of hollow mesoporous silica created 
the unique core@shell nanoparticle. The crystalline core becomes fluorescent in the presence of 
perchlorate ion. By condensing an acid-sensitive gate onto the particle, access to the pores is 
blocked and the crystal is protected. The new nanomaterial obeys Boolean AND logic; only the 
presence of both the analyte (ClO4-) and acid results in the optical response. 
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1.2 Introduction to nanomachines and other caps on mesoporous silica nanoparticles for 
drug delivery 
We reviewed the research work in Professor Jeffrey I. Zink’s group in Accounts of Chemical 
Research. This review article provides a good introduction to the subjects of my dissertation. The 
following sections are adapted from Wei Chen, Carlotta A. Glackin, Marcus A. Horwitz, Jeffrey I. 
Zink Accounts of Chemical Research 2019, 52, 1531–1542. Copyright 2019 American Chemical 
Society. 
Mesoporous silica nanoparticles (MSNs) are delivery vehicles that can carry cargo molecules 
and release them on command. The particles used in the applications reported in this Account are 
around 100 nm in diameter (about the size of a virus) and contain 2.5 nm tubular pores with a total 
volume of about 1 cm3/g. For the biomedical applications discussed here, the cargo is trapped in 
the pores until the particles are stimulated to release it. The challenges are to get the particles to 
the site of a disease and then to deliver the cargo on command. We describe methods to do both, 
and we illustrate the applicability of the particles to cure cancer and intracellular infectious disease. 
Our first steps were to design multifunctional nanoparticles with properties that allow them to 
carry and deliver hydrophobic drugs. Many important pharmaceuticals are hydrophobic and cannot 
reach the diseased sites by themselves. We describe how we modified MSNs to make them 
dispersible, imageable, and targetable and discuss in vitro studies. We then present examples of 
surface modifications that allow them to deliver large molecules such as siRNA. In vivo studies of 
siRNA delivery to treat triple-negative breast and ovarian cancers are presented. The next steps 
are to attach nanomachines and other types of caps that trap drug molecules but release them when 
stimulated. We describe nanomachines that respond autonomously (without human intervention) 
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to stimuli specific to disease sites. A versatile type of machine is a nanovalve that is closed at 
neutral (blood) pH but opens upon acidification that occurs in endolysosomes of cancer cells. 
Another type of machine, a snap-top cap, is stimulated by reducing agents such as glutathione in 
the cytosol of cells. Both of these platforms were studied in vitro to deliver antibiotics to infected 
macrophages and in vivo to cure mice infected with intracellular bacteria Mycobacterium 
tuberculosis and Francisella tularensis. The latter is a tier 1 select agent of bioterrorism. Finally, 
we describe nanomachines for drug delivery that are controlled by externally administered light 
and magnetic fields. A futuristic dream for nanotherapy is the ability to control a nano-object 
everywhere in the body. Magnetic fields penetrate completely and have spatial selectivity 
governed by the size of the field-producing coil. We describe how to control nanovalves with 
alternating magnetic fields (AMFs) and superparamagnetic cores inside the MSNs. The AMF heats 
the cores, and temperature-sensitive caps release the cargo. In vitro studies demonstrate dose 
control of the therapeutic to cause apoptosis without overheating the cells. Nanocarriers have great 
promise for therapeutic applications, and MSNs that can carry drugs to the site of a disease to 
produce a high local concentration without premature release and off-target damage may have the 
capability of realizing this goal. 
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Figure 1.1. Table of content figure of nanomachines and other caps on mesoporous silica nanoparticles for 
drug delivery. 
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1.2.1 Introduction and background 
The development of mesoporous silica nanoparticles in our research group for biomedical 
applications began with a completely unrelated line of research: investigation of transparent 
matrices for room temperature matrix isolation spectroscopy. The popularity of sol-gel synthesis 
of inorganic metal oxides was on the rise, and silica seemed to be a promising matrix candidate. 
The precursors, tetraalkoxy silanes, alcohol and water were readily available, and the formation of 
monolithic silica glass by hydrolysis and condensation occurred at room temperature in the air.1 
 Molecules of spectroscopic interest to us dissolved in the initial sol and the glass formed 
around them and trapped them. Under acidic conditions and slow drying (to prevent cracking) in 
a cuvette, beautiful transparent rectangular prismatic pieces of glass were formed. Because of the 
mild synthesis conditions, even delicate biomolecules such as enzymes and other proteins could 
be trapped and retain their functions.2–5 
 The next important step was stimulated by reports that surfactant molecules coupled with the 
sol-gel synthesis could template well-ordered pores.6 Liquid crystalline phases such as rods or 
sheets could template tubular and lamellar structures. When the surfactant was removed by 
extraction or heating the former phase produced 2-dimensional hexagonal pores. (These structures 
were actually reported in the patent literature 20 years earlier but not appreciated at that time.)7 
The original morphologies were macro-sized translucent pieces, but we wanted uniform 
transparent pieces so we explored and develop methods of synthesizing thin films.8–11 We prepared 
and studied photophysical properties of molecules trapped in films on the order of 100 nm thick. 
 The final step was the discovery that under basic conditions, nanoparticles of the templated 
 11 
silica could be prepared.12 Formation of monodisperse particles was very sensitive to not only the 
concentrations of reactants but also to temperature and stirring speed in a flask. A cascade of 
synthetic papers followed and now it is standard to produce particles under 100 nm in diameter 
with highly ordered porosity.13–18 These particles are generally called “mesoporous silica 
nanoparticles” or MSNs (Figure 1.2AB). The MSNs that will be described in this account typically 
have a diameter of about 100 nm with 2.5 nm tubular pores, a surface area of about 1000 m2/g and 
a volume of about 1 cm3/g.19,20 
 
 
Figure 1.2. Collage of MSNs described in this Account. (A) Overview of functionalities of MSNs. Portrait 
of (B) MSNs and (C) magnetic core@shell nanoparticles. (D) Polymer coating. (E) Stimuli-responsive drug 
release particles.  
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As the synthetic challenges were being overcome, the question became what to do with the 
particles? In our work, we adapted multiple techniques that we had developed for attaching 
molecules to films to derivatizing the particles’ surfaces (both the outer particle surface and the 
huge internal pore surfaces).19 Attachment of fluorescent dye molecules enabled the particles to be 
tracked by optical spectroscopy (even though the particles themselves were only imageable by 
transmission electron microscopy). After derivatization and surfactant extraction, the empty pores 
invited being filled with other molecules, and drug molecules brought the MSNs into the 
biomedical world. 
1.2.2 In Vitro hydrophobic drug delivery 
Our first foray into in vitro applications of our particles involved hydrophobic anticancer drugs 
as the cargo molecules in the pores.21 A challenge in cancer therapy is to deliver hydrophobic drugs 
to the sites of the disease. Many important anticancer drugs are poorly soluble and some sort of 
delivery system is needed. (The most important such systems currently in use are liposomes and 
albumins.) We wanted to see if MSNs could be suitable. A problem immediately arose: MSNs as 
synthesized aggregated extensively in water and biorelevant fluids. To achieve dispersity, we 
attached and tested many different types of molecules and settled on phosphonate for our initial 
studies and fluorescein as our fluorescent label. Anionic phosphonate groups were attached by 
using trihydroxylsilylpropylphosphonate (THMP). This choice was unconventional because the 
current lore stated that positively charged particles would be better taken up by cells. It turned out 
to be a great choice because the particles had good circulation times in mice, were endocytosed 
readily by cancer cells, and accumulated in xenograft tumors as will be discussed later. 
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 Our first demonstration of hydrophobic drug delivery used camptothecin (CPT), a 
representative anticancer drug that is also fluorescent. Derivatives of CPT are promising and 
effective drugs against a wide variety of carcinomas, but have much lower cytotoxicity than CPT.  
(FDA approved Irinotecan has a potency of 10% of that of CPT.) CPT was loaded into the pores 
by soaking MSNs in a DMSO solution of the drug overnight. The loaded nanoparticles were 
sonicated and washed with PBS solution to remove any weakly adsorbed drugs from the surfaces.  
A dispersion of the CPT-loaded MSNs was added to PANC-1 cells to determine if the nanoparticles 
transported the CPT into the cells and fluorescence microscopy was used to monitor the uptake. 
The delivery inhibited growth and caused apoptotic cell death. 
We have also utilized mesoporous organosilica nanoparticles (MONs) and a chaperone-
assisted strategy to facilitate both the loading and the release of hydrophobic drugs from 
nanoparticles. MONs have bridged organoalkoxysilanes in their frameworks that enable a very 
high loading of hydrophobic drugs in their pores. We used biodegradable oxamide-phenylene 
based MONs to achieve 84 wt% of hydrophobic CPT and CPT delivery in lung cancer cells.22 For 
pure MSNs, we recently developed a chaperone-assisted strategy to achieve both substantial 
loading and release amounts of the water-insoluble drug clofazimine (CFZ).23 The interaction 
between the chaperone acetophenone (AP) molecules and CFZ provides the driving force for AP 
to carry large concentrations of CFZ into the pores, and thus significantly enhances the release of 
CFZ in buffer solution. In vitro studies show that the optimized CFZ-loaded MSNs effectively kill 
Mycobacterium tuberculosis in macrophages. This chaperone-assisted delivery strategy can be 
applied to the loading and delivery of other hydrophobic drugs with their suitable chaperone 
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molecules. 
1.2.3 Multifunctional MSNs 
The MSNs used in the hydrophobic CPT delivery study had two different molecules attached 
to their surfaces: phosphonate for dispersibility and fluorescein for optical imaging. We wanted to 
push the limits and to demonstrate that more functionality and versatility could be achieved (Figure 
1.2A). To that end, we synthesized a different type of MSN containing a superparamagnetic iron 
oxide core for magnetic manipulation and MRI imaging (Figure 1.2C).19 The pores were available 
for filling with cargo. On the outer surface we attached a biomolecule, folate, that we wanted to 
test for active targeting of cancer cells. The resulting paper had a large impact because it brought 
attention to the versatility of MSNs as a platform for multiple actions including imaging and drug 
delivery. 
 An important aspect of our explorations of multifunctional MSNs was our investigation of 
active targeting agents. In order to be effective therapeutic agents, MSNs need to be carried 
“passively” by the blood to the site of the tumor. In addition, “active” targeting of specific receptors 
on tumor cells could be achieved by attaching appropriate molecules to the MSNs. Our initial 
studies involved folate and we found that uptake of the particles by cells having folate receptors 
was almost always enhanced in vitro but that in vivo tumor shrinkage was often but not always 
enhanced. Similar results were obtained with MSNs containing attached ferritin and an RGD 
peptide.24 Excellent results with hyaluronic acid are discussed in the following section. It is clear 
that active targeting can occur but each type of targeting agent must be evaluated on a case by case 
basis. 
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 We further extended the functionality of MSNs by coating the outside surface with polymers. 
The two most important polymers (evidenced by the in vitro and in vivo studies described in detail 
below) were PEG and low molecular weight PEI (Figure 1.2D). In some cases, we chemically 
bonded the PEI to the particles and in others we used electrostatic attraction of the cationic PEI to 
the anionic phosphonate-coated surface. We showed that low molecular weight PEI (1.2 kD) has 
negligible toxicity compared to that of the high molecular weight polymer.25 Its importance lies in 
its abilities to carry, protect and deliver siRNA (next section) as well as to facilitate endosomal 
escape through the proton sponge effect for the nucleotide delivery. The PEG coatings were used 
to improve dispersibility and also for their ability to increase circulation time in mice (stealth 
particles).26 
1.2.4 Nanoparticle delivery of small interfering RNAs – from basic science to clinical 
applications 
Recently efforts have begun to use siRNA as a therapeutic agent.27 Preclinical and clinical 
trials have demonstrated that siRNA can be delivered to cells in vivo and retain its function, 
knocking down target genes in both prostate cancer and melanoma.27 A drawback to RNAi-based 
therapy is that RNA tends to be susceptible to nuclease degradation, and is thus unstable in the 
body. Our polymer-coated MSNs proved to be very effective in protecting siRNA and carrying it 
to tumors in mice. 
 RNA interference (RNAi) using double-stranded RNA was first demonstrated in C. 
elegans.27,28 In mammals, 21-nucleotide long RNA fragments called small interfering RNAs 
(siRNAs) are the effectors of RNAi.29 These fragments bind to a target mRNA, and then form the 
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RNA induced silencing complex (RISC).30 RISC also contains Argonaute proteins, specifically 
Ago2, that cleave the mRNA, thus preventing protein translation.31  
Our earliest successful demonstration of RNA delivery using MSNs involved delivery of 
siRNA to drug-resistant KB-V1 cells to silence the expression of efflux transporter P-glycoprotein 
(PPgp). We used low molecular weight cationic PEI coating (described in section 1.2.3) in which 
the anionic siRNA was entrained and protected. Dox was loaded in the pores.32 The dual delivery 
demonstrated that MSN delivery effectively knocked down gene expression of a drug exporter and 
increased intracellular DOX levels to improve cytotoxic killing.32 
We have recently shown in vivo efficacy of MSN-delivered siRNA in a mouse model of 
melanoma. Mice treated with siRNA against TWIST had smaller, less vascularized tumors, likely 
the result of inhibition of CCL2-driven angiogenesis within the growing tumors.33 We obtained 
similar data in ovarian cancer, where mice treated with siTWIST-MSN plus chemotherapy had 75% 
less tumor burden than control mice treated with chemotherapy only.34   
 In a second series of studies, we combined active targeting of Cancer Stem Cells (CSC) with 
siRNA delivery (Figure 1.3).35 Cluster of differentiation 44 (CD44) is a ubiquitously present 
glycoprotein on the surface of mammalian cells. Since the discovery that the receptor is over-
expressed in a variety of solid tumors, such as pancreatic, breast and lung cancer, many studies 
have focused on methods for targeting CD44 in an attempt to improve drug delivery and 
discrimination between healthy and malignant tissue, while reducing residual toxicity and off-
target accumulation. Hyaluronic acid (HA), the primary CD44 binding molecule, has proved a 
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significant ally in developing nanocarriers that demonstrate preferential tumor accumulation and 
increased cell uptake. 
 
 
Figure 1.3. (A) Bioluminescence imaging of Ovcar8-IP tumors. Tumors treated with cisplatin emit 
noticeably weaker signal than siTWIST or siQ only control mice, while those treated with siTWIST-MSNs 
plus cisplatin exhibit a further loss of signal. siTWIST-MSN-HAs plus cisplatin exhibit a greatest loss of 
signal. (B) Quantification of bioluminescence depicted in A. Units for luminescence are 
photons/sec/cm2/steradian. Adapted with permission from ref. 35. Copyright 2018 Elsevier. 
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 We studied HA-coated MSNs as a therapeutic approach to deliver oligonucleotides to tumors 
that overexpress CD44+ (Figure 1.4).35 We delivered TWIST siRNA to breast and ovarian cancer 
xenografts and reduced tumor burden.33–35 Our particles inhibited EMT signaling, reduced tumor 
burden and exhibited synergistic efficacy in combination with cisplatin.35 These results 
demonstrated a useful therapeutic strategy for chemoresistant ovarian cancer. Successful 
application of these types of approaches could pave the way for future RNA-based therapies 
against other targets of interest currently thought to be “undruggable”. 
 
 
Figure 1.4. Quantification of the weight loss of (A) tumor, (B) metastasis, and (C) ascites of mice treated 
as described in Figure 2. The combination of HA targeted MSNs carrying siRNA and cisplatin was the most 
efficacious. Adapted with permission from ref. 35. Copyright 2018 Elsevier. 
 19 
1.2.5 Nanomachines 
Our next major goal was to design a system that could carry a therapeutic through the blood 
stream to the site of a disease with no leakage, release a high local concentration of the drug, 
release it only on an autonomous or external command, and kill the cancer cells or an infectious 
agents. The release itself required a pore cap that could be closed to trap cargo molecules and open 
in response to a desired stimulus and release the cargo.13,15,20,36 We named our original system a 
“nanovalve” which consisted of a stalk and a large cyclic molecule that blocked the pore in the 
closed position and slid along the stalk away from the pore opening to release the pore’s contents. 
The large amplitude motion of this nanomachine, like that of any machine, needs a power supply. 
What kinds of motions and what kinds of stimuli could we use that would be compatible with a 
machine deep in the body of an animal? Answering these questions and making suitable machines 
required both imagination and hard work. 
 We categorize nanomachines according to the source of the stimulus required to operate them 
(Figure 1.2E).14 When the stimulus is a direct result of human intervention, we call it “external”. 
The most important external sources are light, magnetism and ultrasound. Each of these sources 
can produce large amplitude motion in molecules by multiple mechanisms. For example, light 
energy can cause photochemical reactions, produce heat that causes a chemical reaction, or be 
absorbed by “transducer” molecules that change the pH (photoacids) or cause electron transfer 
(photooxidants or reductants). Heat production is the primary usable effect of alternating magnetic 
fields and ultrasound. 
 The second category of operation we call “internal” or “autonomous”. The stimulus for 
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operation originates from the change in the particles’ surroundings. For example, when the 
machine goes from the blood stream to a cell’s endolysosome as a result of endocytosis, the pH 
changes from 7.4 to less than 6 and a pH sensitive valve opens. When it enters the cytosol, the 
presence of antioxidants such as glutathione cause a redox active valve to open. No external 
intervention is required. Autonomous nanomachines such as these are the most widely studied in 
vitro and in vivo. 
 
 
 
Figure 1.5. Schematic illustration of the pH-responsive benzimidazole nanovalve. Adapted with permission 
from ref. 37. Copyright 2010 American Chemical Society. 
 
 The most actively studied pH valve is based on the design principle of a cyclic cap that has a 
large binding constant to a stalk that is hydrophobic at the pH of blood but becomes protonated 
and hydrophilic in the acidic environment of an endolysosome. A widely used example is shown 
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in Figure 1.5.37 The cyclic molecule is β-cyclodextrin (βCD), a cyclic sugar with a hydrophobic 
interior. The stalk is a specific benzimidazole with a pKa of about 7. Above pH 7, the hydrophobic-
hydrophobic non-covalent interaction holds the pseudorotaxane together but at lower pH it 
dissociates. When the stalk is attached at a pore opening on MSNs, the βCD traps cargo molecules 
in the pore but releases them upon acidification. In vivo applications of this autonomous pH 
nanovalve are discussed in the following section. 
 
 
Figure 1.6. Schematic illustration of the redox-responsive disulfide nanovalve. 
 
 The most-used redox activated system that we named a “snap-top” is based on the design 
principle that a redox-sensitive chemical bond can be broken in the presence of reducing agents in 
the cytosol of a cell.38 This simple design utilizes a disulfide stalk containing a bulky cap on its 
end (Figure 1.6). When attached at an MSNs pore surface the cap traps the cargo, but when the 
particle escapes the lysosome the reducing agents such as glutathione cause the disulfide to 
dissociate into two thiols, releasing the bulky group and the trapped drug molecules. In vivo studies 
using this redox snap-top are described in the following section. 
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 Many other autonomous nanomachines and capping agents have been studied and several 
thorough reviews have been published recently.13,15,20 One additional example from our group is 
the original enzyme-activated snap-top in which a βCD slides on a stalk but is blocked from leaving 
by a bulky stopper held in place by a functional group (an ester) that is a substrate for an enzyme 
(porcine liver esterase).39 When the particle encounters the enzyme the bulky group is “snapped 
off” and the cargo is released. This type of snap-top is a prototype for a nanocarrier that could 
respond only to a specific enzyme overexpressed by a particular cancer cell. 
1.2.6 Nanoparticles against infectious diseases caused by intracellular pathogens 
We used both of the nanomachines in Figures 1.5 and 1.6 to kill pathogenic bacteria in 
phagocytes in vitro and in vivo. Mononuclear phagocytes, primarily monocytes and tissue 
macrophages, are known as professional phagocytes because of their reputation for avidly 
ingesting particles of many kinds. Such particles include numerous pathogens that are readily 
killed by macrophage antimicrobial armaments. However, one class of pathogens, known as 
intracellular parasites, intentionally induce their uptake by macrophages with the aim of hijacking 
host cell machinery towards their own end – survival and intracellular replication. Intracellular 
pathogens include the agents of tuberculosis and what are referred to by the US government as 
Tier 1 Select Agents because of especially high concern that they may be intentionally employed 
in a bioterrorist attack. Such pathogens include Francisella tularensis, the agent of tularemia. 
 For treatment of many diseases, mononuclear phagocytes – especially those in the liver, 
spleen and lung – pose an obstacle to MSN delivery of nanotherapeutics, since they readily ingest 
intravenously administered nanoparticles intended for delivery elsewhere, e.g. to cancer cells. 
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MSNs designed for cancer therapy need to be specially designed to evade macrophages, but for 
treatment of diseases caused by intracellular pathogens, the avidity with which macrophages ingest 
MSNs provides a tremendous advantage – no specific targeting ligands are necessary to deliver 
copious amounts of antibiotic-loaded particles to macrophages harboring intracellular pathogens. 
Nanotherapeutic delivery of antibiotics maximizes antibiotic delivery to infected host 
macrophages while minimizing systemic toxicity. 
 Our nanotherapeutics have been designed primarily to treat two diseases caused by 
intracellular pathogens – tuberculosis, caused by Mycobacterium tuberculosis (Mtb),23,40,41 and 
tularemia, caused by Francisella tularensis (Ft).42,43 Both diseases pose major challenges to 
treatment with conventionally delivered antibiotics. TB caused by drug-sensitive organisms 
requires 6-9 months treatment and drug-resistant Mtb, which is even more difficult to treat requires 
multidrug therapy for up to 2 years. Hence, more efficient delivery of antibiotics to host 
macrophages via nanotherapeutics has the potential to shorten the treatment course, improve 
adherence, impede the emergence of drug resistance, and reduce systemic drug toxicity. 
 Tularemia, a bacterial zoonosis, can manifest as one of several syndromes depending upon 
the mode of Ft transmission. Pneumonic tularemia, the most dangerous form and the one of 
greatest concern from a bioterrorism perspective, is contracted via inhalation. With current therapy, 
tularemia can still be fatal, resolve slowly, or relapse. Hence functionalized nanotherapeutics 
targeting infected macrophages have the potential for more rapid cure, reduced time in intensive 
care, and less frequent relapse. 
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Figure 1.7. MSNs are avidly ingested by human macrophages infected with Mycobacterium tuberculosis 
(A) and Francisella tularensis (B). (A) Human THP-1 macrophages were infected with GFP-expressing 
Mtb, incubated with red fluorescent MSNs loaded with rifampin (NP-RIF), fixed, stained with nuclear stain 
DAPI, and imaged by confocal microscopy. Large numbers of NP-RIF (a) and an Mtb bacillus (b, arrow) 
are observed in the macrophage, whose nucleus is stained blue (c); the merged image is shown in panel d. 
Adapted with permission from ref. 41. Copyright 2012 American Society for Microbiology. (B) Human 
THP-1 macrophages were infected with GFP-expressing Ft, incubated with RITC-labelled MSN-MBI, 
fixed, stained with DAPI, and imaged by confocal microscopy. Green Ft (a, c, arrows), red MSNs (b, c, 
arrowheads) and DAPI-stained nucleus (a, c, blue) are seen in individual images (a, b) and merged image 
(c). Adapted with permission from ref. 42. Copyright 2015 American Chemical Society. 
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We designed and evaluated PEI-coated MSNs (~100 nm) loaded with the antibiotic drug 
Rifampin for treatment of TB.41 These MSNs were all avidly ingested by Mtb-infected human 
macrophages (Figure 1.7A). By fluorescence microscopy, the MSNs co-localized with CD63, 
indicating uptake into endolysosomes.41 In In vitro studies in which these MSNs were added to 
human macrophages infected with the highly virulent Mtb Erdman strain, the MSNs readily killed 
Mtb, and they did so significantly more efficiently than an equivalent amount of free drug (Figure 
1.8A). 
We developed MSNs with pH- and redox potential- sensitive nanovalves for delivery of the 
antibiotic moxifloxacin (MXF).42,43 Both types of MSNs were avidly ingested by Ft-infected 
macrophages (Figure 1.7B) and rapidly killed intramacrophage Ft in a dose-dependent fashion. 
These MSNs were evaluated for efficacy in a murine model of lethal pneumonic tularemia in which 
mice were infected intranasally with a lethal dose of Ft LVS (6xLD50). The mice were treated with 
free MXF or MXF-loaded MSNs intavenously every other day for three doses; euthanized one day 
later; and Ft CFU assayed in lung, liver, and spleen. In untreated mice, bacteria multiplied to high 
levels (~7.5 logs in the lung) and the mice lost 12-24% of their total body weight. In contrast, mice 
treated with MXF-loaded MSNs maintained their body weight and CFU in the lungs decreased by 
1-2 logs (Figure 1.8B).43 The MXF-loaded MSNs were significantly more effective than an 
equivalent amount of free drug in reducing CFU in all organs; in the lung, they were more effective 
than ~3 fold greater dose of free MXF. 
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Figure 1.8. Antibiotic-loaded MSNs rapidly kill M. tuberculosis in vitro (A) and F. tularensis in vivo (B). 
(A) MSNs loaded with Isoniazid (INH) or Rifampin (RIF) kill Mtb to a greater extent than an equivalent 
amount of free drug. Compared with no treatment, the INH- and RIF-loaded MSNs reduced the colony-
forming units (CFU) by 3.8 and 3.3 log CFU, respectively, and compared with an equivalent amount of free 
drug, they reduced CFU by an additional 1.5 and 1.7 log CFU, respectively. Adapted with permission from 
ref. 41. Copyright 2012 American Society for Microbiology. (B) MXF-loaded MSNs rapidly kill Ft in vivo 
in a mouse model of lethal pneumonic tularemia and are much more efficacious in reducing the lung burden 
of Ft than equivalent amounts of free MXF (Efficacy ratios 3-5:1).43 The CFUs in lung, liver and spleen 
were determined on day 6. Adapted with permission from ref. 43. Copyright 2016 Wiley-VCH. 
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1.2.7 Externally operated nanomachines and caps 
A futuristic dream for nanotherapy is the ability to control a nano-object everywhere in the 
body. Although total control including mobility is far from reality, it is possible to stimulate 
nanocarriers anywhere and to release therapeutic molecules with spatial and temporal accuracy.  
The major methods of external control are light, ultrasound and magnetism. For diseases on or 
near the skin, photothermal therapy is useful, but for tumors deep in the body, magnetism 
penetrates the best. Externally operated drug release is a step beyond autonomous release because 
it can be turned on and off at will and does not have to rely on specific chemical changes or the 
presence of specific molecules in order to operate. It is also more complex than autonomously 
stimulated release because the external control also requires external instrumentation and an 
operator. These issues contribute to the sparsity of in vivo studies reported to date. 
 Progress in synthesizing and making functioning nanomachines and caps that can be remotely 
activated has been rapid.13,14,20,36 The most prevalent and highly developed systems are light 
activated. We were interested in using light to power nanomachines, including by direct 
photochemical bond breaking or photoisomerization and by indirect phototransducers to activate 
pH and redox valves. Direct photocleavage is a convenient way to remove caps from pores. 
Molecules in their excited state can transfer protons (photoacids)44 or electrons (photo-redox)45 
and can be used to activate machines originally designed to be activated by chemical acidification 
or redox. Excited state energy transfer from molecules with high two photon cross sections can 
trigger the above reactions using two near infrared photons. 
 We used our impeller for our first in vitro studies.46 Photo-induced trans-cis isomerization of 
 28 
azobenzene derivatives bonded to the insides of MSN pore walls trap cargo molecules in the dark 
but allow them to escape when they wag back and forth.47,48 We delivered an anticancer drug into 
pancreatic cancer cells and observed no killing in the dark but efficient apoptosis when the 
impellers were excited.46  
 Other photo-responsive gatekeepers include azobenzene and cyclodextrin supramolecular 
complex,49,50 photolabile coumarin-based nanovales,51 cucurbit[6]uril (CB[6]) and stalk 
supramolecular complexes,52 photoacid molecules and pH-sensitive nanovalves,44 and photo-
transduced molecules and redox environment-sensitive nanovalves.53 We later demonstrated two 
photon near IR excitation of a transducer molecule that transferred energy to the azobenzene 
molecules and released cargo.54 Interesting progress continues to be made in the two-photon field 
for potential biomedical applications. 
In our current research for biological applications, we are focusing on magnetism as the 
stimulus, specifically alternating magnetic fields (AMF). Nanoparticles containing 
superparamagnetic components are heated by the AMF and thermo-stimulated machines or caps 
can be activated by the heat to release cargo. Magnetic heating is currently being used to kill cells 
or destroy tumors by hypothermia,55–57 but it can also create tumor metastasis. We are focusing on 
drug delivery by taking advantage of the localized particle heating without bulk heating. 
To understand what degree of local heating can be attained, we designed nanothermometers 
in the MSNs containing the superparamagnetic heaters and measured internal temperature changes 
of over 20 °C above that of the surrounding aqueous medium, more than enough to activate 
thermosensitive caps without causing hyperthermia.58–60 
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Figure 1.9. Schematic illustration of the construction and operation of the thermo-responsive 
cucurbit[6]uril nanovalve. Fluorescence microscope images show breast cancer cells were killed by the 
released DOX after the exposure to an AMF. Adapted with permission from ref. 61. Copyright 2010 
American Chemical Society. 
 
Our first in vitro study used core@shell nanoparticles to carry and deliver drugs actuated by 
AMF and used a supramolecular valve comprised of a bulky cucurbit[6]tril (CB[6]) ring and an 
alkylammonium thread attached on the surface of MSNs that acts as a thermo-sensitive gatekeeper 
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(Figure 1.9).61 When the temperature increases, the binding constant between the CB[6] ring and 
the alkylammonium thread decreases leading to the detachment of CB[6] from the thread followed 
by drug release. The release of drugs was not triggered by bulk heating from the solutions but by 
localized heating generated from the interior magnetic cores. We showed that doxorubicin released 
intracellularly by AMF stimulation effectively kills MDA-MB-231 breast cancer cells. 
 
 
Figure 1.10. Schematic illustration of the synthesis and operation of the thermo-sensitive azo cap. Adapted 
with permission from ref. 62. Copyright 2019 American Chemical Society. 
 
Very recently, we demonstrated spatial, temporal, and dose control of drug delivery using 
superparamagnetic MnFe2O4@CoFe2O4 nanoparticles with high specific loss power (1510.8 W/g) 
and high saturation magnetization (105 emu/g) (Figure 1.10).62 Thermo-sensitive gatekeepers that 
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contain an aliphatic azo moiety release a bulky cap and regulate the release of drugs. The dose of 
the drug release was controlled by the AMF exposure time and triggered by the localized high 
temperature from the interior magnetic core and not by bulk heating. Multiple sequential exposure 
of AMF causes drug release in a step-wise manner. In vitro studies show that the drug delivery 
platform is biocompatible, that drug-loaded nanocarriers do not kill the cells without the AMF 
stimulation, and that cell death was correlated with the AMF exposure time (Figure 1.11). Thermo-
responsive drug delivery stimulated by an AMF offers the potential of becoming an innovative 
chemotherapy that noninvasively, remotely, and precisely controls the dosage of drugs, avoiding 
the risk generated when overheating the bulk solution. 
 
Figure 1.11. Effects of AMF stimulated DOX release on PANC-1 cells. In vitro cellular killing and 
fluorescence microscope images of DOX-loaded nanoparticles after AMF exposure are shown left and right, 
respectively. Adapted with permission from ref. 62. Copyright 2019 American Chemical Society. 
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1.2.8 Future perspectives 
Mesoporous silica is a versatile platform for drug delivery applications. The nanoparticles are 
nontoxic, carry large payloads of therapeutic drugs, and can be capped to prevent premature drug 
release until the nanoparticles reach their target where they can then be stimulated to release a high 
local concentration of the therapeutic. The particles can carry other important therapeutic 
molecules such as siRNA, protect them from enzymes and degradation, and release them 
intracellularly. Their potential for curing cancer occupies most current research attention, but they 
can be used to treat other diseases including infectious diseases.  
The route of administration is important. We emphasized intravenous administration, but for 
treatment of intracellular pathogens, we found that intramuscular injection was extremely 
beneficial because of superior pharmacokinetics.63 Preliminary studies show inhalation 
administration to be extremely promising for treatment of lung infections. 
The multifunctionality of nanotherapeutics including MSNs promises to revolutionize drug 
delivery. It allows for active targeting of drug-loaded particles (– our best in vivo example of a 
successful agent is hyaluronic acid – other targeting agents (e.g. folic acid, and RGD peptide) 
toward their specific cancer cells were also demonstrated). The drug-loaded particles can 
additionally contain molecules for image guided therapy, such as paramagnetic metals or 
superparamagnetic cores for imaging by MRI, fluorescent dyes (especially in near-IR for optical 
imaging), and atoms for PET imaging. The multifunctionality of nanotherapeutics also allows for 
theranostics – the combining of therapeutic and diagnostic agents into a single nanoparticle. Finally, 
the multifunctionality of nanotherapeutics allows for the delivery of combination drug therapy at 
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optimal drug dose ratios, thereby enhancing drug synergy and safety. 
It would be extremely beneficial if MSNs could move forward toward clinics. Before then, 
many prerequisites need to be fulfilled, such as industrial-scale production of MSNs under Good 
Manufacturing Practice (GMP) to guarantee that the properties of the MSNs are reproducible from 
batch to batch, detailed investigations of the potential toxicity, bio-distribution, and clearance from 
the animal body, and whether drug-loaded MSNs have higher treatment efficacy and fewer side 
effects than those of the free drugs alone. It is a long and complicated road to clinical trials and 
eventual use in the clinic, but the attractive properties make MSNs worthy of the attention that 
they are being given. 
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Chapter 2 
Facile Strategy Enabling Both High Loading and High 
Release Amounts of the Water-Insoluble Drug Clofazimine 
Using Mesoporous Silica Nanoparticles 
 
This chapter of the dissertation was adapted and reprinted with permission from Wei Chen, Chi-
An Cheng, Bai-Yu Lee, Daniel L. Clemens, Wen-Yen Huang, Marcus A. Horwitz, Jeffrey I. Zink 
ACS Applied Materials & Interfaces 2018, 10, 31870–31881. Copyright 2018 American Chemical 
Society. Co-author contributions: Chen W., Cheng C. A., and Huang W. Y. performed the 
chemistry-related studies. Lee B. Y., and Clemens D. L. performed the cells and bacteria studies. 
Marcus A. Horwitz, and Jeffrey I. Zink were the P.Is. 
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Abstract 
The use of nanocarriers to deliver poorly soluble drugs to the sites of diseases is an attractive 
and general method, and mesoporous silica nanoparticles (MSNs) are increasingly being used as 
carriers. However, both loading a large amount of drugs into the pores and still being able to release 
the drug is a challenge. In this work, we demonstrate a general strategy based on a companion 
molecule that chaperones the drug into the pores and also aids it in escaping. A common related 
strategy is to use a miscible co-solvent dimethyl sulfoxide (DMSO), but although loading may be 
efficient in DMSO, this co-solvent frequently diffuses into an aqueous environment, leaving the 
drug behind. We demonstrate the method by using acetophenone (AP), an FDA-approved food 
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additive as the chaperone for clofazimine (CFZ), a water-insoluble antibiotic used to treat leprosy 
and multidrug-resistant tuberculosis. AP enables a high amount of CFZ cargo into the MSNs and 
also carries CFZ cargo out from the MSNs effectively when they are in an aqueous biorelevant 
environment. The amount of loading and the CFZ release efficiency from MSNs were optimized; 
4.5 times more CFZ was loaded in MSNs with AP than that with DMSO and 2300 times more 
CFZ was released than that without the assistance of the AP. In vitro treatment of macrophages 
infected by Mycobacterium tuberculosis with the optimized CFZ-loaded MSNs killed the bacteria 
in the cells in a dose-dependent manner. These studies demonstrate a highly efficient method for 
loading nanoparticles with water-insoluble drug molecules and the efficacy of the nanoparticles in 
delivering drugs into eukaryotic cells in aqueous media. 
Table of Content Figure 
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2.1 Introduction 
Poor water solubility of drug molecules is a significant problem because almost 40% of the 
newly discovered drug molecules are hydrophobic which reduces their bioavailability and thus 
suppresses their efficacy.1 Great effort has been devoted to solving the problem of getting them to 
the site of the disease. One important strategy is to use nanomaterials as carriers to deliver insoluble 
drugs.2 Mesoporous silica nanoparticles (MSNs) have aroused much attention in this regard 
because their  properties include high surface area (about 1000 m2/g), large pore volume (1 cc/g), 
tunable pore sizes (2-20 nm), easy surface functionalization, and high biocompatibility.3–12 These 
excellent intrinsic properties enable MSNs to carry a wide variety of cargos, including drugs,13–17 
genes,18–21 proteins,22,23 and other biomolecules for in vitro or in vivo biomedical applications.24,25 
Additionally, MSNs can incorporate fluorescence and magnetic properties, and simultaneously 
serve as image contrast agents by integrating the relevant functional materials for diagnostics and 
therapeutics.26–28 Accordingly, these preeminent “theranostic” (therapeutic plus diagnostic) 
nanoparticles, serving as the excellent nanocarriers, are being broadly explored in biomedical 
applications.29–35 
The major challenges are to get the insoluble drug into the pores and then allow the drugs to 
escape. One of the most widely-used methods to load the poorly water-soluble drugs in MSNs is 
to dissolve the drugs in dimethyl sulfoxide (DMSO).14 The loading step is done by soaking MSNs 
in the DMSO solution which allows the drug molecules to diffuse into the channels of MSNs 
efficiently. After the loading step, the drug-loaded MSNs are washed with water or buffer solutions 
thoroughly to remove DMSO from the pores. However, during this washing step, some of drugs 
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may be removed as well considering weak interactions between the hydrophobic drug molecules 
and the hydrophilic porous surface, thus decreasing the loading weight percent of drugs (defined 
as (weight of drugs / weight of MSNs) x 100%).2,14 To attempt to solve this problem of low drug 
loading, the channels of MSNs were functionalized with hydrophobic groups to increase the 
hydrophobic interactions between the drugs and the channels.36,37 However, those further surface 
modifications complicate the delivery systems and lead to colloidal instability in aqueous 
environment. Another critical challenge that remains is that the amount of the hydrophobic drug 
released from the carriers into an aqueous environment is poor, even though MSNs are able to 
carry the drugs to the location of a disease.36–38 Consequently, the bioavailability of the drugs may 
be reduced to a level insufficient for effective treatment, or an extremely high dosage of the 
particles may be required to achieve a sufficient local concentration of free drug for it to be 
effective. Hence, to enhance the bioavailability of the drug, it is essential to improve its release 
efficiency from the nanocarriers.  
Hydrotropy is a technique that increases the water solubility of water insoluble molecules by 
adding a second solute (i.e. hydrotrope).39,40 Hydrotropes are short chain amphiphilic molecules, 
usually containing both the hydrophobic and hydrophilic moieties in their chemical structures, in 
which the hydrophobic part interacts with water-insoluble drugs through hydrophobic interactions, 
and the hydrophilic part helps solubilize the drug-hydrotropes complexation structure in water. 
The hydrotrope-assisted solubilization of water-insoluble drugs in water possesses a signature 
feature of a sigmoidal solubility curve.41,42 At low concentration of hydrotropes, the solubility of 
water-insoluble drugs hardly increases. The solubility of water-insoluble drugs significantly 
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increases above a certain hydrotrope concentration, usually called a minimum hydrotrope 
concentration (MHC), when self-aggregation of the hydrotropes happens.42,43 Other mechanisms 
may also involve in the hydrotrope-assisted solubilization of water-insoluble drugs.44–47 Two 
advantages of using hydrotropy are that it obviates the need for chemical modification of the drugs, 
which may interfere with pharmaceutical activity; and it does not require a specific formulation 
for emulsification. The water solubility of water-insoluble drugs could be enhanced from several 
folds to several orders of magnitude by the hydrotrope-assisted solubilization especially if the 
hydrotropes associate well with the drugs.40,41,48 
In this study, we choose clofazimine (CFZ) as an example of a water-insoluble drug (defined 
as having water solubility of less than 100 µg/mL) to demonstrate our strategy for hydrophobic 
drug delivery. CFZ has an extremely low (0.2 µg/mL) water solubility. The motivation for 
improving the delivery of CFZ lies in the fact that it has good efficacy against multidrug-resistant 
Tuberculosis (TB).49–52 TB is a serious contagious disease caused by the bacterium Mycobacterium 
tuberculosis (M. tuberculosis) and has becoming a global health problem; in 2016, there were 
approximately 10.4 million new TB cases and 1.3 million TB deaths worldwide.53 However, the 
extremely low water solubility of CFZ complicates its delivery by nanoparticles or other novel 
approaches e.g. via inhalation. 
Herein, we developed a facile “chaperone-assisted” delivery strategy which improves the 
loading of CFZ and delivers a large amount of CFZ with MSNs into an aqueous environment 
(Figure 2.1). First, we found acetophenone (AP) is the most promising chaperone among 9 
candidate molecules tested. Then, we compared the efficacy of AP and DMSO as non-aqueous 
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solvents for CFZ loading and release. Next, we measured the effect of CFZ loading concentration 
on CFZ release and AP release and determined the optimized CFZ loading concentration. The 
effect of the location of AP relative to MSNs on CFZ was also explored. Finally, using the 
optimized AP/CFZ loaded MSNs, we investigated the antibacterial effect of this hydrotropy-based 
delivery strategy on intracellular M. tuberculosis to further validate their potential use in medicine 
and biomedical research. To the best of our knowledge, this is the first work to demonstrate 
appropriate chaperone for CFZ and to apply the strategy to the construction of nanoparticles with 
enhanced CFZ loading and release efficiency. 
 
Figure 2.1. Chaperone-assisted delivery strategy for water-insoluble drugs. Clofazimine (CFZ) was chosen 
as an example of a water-insoluble antibiotic. Acetophenone (AP) acts like a chaperone bringing CFZ cargo 
into the vehicle — mesoporous silica nanoparticles (MSNs) and then carrying CFZ cargo out from the 
MSNs effectively. 
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2.2 Experimental Section 
2.2.1 Materials 
Hexadecyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 
98%), clofazimine (CFZ, 98+%), acetophenone (AP, 99%), 2-heptanone (98%), 2-
hydroxyacetophenone (98%), sodium benzoate (99%), pyradinamide (97.5+%), nicotinamide 
(99.5+%), isoniazid (99+%), hexanoic acid (99+%), benzoic acid (99.5+%), sodium hydroxide 
(NaOH) (97+%), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 99.5+%), and 
ammonium nitrate (NH4NO3, 98+%) were purchased from Sigma-Aldrich. Dimethyl sulfoxide 
(DMSO, 99.9+%) was purchased from Fisher Chemical. Absolute ethanol (200 proof) was 
purchased from Decon Labs, Inc. All chemicals were used without further purification. 
2.2.2 Characterization 
The size and morphology of mesoporous silica nanoparticles (MSNs) were investigated by 
transmission electron microscopy (TEM, Tecnai T12). MSNs were dispersed in ethanol at a very 
low concentration (0.2 mg/mL). Ten microliters of the suspension were dropped onto the carbon-
coated copper grid and dried at room temperature. The N2 adsorption-desorption isotherms of 
MSNs were obtained at liquid N2 temperature (77K) on a Autosorb-iQ (Quantachrome Instruments) 
apparatus. MSNs were degassed at 110 °C for 12 h before the measurement. The surface area and 
pore size distribution of MSNs were determined by Brunauer-Emmett-Teller (BET) and Barrett-
Joyner-Halenda (BJH) methods. The dynamic light scattering (DLS) size and zeta potential value 
of MSNs were examined by a laser particle analyzer LPA-3100 at room temperature. The loading 
capacity, release capacity, and release efficiency of CFZ or AP were determined by UV-Vis 
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Spectroscopy (Cary 5000). The absorbance of the peaks was used for quantification by Beer-
Lambert Law. 
2.2.3 Synthesis of mesoporous silica nanoparticles (MSNs) 
CTAB (250 mg) was dissolved in a mixture of deionized water (120 mL) and 2 M NaOH (875 
µL) under vigorous stirring. The solution was heated to 80 °C and tetraethyl orthosilicate (TEOS) 
(1.25 mL) was then added dropwise to the solution for about 20 seconds. The reaction was kept at 
80 °C for 2 h. Subsequently, the solution was cooled to room temperature and MSNs were 
centrifuged and washed 3 times with ethanol. MSNs were then dispersed in 100 mL of ethanol 
containing 2 g of NH4NO3 and the reaction was refluxed for 1 h to remove the surfactant. The 
surfactant removal procedures were repeated twice and MSNs were washed thoroughly with 
ethanol and D.I. water to obtain the surfactant-free MSNs. 
2.2.4 Screening of possible hydrotropes for CFZ 
Nine different small molecules – nicotinamide, sodium benzoate, pyradinamide, isoniazid, 2-
hydroxyacetophenone, benzoic acid, hexanoic acid, 2-heptanone, and acetophenone – were 
screened to investigate their hydrotropic ability for CFZ in H2O. For the control lacking a 
hydrotrope, 1 µmol of CFZ and 1 mL of H2O were added into a 20 mL of glass vial and sonicated 
for 10 min to suspend CFZ in H2O. The undissolved CFZ was removed by centrifugation at 14000 
rpm for 15 min. Then, the supernatant was collected and measured by UV-Vis spectroscopy. For 
experimental samples with hydrotropes, 1 µmol of CFZ, 1 mL of H2O, and the respective 
hydrotrope [sodium benzoate (50 µmol, 500 µmol, or 1 mmol), pyrazinamide (50 µmol, 500 µmol, 
or 906 µmol), nicotinamide (50 µmol, 500 µmol, or 1 mmol), isoniazid (50 µmol, 500 µmol, 1 
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mmol), 2-hydroxyacetophenone (50 µmol), hexanoic acid (50 µmol), benzoic acid (28 µmol), 2-
heptanone (38 µmol), or acetophenone (50 µmol)] were added into 20 mL glass vials and sonicated 
for 10 min. The undissolved CFZ was removed by centrifugation as described above. Finally, the 
supernatant was collected and measured by UV-Vis spectroscopy. The solubility enhancement was 
determined by the change in absorbance at 490 nm. 
2.2.5 Concentration dependent hydrotropy effect of AP 
To investigate the hydrotropic effect of AP in more detail, we prepared concentrations ranging 
from 0 to 60 mM of AP in H2O to dissolve CFZ. Similarly, 1 µmol of CFZ, 1 mL of H2O, and the 
respective concentration of AP were added into 20 mL glass vials and sonicated for 10 min. The 
undissolved CFZ was removed by centrifugation as described above. The solubility enhancement 
was determined by the change in absorbance at 490 nm. 
2.2.6 Creation of calibration curve of CFZ in AP, CFZ in ethanol-water mixture, and AP in 
ethanol-water mixture 
To determine the loading capacity, release efficiency, and release capacity of CFZ, the 
calibration curves were created by dissolving CFZ in AP. The concentration of CFZ in AP ranged 
from 0 to 50 µM. The absorption spectra of the solutions were measured by UV-Vis spectroscopy, 
and the absorbance maximum (490 nm for CFZ and 244 nm for AP) was used to plot the calibration 
curve. The calibration curves ranging from 0 to 25 µM of CFZ dissolved in a mixture of ethanol 
and HEPES buffer solution (10 mM, pH = 7.4) (v/v = 1/1) were also generated. To determine the 
release capacity and release efficiency of AP, the calibration curve of AP was generated by 
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dissolving AP in a mixture of ethanol and HEPES buffer solution (10 mM, pH = 7.4) (v/v = 1/1). 
The concentration of AP ranged from 0.25 to 66 µM. 
2.2.7 Loading capacity analysis of clofazimine (CFZ) 
The loading of CFZ was studied using DMSO or AP as loading solvents. In general, 10 mg 
of MSNs were dispersed in AP or DMSO with 0.1, 1, 10, or 50 mM CFZ, respectively. After 24 h 
stirring, the CFZ loaded MSNs were centrifuged at 14000 rpm for 10 min and the pellets were 
washed three times with H2O under sonication to remove the excess CFZ. Then, the CFZ loaded 
MSNs with AP or DMSO were washed with AP or DMSO, respectively, and pelleted by 
centrifugation. The washing steps were repeated several times until the supernatant was clear. The 
supernatants were collected and measured by UV-Vis spectroscopy. The loading capacity of CFZ 
was calculated using the maximum absorbance at 490 nm based on Beer’s law, its calibration curve, 
and the following definition of loading capacity: (mass of loaded CFZ / mass of MSNs) x 100%. 
2.2.8 Release of CFZ and AP in HEPES buffer 
The release of CFZ and AP from MSNs was carried out in HEPES buffer solution (pH = 7.4, 
10 mM). In general, 10 mg of MSNs loaded with 0.1, 1, 10, or 50 mM CFZ in AP were dispersed 
in 1 mL of HEPES buffer solution and stirred for 1, 2, 3, or 5 days, respectively. Afterwards, the 
CFZ loaded MSNs were spun down at 14000 rpm for 10 min. The supernatant was collected and 
mixed homogeneously with ethanol, which was then diluted and measured by UV-Vis spectroscopy. 
The release efficiency of CFZ and AP were calculated using their maximum absorbance at 490 nm 
and 244 nm, respectively, based on Beer’s law, their calibration curves, and the definition of release 
efficiency: (mass of released CFZ / mass of loaded CFZ) x 100%. 
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2.2.9 Release of CFZ in HEPES buffer with addition of AP 
To gain insight into whether the AP residing outside of the pores of MSNs would affect CFZ 
release, we added AP into the release buffer. After MSNs were loaded with 1 mM CFZ in DMSO, 
10 mg of MSNs were dispersed in 1 mL of HEPES buffer (10 mM, pH = 7.4) with the addition of 
10 µL of AP. The solution was stirred for 24 h and then centrifuged at 14000 rpm for 10 min. The 
supernatant was collected and measured by UV-Vis spectroscopy; the pellet of CFZ loaded MSNs 
was resuspended by sonication in 1 mL of HEPES buffer with the addition of 10 µL of AP and 
stirred for another 24 h. Again, the supernatant was collected as described above and measured by 
UV-Vis spectroscopy. The same procedures were repeated and the supernatant was collected and 
analyzed at 72 h and 120 h as described above. 
2.2.10 Assay for killing of M. tuberculosis in macrophages 
Human monocytic THP-1 cells (ATCC TIB202) were maintained in RPMI-1640 
supplemented with 10% fetal bovine serum, GlutaMAX, and Penicillin-Streptomycin (100 IU-100 
μg/mL). Prior to infection, the cells were treated with phorbol 12-myristate 13-acetate (PMA) for 
3 days to differentiate them into macrophage-like cells.  M. tuberculosis virulent strain Erdman 
(ATCC 35801) was cultured on Middlebrook 7H11 plates for 10 days. Lawns of bacteria were 
scraped from the plates, suspended in RPMI with 20 mM HEPES, and a single bacterial suspension 
was prepared by sonication and repeated centrifugation to remove bacterial clumps. After 
opsonization with human serum type AB containing active complement, the bacteria were used to 
infect PMA-differentiated THP-1 macrophages at a multiplicity of infection of 1:1 
(bacterium:macrophage). The bacteria were incubated with macrophages for 1 hour at 37 °C, after 
 51 
which MSNs loaded with AP (AP-MSN), MSNs loaded with 10 mM CFZ in AP hydrotrope 
(AP/CFZ-MSN), or free CFZ were added to the culture of the M. tuberculosis infected 
macrophages. The concentrations of AP-MSN were 11 and 22 µg/mL. The concentrations of 
AP/CFZ-MSN were 5.5, 11, and 22 µg/mL, corresponding to 0.5, 1, and 2 µg/mL of CFZ, 
respectively. Free CFZ was dissolved in DMSO first, and then added to M. tuberculosis infected 
macrophages at concentrations of 0.5, 1, and 2 µg/mL, those concentrations of free CFZ had 
0.005%, 0.01%, and 0.02% DMSO, respectively. The cells were incubated for 4 days at 37 °C, 5% 
CO2-95% air, lysed with 0.1% SDS, serially diluted in Middlebrook 7H9 broth supplemented with 
ADC enrichment and 0.05% Tween 80, and plated on Middlebrook 7H11 agar plates. The number 
of bacterial colonies on the plates was enumerated after incubation for 2.5 weeks at 37 °C, 5% 
CO2-95% air.32,54 
2.3. Results and Discussion 
2.3.1 Synthesis and characterization of mesoporous silica nanoparticles (MSNs) 
MSNs were synthesized by a sol-gel synthetic strategy in the presence of cationic surfactant 
template.15,55 By transmission electron microscopy (TEM) (Figure 2.2a), MSNs have a well-
ordered hexagonal mesoporous structure and the average size is 100 nm in diameter. The diameter 
of MSNs measured by dynamic light scattering (DLS) is 165.7 nm (Figure 2.2b), which implies 
that MSNs are well-suspended in deionized (D.I.) H2O. The zeta potential value of MSNs is –21.2 
mV in D.I. H2O. Nitrogen adsorption/desorption isotherms of MSNs were measured at 77 K. The 
surface area, pore volume, and pore size are 1060 m2/g, 1.12 cm3/g, and 2.8 nm, respectively 
(Figure 2.2c and 2.2d). The high surface area, characteristic of MSNs,8,18 provides an advantage 
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for loading cargos such as clofazimine (CFZ) and acetophenone (AP). 
 
Figure 2.2. (a) TEM image of mesoporous silica nanoparticles (MSNs). Inset shows the enlarged image. 
(b) Dynamic light scattering diameter distribution of MSNs in D.I. H2O. The diameter of the MSNs is 165.7 
nm. (c) Nitrogen adsorption-desorption isotherms of MSNs at 77 K. BET surface area and pore volume are 
1060 m2/g and 1.12 cm3/g, respectively. (d) Pore diameter distribution of MSNs. Average pore diameter of 
MSNs is 2.8 nm. 
 
2.3.2 Clofazimine solubility enhancement  
To enhance the water solubility of CFZ, we applied the concept of “hydrotropy” to the 
MSNs platform. During the past decades, the successful application of hydrotropy to the delivery 
of hydrophobic drugs by nanocarriers has been demonstrated by several research groups. For 
instance, Koo et al. used hydrotropic oligomer-conjugated glycol chitosan nanoparticles for 
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paclitacxel (PTX) delivery.56 Wang, et al. used 70 nm hydrotropic polymer-based nanocarriers to 
load and deliver PTX in in vitro studies.57 Most of their work involved anticancer drugs, especially 
PTX, whose water solubility is 5.6 µg/mL.40,58,59 To the best of our knowledge, no application of 
hydrotropy to the delivery of water-insoluble antibiotics from nanocarriers has been demonstrated. 
 
Figure 2.3. CFZ solubility enhancement in the presence of (a) sodium benzoate, (b) nicotinamide, (c) 
isoniazid, (d) pyrazinamide, (e) 2-hydroxyacetophenone, (f) hexanoic acid, (g) benzoic acid, (h) 2-
heptanone, and (i) acetophenone. The solubility of CFZ in deionized water without the addition of any 
molecule served as a control. 
 
 
It is known that highly effective hydrotropes frequently have either a phenyl ring or 
pyridine in their structures.59,60 For example, sodium benzoate and nicotinamide, with either a 
phenyl ring or pyridine in their structures, are effective hydrotropes for PTX.60 Therefore, sodium 
benzoate, nicotinamide, and other molecules with similar structures, including isoniazid, 
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pyrazinamide, 2-hydroxyacetophenone, benzoic acid, and AP were considered candidates for 
hydrotropes to enhance the water solubility of CFZ. Figure 2.3 shows the solubility enhancement 
of CFZ in H2O in the presence of the various hydrotropes mentioned above. The solubility of CFZ 
was determined from UV-Vis spectra where the maximum absorbance is at 490 nm. It is surprising 
that neither sodium benzoate nor nicotinamide is a good hydrotrope; compared with the control, 
the CFZ solubility enhancement is only 1.3-and 1.5-fold in 1 M of sodium benzoate and 
nicotinamide solution, respectively. The results indicate that isoniazid and pyrazinamide are also 
not effective hydrotropes for CFZ (1.7-fold in 1 M isoniazid and 1.4-fold in 1 M pyrazinamide 
solution). The poor hydrotropic performance of these four molecules may due to their relatively 
high water solubility (629 mg/mL for sodium benzoate, 500 mg/mL for nicotinamide, 140 mg/mL 
for isoniazid, and 50 mg/mL for pyrazinamide) as shown in Table 2.1. It is very difficult to provide 
 
 
Table 2.1. Chemical structures of possible hydrotropes for clofazimine (CFZ) and their water solubilities. 
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the hydrophobic interaction between the possible hydrotropes and CFZ. In this case, the strong 
intermolecular force of CFZ (mainly from the hydrophobic interaction of the phenyl rings of CFZ) 
is much stronger than the interaction between possible hydrotropes and CFZ. Such hydrophilicity 
of these molecules makes them unable to associate well with the hydrophobic CFZ molecules, and 
thus the water solubility of CFZ was only slightly enhanced effectively. 
On the other hand, the water solubility enhancement of CFZ is 1.6-fold, 1.7-fold, 2.0-fold, 
and 2.6-fold for 2-hydroxyacetophenone, hexanoic acid, benzoic acid, and 2-heptanone 
hydrotropes, respectively. Benzoic acid and 2-heptanone have better water solubility enhancement 
than 2-hydroxyacetophenone or hexanoic acid. This is due to the fact that the water solubility of 
benzoic acid and 2-heptanone – only 3.4 mg/mL and 4.3 mg/mL, respectively – is lower than that 
of 2-hydroxyacetophenone and hexanoic acid – 20.0 mg/mL and 10.8 mg/mL, respectively. Thus, 
these hydrotropes may associate better with the hydrophobic CFZ molecules and enhance the water 
solubility of CFZ. In addition, the presence of the phenyl rings in the structure of hydrotropes 
could also contribute to improvement in the water solubility of CFZ because of the hydrophobic 
interactions exists between the phenyl rings of the hydrotropes and hydrophobic moiety (phenyl 
rings) of CFZ. For example, the solubility enhancement of CFZ in the presence of benzoic acid or 
hexanoic acid is 2.0 or 1.7-fold, respectively. By using benzoic acid, the solubility enhancement is 
higher than that of hexanoic acid due to the presence of the phenyl ring in benzoic acid. 
Additionally, the solubility enhancement of CFZ in the presence of 2-heptanone or AP is 2.6 or 
10.1-fold. By using AP as the hydrotrope, the solubility enhancement is about four times greater 
than that with 2-heptanone. Therefore, the phenyl ring could effectively enhance the water 
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solubility of CFZ because either AP or benzoic acid could provide the hydrophobic interaction 
between their phenyl ring and the phenyl ring of CFZ. 
The hydrogen bonding between water molecules and CFZ is not strong enough to solvate 
CFZ since the intermolecular hydrophobic interaction between the phenyl rings of CFZ is strong. 
Therefore, the water solubility of CFZ is low (only 0.2 µg/mL), or water-insoluble by definition. 
However, for AP or 2-heptanone, there exists both a hydrophobic phenyl ring or alkyl chain and a 
polar carbonyl group in their chemical structures. These molecules could provide both the 
hydrophobic interaction between the hydrophobic phenyl ring or alkyl chain of AP or 2-heptanone 
and the hydrophobic moiety of CFZ, and hydrogen bonding between the carbonyl group of AP or 
2-heptanone and amine hydrogen in CFZ. Therefore, the presence of carbonyl group in AP or 2-
heptanone could provide stronger interaction between the possible hydrotropes and CFZ, e.g. the 
CFZ solubility enhancement is 10.1 or 2.6-fold by using AP or 2-heptanone as the hydrotrope, 
higher than those of benzoic acid (2.0-fold) or hexanoic acid (1.7-fold). In terms of polarity of the 
possible hydrotropes, a carboxylic acid group has larger polarity than a ketone. Therefore, if we 
compare 2-heptanone with hexanoic acid, the solubility enhancement of CFZ is 2.6 or 1.7-fold in 
the presence of 2-heptanone or hexanoic acid, respectively. The higher polarity of hexanoic acid 
has less hydrotropic effect to increase the water solubility of CFZ. This could also be proved that 
the solubility enhancement of CFZ is 10.1 or 2.0-fold in the presence of AP or benzoic acid, 
respectively, since benzoic acid has higher polarity. Based on the above observations, AP, with 
good association with CFZ and both a phenyl ring and a ketone in its structure, was chosen as a 
promising hydrotrope for CFZ in this study. The hydrotropic efficacy of AP was examined in more 
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detail in section 3.3. 
2.3.3 Hydrotropic efficacy of AP on CFZ solubility 
The hydrotropic efficacy of AP was examined in more detail using UV-Vis spectra to 
determine the CFZ solubility enhancement as a function of AP concentration in H2O (Figure 2.4a). 
When the AP concentration was below 2.2 mM, the absorbance at 490 nm was almost equal to that 
of the control (0 mM), whereas the absorbance rapidly increased as the AP concentration rose to 
more than 2.2 mM. The result shows that the water solubility of CFZ dramatically increases when 
the concentration of AP reaches around 2.2 mM. Figure 2.4b displays the fold enhancement of 
CFZ solubility by AP compared with the control. The maximum solubility enhancement of CFZ 
reached 12.2-fold at an AP concentration of 60 mM, which is the saturated concentration of AP in 
H2O. Accordingly, the result indicates that the water solubility of CFZ can be enhanced from 0.2 
mg/L to about 2.4 mg/L in the presence of AP in H2O. From Figure 2.4a and 2.4b, no hydrotropic 
efficacy was observed at concentrations of AP below 2.2 mM. Below this threshold, the solubility 
enhancement of CFZ is independent of the AP concentration. In contrast, when the concentration 
of AP is more than 2.2 mM, the solubility enhancement of CFZ increases significantly with AP 
concentration. The critical AP concentration may imply that the minimum hydrotropic 
concentration (MHC) is about 2.2 mM. Above the concentration, the self-aggregation of AP 
occurred,41,42 which is similar to that the surfactant molecules form the ordered micelle structure 
above the critical micelle concentration but not identical.42 Such self-aggregation of hydrotropes 
interact the water-insoluble drugs through hydrophobic interaction between the hydrophobic 
benzene ring of AP and water-insoluble CFZ and simultaneously help the solubilization of CFZ. 
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Therefore, once the concentration of AP is higher than this threshold concentration, the self-
aggregation of AP and its’ hydrotropic effect could help the solubilization of CFZ in water. This 
behavior follows the mechanism of hydrotropy-assisted solubility enhancement of hydrophobic 
drugs which may be attributed to the preferential interaction between AP and CFZ.43 A photograph 
of serial CFZ solutions with different AP concentrations is shown in Figure 2.4c. The color of the 
solutions became darker as the AP concentration increased, indicating that AP helps dissolve CFZ 
in H2O. These results show that the water solubility of CFZ is significantly enhanced by the 
addition of the AP. 
 
Figure 2.4. (a) UV-Vis spectra of CFZ dissolved in H2O in the presence of different concentrations of AP. 
(b) CFZ solubility enhancement (fold increase compared with no AP) in the presence of different 
concentrations of AP in H2O. (c) Photograph of CFZ dissolved in H2O in the presence of different 
concentrations of AP. 
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2.3.4 Clofazimine loading by using different non-aqueous solvents: AP and DMSO  
      To realize whether AP could also facilitate the loading of CFZ in MSNs, we compared the 
loading amount of CFZ by using AP to that of conventional method using DMSO, a widely-used 
loading solvent for dissolving poorly water-soluble drugs.2,14 We called the method of using AP 
the “chaperone-assisted” method due to the preferential interaction between AP and CFZ, making 
AP act like a chaperone carrying the CFZ with it (Figure 2.5a). CFZ loading into MSNs was 
achieved by soaking MSNs in CFZ solutions with various concentrations dissolved in AP or 
DMSO. After 24 h loading of CFZ, the CFZ-loaded MSNs were introduced back to aqueous 
solution. To calculate the loading capacity, which is defined as (the mass of loaded CFZ / the mass 
of MSNs) x 100%, the CFZ loaded MSNs with AP or DMSO were respectively washed with AP 
or DMSO several times until the supernatant after centrifugation was clear. Those supernatants 
were collected and measured by UV-Vis spectroscopy. The total amount of CFZ loaded in MSNs 
was calculated based on Beer’s law and its calibration curve (Figure 2.6). From Figure 2.5b, the 
loading capacity of 0.1, 1, and 10 mM CFZ by using DMSO as the loading solvent were found to 
be 0.2, 0.9, and 5.9 %, respectively. However, with AP as the loading solvent, the higher loading 
capacity were achieved under all loading concentrations of CFZ, which were 0.3, 1.3, 9.6, and 26.8 
% for 0.1, 1, 10, and 50 mM CFZ, respectively. The loading capacity of CFZ increased with the 
loading concentration of CFZ. The higher loading capacity of CFZ by using AP as the loading 
solvent can be explained by two reasons: (1) the CFZ solubility in AP (>71 mg/mL) is higher than 
in DMSO (5 mg/mL), so that the saturated concentration of CFZ in AP (more than 150 mM) is 
much higher than in DMSO (only 10.5 mM); (2) DMSO is miscible with water, so most of the 
 60 
DMSO molecules were removed by water during the washing steps, leading to the release of some 
CFZ molecules from MSNs together with DMSO. However, the water solubility of AP is only 6.1 
mg/mL, so a large amount of AP was still loaded in the pores of MSNs after they were re-dispersed 
in aqueous solution (Figure 2.5a). As will be shown in the next section, the AP in the pores is 
essential for good CFZ release. 
 
 
Figure 2.5. (a) Schematic illustration of conventional method (CFZ in DMSO) or chaperone-assisted 
method (CFZ in AP) for water-insoluble CFZ loading in MSN. By using AP as the chaperone, CFZ release 
from MSNs could be enhanced significantly. Loading capacity of (b) CFZ and (c) AP using 0.1, 1, or 10 
mM CFZ in DMSO or 0, 0.1, 1, 10, or 50 mM CFZ in AP as the loading solution. The concentration of 
MSNs was 10 mg/mL. (d) Time-dependent release efficiency of CFZ in HEPES buffer solution (10 mM, 
pH = 7.4) with 1 mM CFZ in DMSO or 1 mM CFZ in AP as loading solutions. (e) Photographs of 
supernatant after CFZ release collected at selected time points. MSNs were loaded with 1 mM CFZ in 
DMSO or 1 mM CFZ in AP. 
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Figure 2.6. (a) UV-Vis spectra of CFZ in AP as a function of concentration and (b) calibration curve of 
CFZ in AP at room temperature. (c) Photograph of CFZ dissolved in AP. 
 
 
     Based on the significant enhancement of CFZ loading by AP, it was of interest to investigate 
the detailed relationship between the loading of AP chaperone and its cargo CFZ. MSNs were 
loaded with AP itself (no CFZ), or AP with 0.1, 1, 10, and 50 mM solubilized CFZ. The pore 
volume of MSNs is 1.12 cm3/g; hence the maximum volume for cargo loading is 1.12 µL/mg. The 
density of AP is 1.03 g/cm3, and thus the maximum loading capacity would be 115.4%. When AP 
itself (0 mM CFZ), or AP with 0.1, 1, 10, and 50 mM solubilized CFZ were used as the loading 
solvents, the loading capacity of AP was found to be 100.9 %, 102.4 %, 101.1%, 97.2 %, and 71.4 
 62 
%, respectively (Figure 2.5c). The amount of loaded AP in MSNs corresponds to 8397.8, 8522.7, 
8414.5, 8089.9, and 5942.6 nmole/mg, and the amount of loaded CFZ in MSNs was 6.3, 27.5, 
202.8, and 566.1 nmole/mg at those respective CFZ loading concentrations (Table 2.2). This 
implies that when the CFZ loading capacity is low (no higher than 1.3 %, Figure 2.5b), regardless 
of the presence of CFZ, about 88% of the pore volume of MSNs is filled with AP after loading, 
which is reasonable since the low water solubility of AP (only 6.1 mg/mL) makes a large amount 
of AP remain in the pores of MSNs after they are re-dispersed in aqueous solution. The loading 
capacity of AP is lower at higher CFZ concentrations (10 and 50 mM), at which the loading 
capacity of CFZ was enhanced (9.6 % and 26.8 %, Figure 2.5b). This is because part of the pore 
volume of MSNs is occupied by CFZ, thus reducing the volume available for AP loading. The 
mole ratios of AP to CFZ loaded in MSNs with those CFZ loading concentrations was calculated 
to be 1352.8, 306.0, 39.9, and 10.5, respectively (Table 2.2). As CFZ loading concentrations in AP 
increase, both the amount of loaded CFZ and the mole ratio of CFZ to AP increase. 
 
 
Table 2.2. Summary of the amount of loaded CFZ and AP in MSNs (nmole/mg) and the mole ratio of 
AP/CFZ loaded in MSNs. 
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2.3.5 Clofazimine release to aqueous solution by using different non-aqueous solvents: AP 
and DMSO 
     Before applying the methods with AP and DMSO to deliver CFZ to biological systems, we 
examined their capability for facilitating the release of CFZ into aqueous solution. MSNs loaded 
with CFZ (1 mM) either by DMSO or AP were dispersed in HEPES buffer solution (pH = 7.4) for 
1, 2, 3, or 5 days, respectively (Figure 2.5a). Figure 2.7a shows the UV-Vis spectra of the 
supernatant after CFZ released from MSNs in buffer solution with DMSO as the loading solvent. 
The absorption peak of CFZ at 490 nm is not evident, indicating that the release of CFZ is 
negligible even after 5 days. This phenomenon could be explained as a result of the water-insoluble 
property of CFZ, making the drug molecules themselves prefer to stay in the pores of MSNs. On 
the contrary, with AP as the loading solvent, the release of CFZ could be easily found in the UV-
Vis spectra with the apparent peaks at 490 nm (Figure 2.7b). The absorbance peaks at 490 nm 
increased with time between 5 days, and the absorbance is significantly different from those with 
DMSO. To quantify the release amount of CFZ, the time dependent release efficiency of CFZ 
using either DMSO or AP was calculated (Figure 2.5d) based on Beer’s law and its calibration 
curve (Figure 2.8). The release efficiency is defined as (the mass of released CFZ / the mass of 
loaded CFZ) x 100%. By using the “chaperone-assisted” strategy with AP, the release efficiency 
of CFZ achieved 47.2%, which is 2300 times higher than that by the conventional method with 
DMSO (0.02%) (Figure 2.5d). This significant enhancement in the release efficiency of CFZ by 
AP could also be clearly observed in the photograph of the supernatant (Figure 2.5e). 
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Figure 2.7 UV-Vis spectra of time-dependent CFZ release in HEPES buffer solution (10 mM, pH = 7.4) by 
using (a) DMSO or (b) AP as loading solvents. MSNs were loaded with 1 mM CFZ in DMSO or 1 mM 
CFZ in AP. The concentration of MSNs in both loading solution and release buffer solution were 10 mg/mL. 
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Figure 2.8. (a) Concentration dependent UV-Vis spectra and (b) calibration curve of CFZ in EtOH/HEPES 
buffer (10 mM, pH = 7.4) (v/v=1/1) solution at room temperature. (c) Photograph of CFZ dissolved in 
EtOH/HEPES buffer solution (10 mM, pH=7.4) (v/v=1/1). 
 
 
2.3.6 Effect of clofazimine loading concentration on clofazimine release 
To optimize the release of CFZ in aqueous environment using the “chaperone-assisted” 
delivery strategy, we explored the effect of CFZ loading concentration on the long-term release 
behavior of CFZ. The release of CFZ was confirmed by the absorbance peaks at 490 nm in the 
UV-Vis spectra measured from the supernatants collected after spinning down MSNs after 1, 2, 3, 
and 5 days (Figure 2.7b). The time-dependent release capacity of CFZ was calculated based on 
Beer’s law and its calibration curve (Figure 2.8). Release capacity is defined as: (the mass of  
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Figure 2.9. Time-dependent release capacity of (a) CFZ and (c) AP and release efficiency of (b) CFZ and 
(d) AP in HEPES buffer solution (10 mM, pH = 7.4) with 0, 0.1, 1, 10, and 50 mM CFZ in AP as loading 
solutions. The concentration of MSNs in both loading solution and release buffer solution was 10 mg/mL 
(n=3). 
 
 
released CFZ / the mass of MSNs) x 100%. Figure 2.9a shows the time-dependent release capacity 
of CFZ in HEPES buffer solution (pH = 7.4) with four different CFZ loading concentrations (0.1, 
1, 10, and 50 mM) in AP. The absorbance peaks increase with time up to 5 days. Regardless of the 
CFZ loading concentration, the amount of CFZ released gradually increases with time, until it 
levels off at about five days. The amount of CFZ released from MSNs loaded with 0.1 mM CFZ 
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in AP is only 0.10 % on day 5, which is mainly due to the tiny amount of CFZ (0.3 % loading 
capacity) loaded in MSNs. For the MSNs loaded with 1 and 10 mM CFZ in AP, the CFZ release 
capacity on day 5 was 0.56 % and 0.54 %, respectively. Even though the amount of CFZ loaded 
with those two samples (1.3 % and 9.6 % CFZ loading capacity, respectively) differed by 7-fold, 
the amount of CFZ released was nearly the same. However, the CFZ release capacity of the MSNs 
loaded with 50 mM CFZ in AP on day 5 is only 0.27 %, lower than those loaded with 1 and 10 
mM CFZ in AP. This low CFZ release capacity at this high CFZ loading concentration may be due 
to a small amount of AP in the pores of MSNs that contain a large amount of CFZ (26.8 % CFZ 
loading capacity) as referred to Table 2.2, which shows the mole ratio of AP/CFZ to be only 10.5. 
This less amount of AP renders the environment inside the pores much more hydrophobic and thus 
reducing the “chaperone-assisted” effect or the hydrotropic effect. The time-dependent release 
efficiency of CFZ with four different CFZ loading concentrations (0.1, 1, 10, and 50 mM) was also 
calculated (Figure 2.9b). Release efficiency is defined as: (the mass of released CFZ / the mass of 
loaded CFZ in MSNs) x 100%. The time-dependent release efficiency on day 5 for MSNs loaded 
with 0.1, 1, 10, and 50 mM CFZ in AP is 42.3 %, 47.2 %, 4.6 %, and 0.1%, respectively. The 
lowest release efficiency, observed when MSNs were loaded with 50 mM CFZ in AP, indicates 
that most of the loaded CFZ remains in the pores of MSNs, which again may be due to the small 
amount of loaded AP and the enhanced hydrophobicity in the pores of MSNs as described above. 
2.3.7 Effect of clofazimine loading concentration on acetophenone release 
     After the “chaperone-assisted” strategy was successfully demonstrated, we studied the effect 
of CFZ cargo loading concentration on the release of AP chaperone (Figure 2.9c and 2.9d). The  
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Figure 2.10 (a) Concentration dependent UV-Vis spectra and (b) calibration curve of AP in EtOH/ HEPES 
buffer solution (10 mM, pH = 7.4) (v/v=1/1). 
 
 
release efficiency of AP was calculated based on Beer’s law and its calibration curve (Figure 2.10). 
The time-dependent release capacity of AP from MSNs loaded with 0.1, 1, 10, and 50 mM CFZ in 
AP is lower than from MSNs not loaded with CFZ on day 1 (Figure 2.9c). Nevertheless, the release 
capacity of AP from MSNs loaded with CFZ substantially increases on day 2. Finally, the release 
capacity of AP on day 5 reaches 94.2, 90.0, 77.8, and 53.6 % from MSNs loaded with 0.1, 1, 10, 
and 50 mM CFZ in AP, respectively. For the release efficiency of AP from MSNs loaded with 0.1, 
1, 10, and 50 mM CFZ, only 22, 11, 12, and 13 % were found on day 1, much lower than without 
loaded CFZ (33%) (Figure 2.9d). However, on day 2, the release efficiency of AP from MSNs 
loaded with 0.1, 1, 10, and 50 mM CFZ in AP achieves 60, 61, 59, and 57 %, respectively, which 
is close to that without loaded CFZ (58%). Finally, on day 5, the release efficiency of AP reaches 
about 92, 89, 80, and 75 % for MSNs loaded with 0.1, 1, 10, and 50 mM CFZ in AP, respectively, 
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and reaches about 95% for the MSNs loaded with AP itself (0 mM CFZ). Interestingly, the result 
on day 5 shows that the release efficiency of AP decreases as the loading concentration of CFZ 
increases. This finding together with the lower loading capacity of AP at 10 and 50 mM CFZ 
loading concentration (Figure 2.5c) adequately explain the much lower release capacity of AP 
when MSNs are loaded with 10 mM or 50 mM CFZ than when MSNs are loaded with AP without 
any CFZ (95.9%) (Figure 2.9c). 
The sigmoidal release profiles of both CFZ and AP loaded in MSNs are characterized by 
slow release during the first day followed by increased release at later time points, and a final 
leveling off (Figure 2.9b and 2.9d). In the presence of both CFZ and AP in MSNs, almost all of 
the CFZ (Figure 2.9b) as well as the greater part of AP (Figure 2.9d) remain inside the pores on 
day 1, especially for the MSNs loaded with 1, 10, and 50 mM CFZ in AP. This supports that there 
may exist an interaction between CFZ and AP in the pores of MSNs, and that this association 
favors most of the AP molecules residing in the pores of MSNs, reducing the AP release on day 1. 
The loaded CFZ molecules may sterically block the release of AP from MSNs as well. The better 
AP release compared to that of CFZ on day 1 could be explained by the higher water solubility of 
AP than CFZ, so that the release of AP in aqueous environment can occur in a short period of time. 
For MSNs loaded with 0.1 and 1 mM CFZ in AP, the release efficiency of AP increases 
significantly after day 1 (Figure 2.9d), which corresponds to the substantial increase in CFZ release 
efficiency on day 2 (Figure 2.9b). This feature is due to the high mole ratio of AP/CFZ in the pores 
of MSNs with 0.1 and 1 mM CFZ (Table 2.2). The abundant AP chaperone in the pores carry CFZ 
out of MSNs and thus facilitates CFZ release into an aqueous environment. Interestingly, for 
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particles loaded with 10 and 50 mM CFZ, the CFZ release efficiency shows no significant increase 
during those five days compared with the dramatic increase in AP release efficiency after day 1. 
This is because the mole ratio of AP/CFZ is low at those CFZ loading concentrations (Table 2.2), 
and thus the interaction between AP and CFZ is not strong enough to carry CFZ out of MSNs and 
into the aqueous environment. In other words, when the mole ratio of AP/CFZ is low, even though 
the interaction between CFZ and AP in the pores retards the release of AP, the high water solubility 
of AP dominates such that more AP is released into an aqueous environment as the release time 
increases. 
The “chaperone-assisted” delivery strategy makes use of the interaction between CFZ 
cargo and AP chaperone which provides the mechanism for the release of CFZ from MSNs, and 
thus significantly enhances the water solubility of CFZ. By carefully tuning the mole ratio of 
AP/CFZ, we can control the dosage and the release profile of CFZ over time. This would be 
favorable in terms of improving the bioavailability and the efficacy of CFZ, as well as reducing 
the side-effect causing by the overdose of CFZ. 
2.3.8 Effect of external acetophenone on clofazimine release 
As the chaperone, AP is supposed to be stayed together with its CFZ cargo in the pores of 
MSNs to bring its assistance into full play. To further confirm the idea of “chaperone-assisted” 
delivery, we studied the release of CFZ in a buffer solution with or without the addition of 
dissolved AP. Instead of using AP as the loading solvent, DMSO was used for loading CFZ to 
prevent AP from being present in the pores of MSNs. Release buffer with or without the addition 
of AP was used for CFZ release. With DMSO as the loading solution, the release efficiency of  
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Figure 2.11. Time-dependent release efficiency of CFZ in HEPES buffer solution (10 mM, pH = 7.4) with 
or without the addition of AP to the buffer solution. After loading with 1 mM CFZ in DMSO, 10 µL of AP 
was added to the buffer solution (10 mg MSNs/mL, 1 mL) (n=3). 
 
 
CFZ released in HEPES buffer solution (10 mM, pH = 7.4) without the addition of AP is only 
0.02% after 120 h, which indicates that almost all of the CFZ stays in the pores of MSNs (Figure 
2.11). The release efficiency of CFZ released in HEPES buffer solution with the addition of AP, 
on the other hand, is only 4.3% after 120 h. Both of these CFZ release efficiencies are significantly 
lower than that with AP as the loading solvent and HEPES buffer solution as the release buffer 
(47.2%). This result suggests that the CFZ release efficiency is significantly enhanced by the AP 
loaded inside the pores of MSNs together with CFZ, of which the interaction between CFZ cargo 
and AP chaperone inside the pores contributes substantially to the significant improvement of CFZ 
release. On the other hand, AP outside of the MSNs that doesn't have good interaction with CFZ 
 72 
only contributes to about 1/10th of the CFZ release. This slightly greater CFZ release could be 
explained by the increased hydrophobicity of the environment causing by the AP located in 
solution outside of MSNs. This study further strengthens the idea of “chaperone-assisted” delivery, 
where MSNs act like a primary vehicle carrying both a secondary vehicle – the AP chaperone – 
and the CFZ cargo inside. As the chaperone, AP carries the CFZ and brings it out and away from 
MSNs effectively. 
2.3.9 Antibacterial effect of acetophenone-assisted clofazimine delivery by MSNs  
To explore the antibacterial effect of the developed “chaperone-assisted” delivery strategy 
shown in Figure 2.12a, we examined the treatment efficacy of the CFZ loaded MSNs using a 
macrophage model of Mycobacterium tuberculosis (M. tuberculosis) infection. The mole ratio of 
AP/CFZ was tuned and the optimized CFZ loading concentration was found to be 10 mM 
considering both the loading capacity and release capacity of CFZ (Figure 2.5b and 2.9a). The M. 
tuberculosis-infected macrophages were treated with MSNs loaded with 10 mM CFZ in AP 
(AP/CFZ-MSN) for 4 days (Figure 2.12a). As controls, the macrophages were untreated or treated 
with MSNs loaded with AP only (AP-MSN), or with free CFZ dissolved in a mixture of DMSO 
and H2O (CFZ/DMSO). All of the infected macrophages were lysed at day 4 post-infection and 
the lysates were plated for viable M. tuberculosis. The number of M. tuberculosis colony forming 
units (CFUs) recovered from the macrophages was enumerated to determine bacterial viability 
under each treatment. As shown in Figure 2.12b, treatment with AP-MSN (11 and 22 µg/mL) for 
4 days without CFZ had little effect on M. tuberculosis because the number of bacteria in 
macrophage monolayers (6.29, and 6.25 log CFU, respectively) was similar to and not statistically 
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Figure 2.12. (a) Schematic illustration of applying chaperone-assisted CFZ delivery strategy to selectively 
killing M. tuberculosis in macrophage. (b) AP/CFZ loaded MSNs kill M. tuberculosis in vitro in 
macrophage cultures. M. tuberculosis-infected THP-1 macrophages were untreated, treated with MSN 
loaded with AP (AP-MSN), treated with MSN loaded with CFZ and AP (AP/CFZ-MSN), or treated with 
CFZ dissolved in a mixture of DMSO and H2O (CFZ/DMSO) for 4 days. Bacterial colony forming units 
(CFUs) were determined by spreading serially diluted lysates of the infected macrophages on agar plates. 
CFU data are shown as the mean ± standard deviation. Statistical analysis was performed using one-way 
ANOVA with Tukey’s correction for multiple comparisons. ns, not significant; *p < 0.05; **p < 0.01; ***p 
< 0.001 (c) Count of macrophage nuclei per 10x microscopic field normalized to that of the macrophage 
control wells without addition of drug. Count of macrophage nuclei per microscopic field is used as a 
surrogate of macrophage viability, as dead macrophages detach and are lost from the monolayer over the 
long incubation period. Human THP-1 macrophages were either not infected (no bacteria) or infected with 
Mycobacterium tuberculosis in the absence of nanoparticles (no drug) or in the presence of AP-MSN and 
AP/CFZ-MSN with serial two-fold increasing concentration ranging from 3.1 to 25 µg/mL, as indicated. 
At the end of a 4-day incubation, macrophages were fixed with paraformaldehyde and the nuclei were 
stained with DAPI and imaged with an ImageXpress High Content Screening system using a 10x objective 
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lens. The acquired images were analyzed using the Count Nuclei module of MetaXpress software to 
quantitate numbers of nuclei per 10x field. Data shown are mean ± sem of three biological replicates. 
 
 
different from the number in untreated macrophages (6.51 log CFU). In contrast, AP/CFZ-MSN 
killed the intracellular bacteria in a dose-dependent manner. AP/CFZ-MSN at concentrations of 
5.5, 11, and 22 µg/mL correspond to 0.5, 1, and 2 µg/mL of free CFZ dissolved in DMSO. The 
number of viable bacteria after treatment with those concentrations of AP/CFZ-MSN was 5.97, 
5.82, and 5.50 log CFU, respectively, suggesting that 90% of bacteria was killed (the number of 
bacteria decreased by 1 log CFU) in macrophages treated with 22 µg/mL of AP/CFZ-MSN. We 
also compared the effect of free CFZ with that of the MSN-encapsulated CFZ. The treatment 
efficacy of AP/CFZ-MSN dispersed in culture medium was similar to that of an equivalent amount 
of CFZ dissolved in the mixture of DMSO and culture medium without MSNs. This comparison 
shows that with the help of the AP chaperone, most of the CFZ loaded inside MSNs is efficiently 
released in the macrophages and kill the bacteria effectively and selectively (Figure 2.12a). 
To investigate if the “chaperone-assisted” delivery strategy with AP, an FDA approved food 
additive, has any cytotoxicity to the macrophages, we examined the viability of the infected 
macrophages after the treatment with AP-MSN and AP/CFZ-MSN for 4 days. No significant 
decrease in macrophage viability was detected (Figure 2.12c) at the concentrations studied. No 
adverse effect on the morphological appearance of the macrophages treated with AP-MSN or 
AP/CFZ-MSN was observed. Taken together, these results show that the “chaperone-assisted” 
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CFZ delivery strategy via MSNs has no evident toxicity to macrophages but can selectively and 
efficiently kill the bacteria residing inside them due to the significant release of CFZ from MSNs. 
2.4. Conclusions 
In this study, we have developed a novel “chaperone-assisted” strategy based on mesoporous 
silica nanoparticles (MSNs) to both load water-insoluble drugs into MSN carriers and release them 
into aqueous biological environment. First, we utilized the concept of “hydrotropy” to explore the 
nine candidate small molecules for their utility to enhance the water solubility of a water-insoluble 
antibiotics — clofazimine (CFZ), who has good efficacy against multidrug-resistant Tuberculosis 
(TB). Acetophenone (AP) was selected as the most efficacious solvent to enhance 10.1-fold of the 
water solubility of CFZ. Acting as a chaperone, AP not only brought a great amount of CFZ cargos 
(26.8% loading capacity of CFZ) into the MSN nanocarriers, but carried a significant amount of 
CFZ cargos (47.2% release efficiency of CFZ) out from MSNs into the aqueous solution. This 
release efficiency of CFZ achieved is 2300 times higher than that by conventional method using 
DMSO (0.02%). This considerable increase in CFZ release is mainly driven by the release of AP 
chaperone from the chaperone-rich pores of MSNs, which allows CFZ cargo to be carried together 
into the aqueous solution, and can be supported by our three findings: (1) a lower loading 
concentration of CFZ (1 mM) gave a higher release efficiency of CFZ (47.2%) compared with a 
higher loading concentration of CFZ (0.1%); (2) AP in the solution outside of MSNs only 
minimally increased the release efficiency of CFZ (4.3%); (3) without AP, the release efficiency 
of CFZ was only 0.02%. We examined this delivery strategy in a macrophage model of 
Mycobacterium tuberculosis (M. tuberculosis) infection using MSNs loaded with the optimized 
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ratio of CFZ and AP (10 mM CFZ in AP). M. tuberculosis residing inside macrophages were 
efficiently killed (reduced by 1 log CFU) by the high amount of the released CFZ, which is 
comparable to that with the same amount of CFZ dissolved in a mixture of DMSO and culture 
medium. No adverse effect on the morphological appearance of the macrophages treated with 
either MSNs loaded with AP or MSNs loaded with CFZ and AP was observed. This novel 
“chaperone-assisted” delivery strategy for CFZ could also be applied to other hydrophobic drugs 
with their suitable loading solvents (chaperone), opening up opportunities to apply this drug 
delivery strategy for further use in medicine and biomedical research. 
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Chapter 3 
Spatial, Temporal, and Dose Control of Drug Delivery using 
Noninvasive Magnetic Stimulation 
 
This chapter of the dissertation was adapted and reprinted with permission from Wei Chen, Chi-
An Cheng, Jeffrey I. Zink ACS Nano 2019, 13, 1292–1308. Copyright 2019 American Chemical 
Society. Co-author contributions: Chen W., and Cheng C. A. performed the experiments, Jeffrey I. 
Zink was the P.I. 
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dosage-controlled release, chemotherapy 
 
Abstract 
Noninvasive stimuli-responsive drug delivery using magnetic fields in conjunction with 
superparamagnetic nanoparticles offers the potential for the spatial and temporal control of drug 
release. When hyperthermia is not desired and control of the dosage is required, it is necessary to 
design a platform in which local heating on the nanoscale releases the therapeutic cargo without 
the bulk heating of the surrounding medium. In this study, we report a design using a stimuli-
responsive nanoparticle platform to control the dosage of the cargo released by an alternating 
magnetic field (AMF) actuation. A core@shell structure with a superparamagnetic doped iron 
oxide (MnFe2O4@CoFe2O4) nanoparticle core in a mesoporous silica shell was synthesized. The 
core used here has a high saturation magnetization value and a high specific loss power for heat 
generation under an AMF. The mesoporous shell has a high cargo-carrying capacity. A 
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thermoresponsive molecular-based gatekeeper containing an aliphatic azo group was modified on 
the core@shell nanoparticles to regulate the cargo release. The mesoporous structure of the silica 
shell remained intact after exposure to an AMF, showing that the release of cargo is due to the 
removal of the gatekeepers instead of the destruction of the structure. Most importantly, we 
demonstrated that the amount of cargo released could be adjusted by the AMF exposure time. By 
applying multiple sequential exposures of AMF, we were able to release the cargo step-wise and 
increase the total amount of released cargo. In vitro studies showed that the death of pancreatic 
cancer cells treated by drug-loaded nanoparticles was controlled by different lengths of AMF 
exposure time due to different amount of drugs released from the carriers. The strategy developed 
here holds great promise for achieving the dosage, temporal, and spatial control of therapeutics 
delivery without the risk of overheating the particles’ surroundings. 
Table of Content Figure 
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3.1 Introduction 
Precision medicine, defined as “right drug, right dosage at right timing to right patient”, is a 
rapidly developing and popular global trend for cancer treatment.1 This emerging approach takes 
the individual variability into account for personalized disease treatment regimen design.1 
However, the necessity to deliver the desired therapeutic, at the desired time, to the specific site of 
the disease, and with accurate dosage of therapeutics remains a challenge.2 Over the past decade, 
many examples of stimuli-responsive drug delivery platforms responsive to internal cellular 
stimuli (such as pH change,3–6 redox potential,7,8 enzymes9 or biomolecules10,11) and external 
stimuli (such as light,12–15 heat,16–23 or ultrasound24,25) have been developed for cancer treatment 
because they offer the ability to both enhance the therapeutic efficacy at the target sites and reduce 
the premature release of drug molecules thus reducing off-target side effects. Delivery of the 
accurate dosage is a key feature in chemotherapy.26–28 The dosage of the therapeutics should be in 
the optimal range called therapeutic window, where the dosages exceed the threshold concentration 
and can treat disease effectively, while below the concentration which is significantly toxic to 
normal cells.29 In view of this, after getting information from genetic databases to find out the right 
drug to the right patients, the next challenge is to deliver the right dosage of therapeutics in a 
spatio-temporal controlled manner to the desired lesion location.2,30 However, important 
limitations of the above stimuli-responsive drug delivery exist: the platforms responsive to pH 
change, redox potential, and enzyme cannot precisely control the delivery time, the delivery 
location, and the delivery dosage; the light responsive platforms have the most focused spatial 
control (on the order of mm3) but suffer from the limited penetration depth in tissue; the heat 
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responsive platforms create a risk of inducing tumor metastasis when hyperthermia occurs;31–35 
and ultrasound suffers from blockage by bone and air even though under ideal condition can attain 
the spatial focus on the order of 10 mm3.36  
Non-invasive magnetic fields in conjunction with superparamagnetic nanoparticles offer a 
possible solution to overcome these limitations. Magnetic fields are harmless, are localized with 
dimensions governed by the size of the magnetic coil (on the order of cm3), and can be turned on 
and off under precise control. Superparamagnetic nanoparticles have been investigated extensively 
for a wide variety of biomedical applications including magnetic resonance imaging (MRI) 
contrast enhancement,37,38 hyperthermia therapy,39 and drug delivery.22,40–42 Among them, drug 
delivery triggered by heat generated when magnetic nanoparticles are exposed to an alternating 
magnetic field (AMF) actuation is an emerging approach to externally and non-invasively 
triggered drug release.43–49 AMF actuation of drug delivery has the following benefits: (1) the 
release of drugs can be spatially and temporally controlled, offering the advantages for delivering 
a high local concentration of therapeutics to the lesion site and reducing off-site drug delivery from 
the carriers, (2) no penetration depth limitation of the magnetic field, enabling the actuation be 
initiated in the deep animal body without the concern of light scattering or absorption by 
tissues,22,50–52 and (3) less restriction on the type of tissues being treated compared with ultrasound 
stimulation that is strongly attenuated by air and bone structures.36 In hyperthermia therapy, when 
the blood is congested locally during heating, more energy will be provided for the tumor 
growth.31–35,53 In this case, the original tumor cells suffering from necrosis, starvation or 
suffocation due to insufficient internal blood supply may be rescued, thus accelerating tumor cell 
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metastasis.31–35 Therefore, it is critical to monitor the temperature while doing AMF actuation, in 
order to prevent the bulk solution from being overheated.  
Only a limited amount of drugs can be carried on and released from the surface of a magnetic 
nanoparticle. To increase the amount of drugs that can be delivered, polymers,54 dendrimers,55,56 
and lipid bilayers,57 have been attached to magnetic nanoparticles to enhance the payload of drugs. 
Mesoporous silica has aroused much attention during the past decade due to its high surface area 
and large pore volume for cargo loading and delivery.58–66 Additionally, the stability, high 
biocompatibility, high cellular internalization efficiency, and easy surface functionalization of 
mesoporous silica makes it a strong candidate for use as a coating of superparamagnetic 
nanoparticles in a drug delivery platform.17,18,67–70  
To achieve the controllable drug delivery under the magnetic field actuation, various thermal 
responsive gatekeepers have been developed during the past several years. Thomas et al. designed 
the first nanovalve for magnetic triggered release study based on MSNs, in which cucurbit[6]uril 
was used as a cap that released the cargo when the supramolecular interaction between the cap and 
the stalk on the surface of MSNs was decreased.41 Thermo-sensitive polymers such as azo-
functionalized polyethylene glycol,17 poly(N-isopropylacrylamide),21 and poly[(ethylene glycol)-
co-(L-lactide)]23 polymer have also been used as the capping agents to prevent premature release. 
In this paper, we reported small molecular-based gatekeeper that is responsive to the heat generated 
by a superparamagnetic core in an AMF. 
     The nanoplatform consists of 4,4′-azobis(4-cyanovaleric acid) (ACVA), an aliphatic azo-
containing compound which can be irreversibly cleaved by heat and ultrasound,43,71 that was 
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attached on the surface of core@shell nanoparticles consisting of a manganese and cobalt doped 
iron oxide magnetic nanoparticle cores and a mesoporous silica shell (Scheme 3.1). Adamantane 
molecules were conjugated to ACVA through an amide bond coupling reaction. After loading the 
cargo in the pores of core@shell nanoparticles, bulky β-cyclodextrin (β-CD) was used to bind with 
the adamantane forming a well-known supramolecular host-guest complex with a high association 
equilibrium constant (5.2 x 104 M-1).7,14,72–79 The pores of core@shell nanoparticles were blocked 
by this bulky complex and the cargo inside was prevented from being released prematurely. We 
demonstrate that this small molecular-based gatekeeper can be triggered by magnetic heating with 
minimal bulk heating. In addition, we demonstrate that the exposure time to the AMF controlled 
the dosage of the released cargo. We quantify the cargo release efficiency while simultaneously 
monitoring the temperature of the bulk solution, and obtain both dosage and temporal controlled 
release with no dangerous bulk heating. This proof-of-concept of precision on command drug 
delivery establishes the opportunities to enhance the treatment efficacy, reduce the side effect of 
chemotherapy and at the same time avoid the risk of inducing tumor metastasis generated by 
hyperthermia. 
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Scheme 3.1. (a) Schematic illustration of the synthesis of azo snap-top core@shell mesoporous silica 
nanoparticles and triggered release under an alternating magnetic field. (b) Scheme of the conjugation and 
capping of APTS, ACVA, AMA, and β-CD on the surface of core@shell nanoparticles (EDC = 1-ethyl-3-
(-3-dimethylaminopropyl) carbodiimide; NHS = N-hydroxysuccinimide; DMSO = dimethyl sulfoxide). 
After the trigger with heat, the cleavage of C-N bonds of ACVA makes the bulky β-CD and AMA 
complexation leave from the surface, and the cargo could thus be released from Mag@MSN-. 
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3.2 Experimental Section 
3.2.1 Materials 
Iron(III) acetylacetonate (Fe(acac)3, 97%), Manganese(II) acetylacetonate (Mn(acac)2, 21%-
23% Mn), cobalt(II) acetylacetonate (Co(acac)2, 97%), 1,2-dodecanediol (90%), oleic acid (90%), 
oleylamine (70%), benzyl ether (98%), hexane (98.5+%), chloroform (99.5+%), 
hexadecyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 98%), (3-
aminopropyl)triethoxysilane (APTS, 99%), 4,4′-azobis(4-cyanovaleric acid) (ACVA, 98+%) 1-
adamantylamine (AMA, 97%), β-cyclodextrin (β-CD, 97+%), ammonium nitrate (NH4NO3, 
98+%), 1-Ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC, 98+%), N-hydroxysuccinimide 
(NHS, 98%), phosphate-buffered saline (PBS, 10X), bisBenzimide H 33342 trihydrochloride 
(Hoechst 33342, 98+%), and fluorescein sodium salt were purchased from Sigma-Aldrich. 
Doxorubicin hydrochloride (DOX-HCl) was purchased from Cayman Chemical. Dimethyl 
sulfoxide (DMSO, 99.9+%), sodium hydroxide (NaOH, 97+%), hydrochloric acid (HCl, 36.5%-
38%, tracemetal grade), and nitric acid (HNO3, 67%-70%, tracemetal grade) were purchased from 
Fisher Scientific. Dulbecco’s modified Eagle’s medium (DMEM) with high glucose, fetal bovine 
serum (FBS), antibiotics (10,000 U/mL penicillin, 10,000 µg/mL streptomycin, and 29.2 mg/mL 
L-glutamine), Dulbecco’s phosphate-buffered saline (DPBS), and trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) (0.05 %) were purchased from Gibco. Cell 
counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. 
Paraformaldehyde solution (4 % in PBS) was purchased from USB Corporation. Ethanol (200 
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proof) was purchased from Decon Laboratories, Inc. All chemicals were used without further 
purification. 
3.2.2 Characterization 
  The size and morphology of nanoparticles were investigated by transmission electron 
microscopy (TEM, Tecnai T12) with an operating voltage of 120 kV. MnFe2O4@CoFe2O4 or 
Mag@MSN core@shell nanoparticles were dispersed in hexane or ethanol at a low concentration 
(0.2 mg/mL). The suspension (10 µL) of the nanoparticles was dropped onto the carbon-coated 
copper grid and dried at room temperature. The X-ray diffraction pattern of the powder was 
obtained by a PANalytical, X’Per PRO diffractometer with Cu Kα radiation (λ= 1.5418 Å); the 
operating voltage and current were 45 kV and 40 mA, respectively. The field-dependent 
magnetization of MnFe2O4@CoFe2O4 was measured using a superconducting quantum 
interference device (SQUID) Quantum Design MPMS7 magnetometer at 300 K. The 
iron/manganese/cobalt ratio of the MnFe2O4@CoFe2O4 nanoparticles was quantitatively 
determined by ICP-OES using a Shimadzu ICPE-9000 instrument. Typically, 2 mg of 
MnFe2O4@CoFe2O4 powder was dissolved in 0.5 mL of hydrochloric acid solution. The solution 
was diluted with 2 % HNO3 for quantitative measurement. The calibration curves for iron, 
manganese, and cobalt were created from 0 ppm to 10 ppm. The surface area, pore volume, and 
pore size of Mag@MSN core@shell nanoparticles were determined by N2 adsorption-desorption 
isotherm measurements at 77 K (Autosorb-iQ, Quantachrome Instruments). Mag@MSN 
core@shell was degassed at 110 °C for 12 h before the measurement. The surface area and pore 
size distribution of Mag@MSN core@shell were determined by Brunauer-Emmett-Teller (BET) 
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and Barrett-Joyner-Halenda (BJH) methods. The dynamic light scattering (DLS) size and zeta 
potential values were determined by a laser particle analyzer LPA-3100 at room temperature. The 
functional groups on the surface of Mag@MSN core@shell were characterized by Fourier 
transform infrared spectroscopy (FTIR, JASCO FT/IR-420) spectrometer in the range of 4000–
400 cm-1. Thermogravimetric analysis (TGA) was performed on a Perkin-Elmer Pyris Diamond 
TG/DTA machine under air flow. About 10 mg of Mag@MSN core@shell were loaded in 
aluminum pans and the data were recorded from 50 °C to 550 °C at a scan rate of 10 °C/min. An 
empty aluminum pan was used as the reference. The loading capacities of fluorescein or DOX 
were determined by UV-Vis Spectroscopy (Cary 5000). The absorbance of the peaks at 477 nm 
(fluorescein) or 503 nm (DOX) was used for quantification, respectively. The release of fluorescein 
or DOX was measured by an Acton Spectra Pro 2300i CCD cooled with liquid nitrogen. 
Fluorescein or DOX were excited by a CUBE 445-40C laser (Coherent Inc.) at a wavelength of 
448 nm and a power of 4 mW (fluorescein) or 2 mW (DOX). 
3.2.3 Synthesis of magnetic MnFe2O4@CoFe2O4 nanoparticles 
Synthesis of 6.3 nm MnFe2O4 nanoparticles: MnFe2O4 nanoparticles were synthesized 
following a previously reported method with a slight modification.37,38 Two mmol of Fe(acac)3, 1 
mmol of Mn(acac)2, 10 mmol of 1,2-dodecanediol, 6 mmol of oleic acid, and 6 mmol of oleylamine 
were dissolved in 20 mL of benzyl ether in a three-neck flask. The reaction was heated to 200 °C 
under the flow of nitrogen with vigorously stirring and kept at that temperature for 1 h. The reaction 
mixture was then heated up and refluxed for 1 h (298 °C). Afterwards, the resulting solution 
containing MnFe2O4 nanoparticles was cooled to room temperature. The nanoparticles were 
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precipitated by adding 40 mL of ethanol and further separated by centrifugation (7830 rpm, 10 
min). Finally, MnFe2O4 nanoparticles were dispersed in 10 mL of hexane with 50 µL of oleic acid 
and 50 µL of oleylamine. 
 Synthesis of 8.2 nm MnFe2O4 nanoparticles: The larger MnFe2O4 nanoparticles were 
synthesized by growing MnFe2O4 on the MnFe2O4 nanoparticles prepared previously. Generally, 
two mmol of Fe(acac)3, 1 mmol of Mn(acac)2, 10 mmol of 1,2-dodecanediol, 2 mmol of oleic acid, 
and 2 mmol of oleylamine were dissolved in 20 mL of benzyl ether in a 100 mL three-neck flask. 
The MnFe2O4 nanoparticles (90 mg) obtained previously in 10 mL of hexane were added to the 
reaction mixture. The reaction mixture was heated to 90 °C and kept at that temperature for 30 min 
to remove hexane. Then the reaction mixture was heated to 200 °C under the flow of nitrogen with 
vigorously stirring. After 1 h, the reaction mixture was heated to 298 °C and refluxed for 1 h. The 
nanoparticles were precipitated by adding 40 mL of ethanol and further separated by centrifugation. 
Finally, the MnFe2O4 nanoparticles were re-dispersed in 10 mL of hexane with 50 µL of oleic acid 
and 50 µL of oleylamine. 
 Synthesis of 10.1 nm MnFe2O4@CoFe2O4 nanoparticles: To coat CoFe2O4 on the surface of 
MnFe2O4 nanoparticles, two mmol of Fe(acac)3, 1 mmol of Co(acac)2, 10 mmol of 1,2-
dodecanediol, 2 mmol of oleic acid, and 2 mmol of oleylamine were dissolved in 20 mL of benzyl 
ether in a 100 mL three-neck flask. MnFe2O4 (8.2 nm) nanoparticles (180 mg) obtained previously 
in 10 mL of hexane were added to the reaction mixture. The synthetic procedure and reaction 
temperature were the same as that of the 8.2 nm MnFe2O4 nanoparticles synthesis. Finally, 
MnFe2O4@CoFe2O4 nanoparticles (10.1 nm) were re-dispersed in 10 mL of hexane with 50 µL of 
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oleic acid and 50 µL of oleylamine. 
Synthesis of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles: To coat CoFe2O4 on the surface of 
MnFe2O4@CoFe2O4 (10.1 nm) nanoparticles to obtain the larger nanoparticles, two mmol of 
Fe(acac)3, 1 mmol of Co(acac)2, 10 mmol of 1,2-dodecanediol, 2 mmol of oleic acid, and 2 mmol 
of oleylamine were dissolved in 20 mL of benzyl ether in a 100 mL three-neck flask. 
MnFe2O4@CoFe2O4 (10.1 nm) nanoparticles (270 mg) obtained previously in 10 mL of hexane 
were added to the reaction mixture. The synthetic procedure and reaction temperature were the 
same as that of 10.1 nm MnFe2O4@CoFe2O4 nanoparticle synthesis. Finally, MnFe2O4@CoFe2O4 
nanoparticles (11.4 nm) were re-dispersed in 10 mL of hexane with 50 µL of oleic acid and 50 µL 
of oleylamine for further use. 
3.2.4 Measurement of specific loss power 
 Measurement of the heat generation from 11.4 nm MnFe2O4@CoFe2O4 nanoparticles was 
performed using a magnetic hyperthermia system (MSI Automation, Inc.) The diameter of the 
five-turn copper coil was 50 mm. The alternating frequency, induction power, and magnetic field 
strength were 375 kHz, 5 kW, and 20 kAm-1, respectively. The MnFe2O4@CoFe2O4 nanoparticles 
were dispersed in toluene in a 2 mL of glass sample vial and the concentrations were 2.5, 1, or 0.5 
mg/mL. The temperature of the solution was recorded after the exposure to the AMF as a function 
of time. The specific loss power of MnFe2O4@CoFe2O4 was calculated using equation (1), where 
C is the volumetric heat capacity of solvent, Vs is the sample volume, m is the mass of 
MnFe2O4@CoFe2O4, and dT/dt is the initial slope of the time-dependent temperature increase 
curve. 
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                       Specific loss power	= CVs
m
dT
dt
    (1) 
3.2.5 Synthesis of APTS-functionalized MnFe2O4@CoFe2O4@mesoporous silica 
(Mag@MSNs-APTS) core@shell nanoparticles 
MnFe2O4@CoFe2O4 nanoparticles (11.4 nm, 2.5 mg) were dispersed in 0.2 mL of chloroform. 
2 mL of CTAB aqueous solution (40 mg of CTAB, 54 mM) was added to the MnFe2O4@CoFe2O4 
colloidal solution, and the mixture was sonicated for 10 min with a fully sealed cover to generate 
oil-in-water emulsion. The emulsion was then sonicated for 1 h to evaporate chloroform. The clear 
well-dispersed MnFe2O4@CoFe2O4 colloidal aqueous solution (2 mL) was obtained and 
designated as MnFe2O4@CoFe2O4@CTAB. Meanwhile, 40 mg of CTAB was dissolved in 18 mL 
of water with 120 µL of NaOH solution (2 M) in a 100 mL flask. Then, the previous 2 mL of 
MnFe2O4@CoFe2O4@CTAB colloidal solution was added to the reaction solution with vigorously 
stirring, and the temperature of the solution was brought up to 70 °C. To coat mesoporous silica 
shell on the surface of MnFe2O4@CoFe2O4@CTAB, 200 µL of TEOS and 1.2 mL of ethyl acetate 
were added dropwise into the solution. After stirring for 2 h, 40 µL of APTS was added dropwise 
into the solution and stirred for another 2 h to generate amine functionalized 
MnFe2O4@CoFe2O4@MSNs (Mag@MSNs-APTS, Mag denotes magnetic). Afterwards, the 
solution was cooled to room temperature and Mag@MSNs-APTS was centrifuged and washed 3 
times with ethanol. Subsequently, Mag@MSNs-APTS was dispersed in 20 mL of ethanol 
containing 120 mg of NH4NO3 and the reaction was stirred at 60 °C for 1 h to remove the 
surfactants. The surfactant removal procedures were repeated twice and Mag@MSNs-APTS was 
washed several times with D.I. water and ethanol to obtain the surfactant-free Mag@MSNs-APTS. 
3.2.6 Synthesis of ACVA functionalized Mag@MSNs-APTS (Mag@MSNs-ACVA) 
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The conjugation of 4,4′-azobis(4-cyanovaleric acid) (ACVA) on the surface of Mag@MSNs-
APTS was carried out by using an amide bond coupling reaction. At first, the carboxylic acid of 
ACVA (20 mg) was activated by 40 mg of EDC and 20 mg of NHS in 4 mL of DMSO. To crosslink 
the activated ACVA to the primary amine of APTS, after 30 min activation at room temperature, 
20 mg of Mag@MSNs-APTS dispersed in 4 mL of DMSO were added dropwise to the activated 
ACVA in DMSO and stirred for 24 h. The ACVA functionalized Mag@MSNs-APTS 
(Mag@MSNs-ACVA) was washed, centrifuged, and re-suspended in DMSO 3 times to remove 
the excess ACVA, EDC, and NHS. 
3.2.7 Synthesis of AMA functionalized Mag@MSNs-ACVA (Mag@MSNs-AMA) 
The conjugation of 1-adamantylamine (AMA) on the surface of Mag@MSNs-ACVA was 
carried out through amide bond formation between the carboxylic acid group of ACVA and the 
primary amine of AMA. Typically, the carboxylic acid groups of Mag@MSNs-ACVA (20 mg) 
were activated by 40 mg of EDC and 20 mg of NHS in 4 mL of DMSO. To crosslink ACVA to 
AMA, after 30 min activation at room temperature, 20 mg of AMA dissolved in 4 mL of DMSO 
was added to the activated Mag@MSNs-ACVA in DMSO and stirred for 24 h. Finally, AMA 
functionalized Mag@MSNs-ACVA (Mag@MSNs-AMA) was washed, centrifuged, and re-
suspended in DMSO 3 times to remove the excess AMA, EDC, and NHS. 
3.2.8 Loading of fluorescein or DOX in Mag@MSNs-AMA and snap-top attachment 
(Mag@MSNs-AMA-CD) 
The loading of fluorescein or DOX was carried out by using water as the solvent. In general, 
1 mg of Mag@MSNs-AMA was dispersed in 1 mL of D.I. water with 3 mM fluorescein or 2.6 
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mM DOX. After stirring for 24 h, 16 mg of the β-CD capping agent was added to the solution to 
prevent fluorescein or DOX from being released. The sample was designated as Mag@MSNs-
AMA-CD. After mixing for 48 h, the fluorescein or DOX-loaded Mag@MSNs-AMA-CD was 
centrifuged and washed with water 5 times (fluorescein) or with water 7 times followed by PBS 2 
times (DOX) to remove the free fluorescein or DOX molecules. The final product was suspended 
in 2 mL of D.I. water for the water bath heating or magnetic heating triggered release experiments. 
3.2.9 Triggered release of fluorescein from Mag@MSNs-AMA-CD by water bath heating 
0.5 mg of fluorescein loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water in an 
Eppendorf tube. Water baths at 37, 60, or 80 °C were prepared. The samples were heated in the 37, 
60, or 80 °C water baths for 10 min per heating cycle (heating on = 10 min). After each heating 
cycle, the solution was centrifuged and 20 µL of supernatant was collected and diluted. The 
released fluorescein molecules were then monitored by fluorescence spectroscopy, followed by 
another heating cycle. The time period between each heating cycle was 10 min (heating off = 10 
min). In total, 9 such heating/monitoring cycles were performed for the samples in both the 37 °C 
and the 60 °C water baths; 4 such heating/monitoring cycles were performed for the sample in the 
80 °C water bath. For comparison, the supernatant of the sample in the air at room temperature (23 
°C) was collected and the released fluorescein was monitored at the same time with the samples 
heated in water baths. The intensity of the fluorescein released from Mag@MSNs-AMA-CD was 
integrated from 510 nm to 520 nm. 
3.2.10 Triggered release of fluorescein or DOX from Mag@MSNs-AMA-CD by single cycle 
of magnetic heating  
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0.5 mg of fluorescein or DOX-loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water 
in an Eppendorf tube. Before being triggered by magnetic heating, the fluorescein or DOX loaded 
nanoparticle solution at room temperature was centrifuged and 20 µL of supernatant was collected 
every 20 min (fluorescein) or 30 min (DOX) and measured by fluorescence spectroscopy. After 
monitoring the release every 20 min over a period of 40 min (fluorescein) or every 30 min over a 
period of 60 min (DOX) at room temperature, the sample was exposed to an alternating magnetic 
field (AMF) in the center of a water-cooled five-turn copper coil (5 cm height and diameter) at a 
power of 5 kW and a frequency of 375 kHz for 1, 2, 3, 5, and 10 min, respectively, followed by 
monitoring the release of fluorescein or DOX. After that, several monitoring cycles were 
performed every 10 min (fluorescein), or every 30 min over a period of 180 min followed by every 
2 h over a period of 6 h (DOX) until the release of fluorescein or DOX leveled off. The intensities 
of the fluorescein or DOX released from Mag@MSNs-AMA-CD was integrated from 510 nm to 
520 nm or 580 nm to 605 nm, respectively. 
3.2.11 Triggered release of fluorescein from Mag@MSNs-AMA-CD by sequential cycles of 
magnetic heating  
0.5 mg of fluorescein loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water in an 
Eppendorf tube. Before being triggered by magnetic heating, the fluorescein loaded nanoparticle 
solution at room temperature was centrifuged and 20 µL of supernatant was collected every 10 
min and measured by fluorescence spectroscopy. After monitoring the release every 10 min over 
a period of 30 min at room temperature, the sample was exposed to an AMF in the center of a 
water-cooled five-turn copper coil (5 cm height and diameter) at a power of 5 kW and a frequency 
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of 375 kHz for 3 min, followed by monitoring the release of fluorescein. Several monitoring cycles 
were performed every 10 min until the release of fluorescein leveled off, followed by another AMF 
heating for 3 min. In total, 3 such heating/monitoring series were performed to achieve the 
maximum release of fluorescein. The intensity of the fluorescein released from Mag@MSNs-
AMA-CD was integrated from 510 nm to 520 nm. 
3.2.12 Zeta potential value measurement of Mag@MSNs-ACVA after bulk or magnetic 
heating 
 0.5 mg of Mag@MSNs-ACVA was dispersed in 1 mL of water in an Eppendorf tube. For 
bulk heating treatment, the Eppendorf tubes containing the samples were put in a hot water bath 
at 37, 60, or 80 °C for 10 min. Afterwards, the solution was centrifuged and the nanoparticles were 
washed and redispersed in D.I. water. For magnetic heating treatment, the Eppendorf tube 
containing the sample was exposed to an AMF at a power of 5 kW and a frequency of 375 kHz for 
10 min. Similarly, after the treatment, the solution was centrifuged and the nanoparticles were 
washed and redispersed in D.I. water. The zeta potential values of the samples after bulk heating 
or magnetic heating treatment were measured. 
3.2.13 Loading capacity analysis of fluorescein or DOX 
 After loaded with 3 mM fluorescein or 2.6 mM DOX and capped with β-CD, Mag@MSNs-
AMA-CD were washed with water 5 times (fluorescein) or washed with water 7 times followed 
by PBS 2 times (DOX). The supernatants collected during each washing step were collected and 
their absorption spectra were measured by UV-Vis spectroscopy. To calculate the amount of 
fluorescein or DOX loaded in Mag@MSNs-AMA-CD, the amount of fluorescein or DOX 
removed during all the washing steps was subtracted from the total amount of fluorescein or DOX 
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in the initial loading solution. The loading capacities of fluorescein or DOX were calculated using 
the maximum absorbance at 491 nm (fluorescein) or 503 nm (DOX) and the following definition 
of loading capacity: (mass of loaded fluorescein or DOX / mass of particles) x 100%.  
3.2.14 Release efficiency analysis of fluorescein or DOX 
To determine the release efficiency of fluorescein, 0.5 mg of fluorescein or DOX-loaded 
Mag@MSNs-AMA-CD in 1 mL of water was put in a hot water bath at 90 °C. The fluorescein or 
DOX released from the nanoparticles was separated from the nanoparticles by centrifugation and 
recorded by spectrophotometry. The intensities of the fluorescein or DOX released from 
Mag@MSNs-AMA-CD were integrated from 510 nm to 520 nm or 580 nm to 605 nm, respectively. 
The fluorescence intensities corresponding to the fluorescein or DOX released after being heated 
at 90 °C for 50 min was set as the 100% release. The release efficiencies of fluorescein or DOX is 
defined as (mass of released cargo/mass of loaded cargo) x 100%. 
3.2.15 Cell culture 
 Human pancreatic cancer cells (PANC-1) were cultured in T-75 flasks (Corning) with vented 
caps in a high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS), and 1 % antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) 
in a humidity-controlled incubator at 37 °C with 5 % CO2. In all culture conditions, the PANC-1 
culture media were daily changed and the cells were harvested by trypsinization with 0.05 % 
trypsin-ethylenediaminetetraacetic acid (EDTA) for passaging every 2-3 days. 
3.2.16 In vitro cytotoxicity 
 The viabilities of PANC-1 after the treatment of Mag@MSNs-AMA-CD and DOX-loaded 
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Mag@MSNs-AMA-CD were examined by using a cell counting kit-8 (CCK-8) assay. The cells 
were seeded in 96-well plates at a density of 5 x 103 cells per well in 200 µL of Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS and 1% antibiotics in a humidity-
controlled incubator at 37 °C for 24 h attachment. After the attachment, the medium was removed 
and the cells were incubated in 200 µL of fresh DMEM containing 0, 2, 5, 10, 15, 20, and 40 µg 
of Mag@MSNs-AMA-CD (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) for 20 or 70 h in an 
incubator at 37 °C. After incubation, the medium was removed and the treated cells were washed 
twice with DPBS. To measure the cell viability, 100 µL of DMEM and 10 µL of CCK-8 cellular 
cytotoxicity reagent were added to each well. Then, the plates were put in the incubator for 2 h at 
37 °C. To measure the number of the viable cells in each condition, a plate reader (Tecan M1000) 
was used to measure the absorbance at 450 nm and 650 nm (as the reference). The DMEM medium 
(100 µL) mixed with CCK-8 reagent (10 µL) served as a background control. 
3.2.17 In vitro drug delivery triggered by an AMF and cellular cytotoxicity 
 PANC-1 cells were seeded in 8-well chamber slides at a density of 2.5 x 104 cells per well in 
500 µL of DMEM supplemented with 10% FBS and 1% antibiotics in a humidity-controlled 
incubator at 37 °C for 24 h attachment. After the attachment, the medium was removed and the 
cells were incubated in 300 µL of fresh DMEM containing 15 µg of DOX-loaded Mag@MSNs-
AMA-CD (50 µg/mL) for 4 h in an incubator at 37 °C. The control groups including cells not 
treated by nanoparticles and those treated with Mag@MSNs-AMA-CD (50 µg/mL) without DOX 
were also investigated. After 4 h incubation, the medium was removed and the treated cells were 
washed twice with DPBS (500 µL x 2).  
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The chamber slides containing the treated or untreated PANC-1 cells in 500 µL of medium 
were exposed to an AMF in the center of a water-cooled five-turn copper coil at a power of 5 kW 
and a frequency of 375 kHz for 2, 5, and 10 min, respectively. After the AMF treatment, the cells 
were further incubated in an incubator at 37 °C for 12 h. To measure the cell viability after the 
treatment, the medium was removed and 200 µL of DMEM and 20 µL of CCK-8 reagent were 
added to each well. Afterwards, the chamber slides were put in the incubator for 2 h at 37 °C. 
Finally, 100 µL of the reaction solution was transferred to a 96-well plate and the viability was 
measured by a plate reader described above. 
3.2.18 Fluorescence microscope images of PANC-1 cells after treatment 
PANC-1 cells were seeded in 8-well chamber slides at a density of 2.5 x 104 cells per well in 
500 µL of DMEM supplemented with 10% FBS and 1% antibiotics in a humidity-controlled 
incubator at 37 °C for 24 h attachment. After the attachment, the medium was removed and the 
cells were incubated in 300 µL of fresh DMEM containing 15 µg of DOX-loaded Mag@MSNs-
AMA-CD (50 µg/mL) for 4 h in an incubator at 37 °C followed by washing with DPBS 2 times 
(500 µL x 2). The control group including cells not treated by nanoparticles was also investigated. 
After the washing, the chamber slides containing the treated or untreated PANC-1 cells in 500 µL 
of medium were exposed to an AMF in the center of a water-cooled five-turn copper coil at a 
power of 5 kW and a frequency of 375 kHz for 10 min. After the AMF treatment, the cells were 
further incubated in an incubator at 37 °C for 12 h followed by washing with DPBS 3 times (500 
µL x 3) and fixed with 4 % paraformaldehyde in PBS for 20 min. Then, the fixed cells were washed 
with DPBS 3 times (500 µL x 3) with slightly shake. Afterwards, the nuclei of the cells were 
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stained with Hoechst 33342 (500 µL, 5 µg/mL) for 20 min followed by washing with DPBS 5 
times (500 µL x 5). Finally, the stained cells covered by mounting medium cover glass before 
being visualized under a Zeiss fluorescence microscope. 
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3.3. Results and discussion 
3.3.1 Synthesis and characterization of MnFe2O4@CoFe2O4 nanoparticles 
To achieve superior magnetic heating efficacy, we synthesized MnFe2O4@CoFe2O4 
nanoparticles with a magnetically soft MnFe2O4 core, and a magnetically hard CoFe2O4 shell using 
a seed-mediated method (Figure 3.1a).39 First, 6.3 nm MnFe2O4 nanoparticles were synthesized by 
a thermal decomposition method.37,38,80 The larger MnFe2O4 nanoparticles (8.2 nm) were then 
obtained by using the synthesized 6.3 nm MnFe2O4 nanoparticles as the seeds. Next, the CoFe2O4 
shell layer was grown on the surface of the synthesized 8.2 nm MnFe2O4 nanoparticles to form 
10.1 or 11.4 nm MnFe2O4@CoFe2O4 nanoparticles (Figure 3.1bc). Both the MnFe2O4 (6.3 and 8.2 
nm) and the MnFe2O4@CoFe2O4 (10.1 and 11.4 nm) nanoparticles have uniform size distributions 
as measured by transmission electron microscopy (TEM) (Figure 3.1bc and Figure 3.2ab). From 
the corresponding diffraction peaks in high angle X-ray diffraction patterns (Figure 3.3), the 11.4 
nm core@shell MnFe2O4@CoFe2O4 nanoparticles possess the typical spinel structure.81  
To quantify field dependent magnetization of MnFe2O4@CoFe2O4 at 300 K, a superconducting 
quantum interference device (SQUID) was used. The saturated magnetization of 11.4 nm 
MnFe2O4@CoFe2O4 is 105 emu/g (Figure 3.2c), higher than that of Fe3O4 nanoparticles (80 
emu/g).82 The higher magnetization of the MnFe2O4@CoFe2O4 produces a greater magnetic 
heating efficiency compared with Fe3O4 under an AMF (vide infra). The tiny hysteresis loop 
(Figure 3.2c) shows almost no coercive force which validates the superparamagnetic property of 
MnFe2O4@CoFe2O4 nanoparticles. 
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Figure 3.1. (a) Schematic illustration of the synthesis of MnFe2O4@CoFe2O4 nanoparticles by a seed-
mediated thermal decomposition method. (b) Corresponding TEM images and (b) diameter distributions of 
MnFe2O4 and MnFe2O4@CoFe2O4 nanoparticles after each step. 
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Figure 3.2. (a) TEM image and (b) size distribution of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles. Inset 
shows the schematic illustration of magnetic core@shell MnFe2O4@CoFe2O4 structure. (c) Field dependent 
magnetization curve of MnFe2O4@CoFe2O4 nanoparticles at 300 K. Inset shows small scale of field 
dependent magnetization curves and MnFe2O4@CoFe2O4 nanoparticles in hexane were attracted by a 
magnet. (d) Time- and concentration-dependent temperature increase profiles of toluene solution containing 
MnFe2O4@CoFe2O4 nanoparticles triggered by an AMF. 
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Figure 3.3. High angle X-ray diffraction pattern of MnFe2O4@CoFe2O4 nanoparticles. 
 
 
To further confirm the nanoparticle identity, both Fourier transform-infrared (FT-IR) 
spectroscopy and thermogravimetric analysis (TGA) were conducted. In the FT-IR spectrum 
(Figure 3.4a), the three peaks at 2851, 2921, and 2955 cm-1 arise from the CH2 symmetric and 
antisymmetric stretches in oleic acid and oleylamine and confirm that the surface of 
MnFe2O4@CoFe2O4 nanoparticles is covered with oleic acid and oleylamine. The TGA results 
show that the amount of oleic acid and oleylamine on the surface of MnFe2O4@CoFe2O4 
nanoparticles is 13 wt% (Figure 3.4b). Due to the abundant capping agents with long hydrocarbon 
chains, the MnFe2O4@CoFe2O4 nanoparticles can be well suspended in hexane (Figure 3.2c). 
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Figure 3.4. (a) Fourier-transform Infrared (FTIR) spectrum and (b) thermogravimetric analysis (TGA) of 
MnFe2O4@CoFe2O4 nanoparticles. 
  
(a)
2851 cm-1
2921 cm-1
2955 cm-1
13 %
(b)
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To investigate the heat generation efficiency of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles, 
the specific loss power (SLP) was quantified. The SLP of MnFe2O4@CoFe2O4 was calculated 
using equation (1), where C is the volumetric heat capacity of solvent, Vs is the sample volume, m 
is the mass of MnFe2O4@CoFe2O4, and dT/dt is the initial slope of the time-dependent temperature 
increase curve. 
Specific loss power = CVs
m
dT
dt
     (1) 
MnFe2O4@CoFe2O4 nanoparticles were dispersed in toluene and an AMF (375 kHz, 5kW) was 
applied for heat generation. Time- and concentration-dependent temperature increase profiles 
(Figure 3.2d) show that the solution temperature abruptly increased upon the application of AMF 
trigger. The temperature of the toluene solution containing nanoparticles finally achieved 44, 55, 
and 67 °C after 6 min magnetic actuation at the concentrations of MnFe2O4@CoFe2O4 are 0.5, 1, 
and 2.5 mg/mL, respectively. The SLP of the MnFe2O4@CoFe2O4 nanoparticles was calculated to 
be 1510.8 W/g (equation 2), 5 times higher than that of 20 nm Fe3O4 nanoparticles (302.2 W/g) 
(equation 3).83 This superior heating performance of MnFe2O4@CoFe2O4 nanoparticles under the 
AMF shows its potential of serving as an efficacious heat source for thermal-triggered drug release. 
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For MnFe2O4@CoFe2O4: 
Specific loss power = CVs
m
dT
dt
  (1) 
= 
1.5108 "J mL-1K-1# × 1 (mL)
1 × 10-3 (g)  × 1 (K)1 (s)  
=1510.8 Wg     (Fe+Mn+Co)
-1      (2) 
        
For Fe3O4: 
Specific loss power = CVs
m
dT
dt
  (1) 
= 
1.5108 "J mL-1K-1# × 1 (mL)
1 × 10-3 (g)  × 1 (K)5 (s)  
=302.2 Wg     (Fe)
-1      (3) 
 
3.3.2 Synthesis and characterization of Mag@MSNs-APTS core@shell nanoparticles 
To construct nanoparticles with cargo-carrying capability, we synthesized nanoparticles with a 
mesoporous silica shell around the superparamagnetic core. The coating was achieved by 
hydrolysis and condensation of tetraethyl orthosilicate (TEOS) in the presence of 
hexadecyltrimethylammonium bromide (CTAB) surfactant templates in basic solution.84 The 
resulting nanoparticles are designated as Mag@MSNs (Mag denotes magnetic 
MnFe2O4@CoFe2O4 and MSNs denotes mesoporous silica nanoparticles). 
In order to attach thermal sensitive caps, the surface of the mesoporous silica shell was 
functionalized with amine groups by hydrolysis and condensation reactions of 3-
(aminopropyl)triethoxysilane (APTS). The modified nanoparticles are designated as 
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Mag@MSNs-APTS. By using TEM, the average diameter of Mag@MSNs-APTS core@shell 
nanoparticles is 55 nm and their shell thickness is 22 nm with obvious mesoporous structure 
(Figure 3.5a and Figure 3.6). From the dynamic light scattering (DLS) diameter distribution 
(Figure 3.7), the average diameter of Mag@MSNs-APTS is 105.6 nm at room temperature, 
showing that the nanoparticles are well dispersed in water. 
 
 
Figure 3.5. (a) TEM image of APTS functionalized core@shell nanoparticles (Mag@MSNs-APTS). (b) 
Nitrogen adsorption/desorption isotherms of Mag@MSNs-APTS at 77 K. The BET surface area and pore 
volume are 653.4 m2/g, and 1.06 cm3/g, respectively. Inset shows the pore diameter distribution of 
Mag@MSNs-APTS. The average pore diameter is 2.8 nm. 
 
 
N2 adsorption-desorption isotherms and pore diameter distribution were used to further 
characterize the pores of Mag@MSNs-APTS core@shell nanoparticles. The Brunauer-Emmett-
Teller (BET) surface area, Barrett-Joyner-Halenda (BJH) average pore diameter, and total pore 
volume of Mag@MSNs-APTS are 653.4 m2/g, 2.8 nm, and 1.06 cm3/g, respectively (Figure 3.5b). 
In addition, the high surface area and pore volume of Mag@MSNs-APTS – the desired properties 
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of MSNs – suggest that cargos such as small molecules can be loaded inside the pores of 
Mag@MSNs-APTS (vide infra), allowing those cargos to be efficiently carried and delivered by 
the nanoparticles. 
 
Figure 3.6. Size distribution of 55.0 nm Mag@MSNs-APTS core@shell nanoparticles. 
 
 
Figure 3.7. Dynamic light scattering diameter distribution of Mag@MSNs-APTS in deionized H2O at room 
temperature. 
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3.3.3 Synthesis and characterization of Mag@MSNs-APTS, Mag@MSNs-ACVA and 
Mag@MSNs-AMA core@shell nanoparticles 
 
 
Figure 3.8. (a) Zeta potential values, (b) Fourier transform infrared spectroscopy (FT-IR), and (c) 
thermogravimetric analysis (TGA) of Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and 
Mag@MSNs-AMA, respectively. (d) TEM image of Mag@MSNs-AMA. Inset shows the enlarged 
Mag@MSNs-AMA. (e) N2 adsorption/desorption isotherms of Mag@MSNs-AMA at 77 K. Inset shows 
the pore diameter distribution of Mag@MSNs-AMA. The BET surface area, pore volume, and average pore 
diameter are 593.5 m2/g, 0.96 cm3/g, and 2.8 nm, respectively. 
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Particles for magnetically stimulated release need not only cargo-carrying capability but also 
a stimulus-responsive capping mechanism. To introduce the latter functionality to the 
nanoparticles, the surface of the core@shell nanoparticles were conjugated with a thermolabile 
gatekeeper 4,4’-azobis(4-cyanovaleric acid) (ACVA).43,71 ACVA was chemically bonded to 
Mag@MSNs-APTS using 1-ethyl-3-(3-diethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) coupling agents.85 The carboxylic acid on ACVA formed an amide 
bond with the primary amine of APTS, and the resulting particles were designated as 
Mag@MSNs-ACVA (Scheme 3.1b). Subsequently, 1-adamantylamine (AMA) was conjugated on 
the surface of the nanoparticles through the same standard crosslinking method, with the terminal 
carboxylic acid of ACVA forming another amide bond with the primary amine of AMA. The 
nanoparticles modified with AMA were designated as Mag@MSNs-AMA (Scheme 3.1b).  
The successful attachment of APTS, ACVA, and AMA on the surface of Mag@MSNs was 
confirmed by zeta potential measurements, FT-IR, and TGA after each step. The zeta potential of 
Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and Mag@MSNs-AMA were measured 
in deionized water at room temperature (Figure 3.8a). The zeta potential value of Mag@MSNs-
APTS was +46.2 mV, much more positive than that of Mag@MSNs (-26.1 mV), showing abundant 
primary amines on the surface of Mag@MSNs-APTS. Mag@MSNs-ACVA has a negative zeta 
potential value of -21.0 mV. This significant decrease in the zeta potential value indicates that 
ACVA molecules with carboxylates on both ends were successfully attached to the surface of 
Mag@MSNs-APTS, with one end stretching out from the surface of Mag@MSNs-ACVA 
available for further AMA conjugation. Mag@MSNs-AMA with the nearly neutral zeta potential 
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value of -0.45 mV confirms the conjugation of the amine on AMA to the free carboxylate on the 
surface of Mag@MSNs-ACVA, leaving the uncharged functional group on AMA stretching out 
from the surface of the particles (Scheme 3.1b). 
FT-IR spectroscopy was used to characterize surface functional groups after each conjugation 
step (Figure 3.8b). The appearance of two bands in the IR spectrum of Mag@MSNs-APTS due to 
N-H stretching vibrations at ν = 3628 cm-1 and ν	=	3648 cm-1 shows the presence of primary 
amines attached to the surface of Mag@MSNs-APTS. The successful conjugation of ACVA to the 
surface of Mag@MSNs-APTS through secondary amide bond formation was confirmed by a new 
characteristic amide absorption (amide II) at ν	=	1550 cm-1. Additionally, a nitrile absorption 
appears at ν	= 2253 cm-1 (nitrile stretching) from ACVA also supports the successful conjugation 
of ACVA on the Mag@MSNs-APTS. This is also supported by newly emerging absorptions at 
ν = 1719 cm-1 (C=O stretching), ν	= 1451 cm-1 (C-H bending), and three absorption peaks at 
ν	= 2904 cm-1, 	ν	=	2934 cm-1, and 	ν	= 2981 cm-1 (C-H stretching) from ACVA. Finally, the 
conjugation of AMA on the surface of Mag@MSNs-ACVA is confirmed by the appearance of the 
absorption at ν	= 1474 cm-1 (C-H bending) from AMA.  
TGA was used to determine the weight of organic moieties on the particles (Figure 3.8c). The 
weight loss of Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and Mag@MSNs-AMA 
after heating to 550 °C in air were 6 %, 8 %, 11 %, and 13 %, respectively. The increase in weight 
loss after each conjugation indicates that the weight of APTS, ACVA, and AMA modified on the 
surface of core@shell nanoparticles were 2 %, 3 %, and 2 %, respectively. The results from zeta 
potential measurements, FT-IR, and TGA show that APTS, ACVA, and AMA were successfully 
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and sequentially attached on the surface of Mag@MSNs. 
To confirm that the morphology and mesoporous structure of core@shell nanoparticles 
remains intact after surface modification, we conducted TEM and N2 adsorption-desorption 
isotherms analysis of the core@shell nanoparticles after ACVA and AMA conjugation. By TEM, 
Mag@MSNs-AMA (Figure 3.8d) is 55 nm in size with obvious mesoporous structure, very similar 
to that of Mag@MSNs-APTS (Figure 3.5a), indicating that the particles were not damaged after 
the surface functionalization. The BET surface area, total pore volume, and BJH average pore 
diameter of Mag@MSNs-AMA are 593.5 m2/g, 0.96 cm3/g, and 2.8 nm, respectively (Figure 3.8e). 
Similar to Mag@MSNs-APTS (Figure 2b), Mag@MSNs-AMA preserves the characteristics of 
mesoporous structure – high surface area and large pore volume – enabling efficient loading and 
delivery of cargos. AMA and thermolabile ACVA are mainly attached to the outer surface rather 
than to the inner pore wall of the core@shell nanoparticles, as evidenced by the unchanged average 
pore diameter of Mag@MSNs-AMA and Mag@MSNs-APTS. Those thermal sensitive 
gatekeepers selectively bonded on the outer surface of the core@shell nanoparticles can effectively 
bind to β-cyclodextrin (β-CD) that blocks the pore openings to prevent cargos from leakage, and 
act as a thermal-sensitive switch to release the cargos on-demand. 
3.3.4 Thermal responsiveness of the gatekeeper and bulk heating-triggered cargo release  
To investigate the thermal responsiveness of the gatekeeper, we first demonstrated the cleavage 
of the gatekeeper triggered by increasing the temperature of the surrounding water. Sample tubes 
containing Mag@MSNs-ACVA dispersed in deionized water (0.5 mg/mL) were placed for 10 min 
in the hot water baths heated by a hot plate set at 37 °C, 60 °C, and 80 °C (called bulk heating)  
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Figure 3.9. (a) The cleavage of C-N bonds caused by bulk heating for 10 min. (b) Zeta potential values of 
Mag@MSNs-ACVA after 10 min of bulk heating in D.I. water. The concentration of Mag@MSNs-ACVA 
in D.I. water is 0.5 mg/mL. (c) The release of fluorescein from Mag@MSN- caused by bulk heating trigger 
in water bath at 37 °C, 60 °C, or 80 °C. The sample stayed at room temperature (23 °C) was also recorded 
as a control. (d) Release efficiency of fluorescein from Mag@MSNs- after the bulk heating at 23 °C, 37 °C, 
60 °C, or 80 °C trigger for 10 min (N = 3). 
 
(Figure 3.9c). The cleavage of C-N bonds of ACVA was confirmed by the zeta potential 
measurement. After Mag@MSNs-ACVA was heated at 37 °C, 60 °C, and 80 °C for 10 min, the 
zeta potential values were -20.0 mV, -6.7 mV, and 0.3 mV, respectively (Figure 3.9ab). The sample 
heated at 37 °C shows very similar zeta potential value compared to that of the control without 
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heating (-21.0 mV), showing that the gatekeepers were stable at physiological temperature and the 
C-N bonds were intact. However, when the temperature increased, the C-N bonds were cleaved, 
producing fragments of 4-cyanopentanoic acid and nitrogen (Figure 3.9a). The removal of the 
carboxylate group after cleavage explains why the zeta potential becomes increasing after heating. 
The bulk heating-triggered cargo release was studied using fluorescein as a model molecule 
due to its stability and size similar to that of many anticancer drugs (1.5 nm), e.g., doxorubicin or 
paclitaxel. Fluorescein molecules were loaded in Mag@MSNs-AMA by soaking the particles in 3 
mM of the fluorescein solution for 24 h. To trap fluorescein in the pores of core@shell 
nanoparticles, the pores were capped by bulky β-CD, which strongly binds to AMA on the surface 
of the nanoparticles and forms a non-covalent supramolecular bond with adamantane.72,73,86 The 
particles capped by β-CD were designated as Mag@MSNs-AMA-CD. Fluorescein loaded 
Mag@MSNs-AMA-CD were washed thoroughly with deionized water to remove the untrapped 
fluorescein molecules.  
To trigger the release of fluorescein, the bulk heating was performed in hot water baths at 
various temperatures according to the following procedure (Figure 3.9c). Sample tubes containing 
fluorescein loaded Mag@MSNs-AMA-CD dispersed in deionized water (0.5 mg/mL) were placed 
in water baths set at 37 °C, 60 °C, and 80 °C for 10 min. To monitor the fluorescein released from 
Mag@MSNs-AMA-CD, the samples after heating were spun down and aliquots of the 
supernatants were collected for fluorescence measurements. An unheated sample at room 
temperature (23 °C) served as the control. The release efficiency is defined as (mass of released 
fluorescein/mass of loaded fluorescein) x 100 %. Only slight release (less than 3%) of fluorescein  
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Figure 3.10. Time dependent release efficiency of fluorescein from Mag@MSN- caused by bulk heating 
trigger in water bath at 37 °C, 60 °C, and 80 °C. The sample stayed at room temperature (23 °C) was also 
recorded as a control. 
 
from Mag@MSNs-AMA-CD at 23 °C and 37 °C after 10 min heating was observed (Figure 3.9d), 
indicating that the CD cap blocked the pore opening of the particles tightly and minimized 
premature leakage. The release efficiency of fluorescein strongly increased to 39 % upon heating 
at 60 °C for 10 min. When the samples were heated in a hot water bath at a higher temperature (80 
°C), more than half (55 % release efficiency) of the fluorescein was released after 10 min heating. 
In addition, after 3 cycles of 10 min heating at 80 °C, almost all fluorescein (near 100 % release 
efficiency) was released after 3 cycles of 10 min heating (Figure 3.10). To determine the long-term 
release profile of fluorescein, the samples heated at 37 °C, 60 °C, and 80 °C were performed with 
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9, 9, and 4 such heating/monitoring cycles. The time period between each heating cycle is also 10 
min. The cumulative release of fluorescein gradually increased with heating time and finally 
reached 78 % after 9 cycles of 10 min heating at 60 °C (Figure 3.10). On the contrary, the release 
efficiency of fluorescein after 9 cycles of 10 min heating at 37 °C is only 24 %, which is much 
lower than that from 60 °C heating, and is close to the control group at 23 °C (19 %). This implies 
that the CD cap was constructed successfully on the surface of the Mag@MSNs so that little 
premature leakage was observed either at room temperature or physiological temperature. Most 
importantly, the cargo release amount and cargo releasing rate can be controlled simply by tuning 
the temperature of the water bath. 
3.3.5 Alternating magnetic field-triggered cargo release 
 Two types of release studies were conducted by using another heat source – an alternating 
magnetic field (AMF) – which can induce localized heating (here called magnetic heating): (a) a 
single exposure to AMF for different lengths of time, and (b) multiple sequential exposures each 
for the same length of time. Fluorescein loaded Mag@MSNs-AMA-CD particles were dispersed 
in deionized water (0.5 mg/mL) at room temperature. To confirm the tightness of the gatekeeper, 
release of fluorescein before triggering with magnetic heating was monitored by spinning down 
the nanoparticles and collecting aliquots of the supernatants for fluorescence measurements. After 
monitoring the release every 20 min over a period of 40 min at room temperature, the sample was 
placed in a water-cooled five-turn copper coil generating an AMF at a power of 5 kW and a 
frequency of 375 kHz (Figure 3.11a). Exposure times were 1, 2, 3, 5, or 10 min, followed again by 
monitoring the release. To have enough time for dye to diffuse out from the pores, monitoring  
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Figure 3.11. (a) Dose control of cargo release from Mag@MSNs- by adjusting the AMF “ON” time. Time-
dependent release profile of fluorescein from Mag@MSNs- through magnetic actuation under AMF for (b) 
1, (c) 2, (d) 3, (e) 5, and (f) 10 min, respectively. (g) The release efficiency of fluorescein at plateau and the 
solution temperature after the various time periods of trigger under AMF (N = 3). 
 
cycles were performed every 10 min at room temperature until the maximum release of fluorescein 
was achieved. Only slight leakage (less than 5 %) of fluorescein was observed in the first 40 min 
at room temperature before exposure to an AMF, showing the effectiveness of the gatekeeper to 
prevent premature leakage of the dye (Figure 3.11b-f). The release efficiency of fluorescein was 
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10 % immediately after 1 min of the AMF trigger, showing that some caps were successfully 
removed by the magnetic heating. The amount of released fluorescein gradually increased over 
time at room temperature until it leveled off (total release efficiency of 23.6 %) at 70 min post-
AMF trigger (Figure 3.11b). After the caps are removed, it takes time for fluorescein molecules to 
diffuse out from the pores of nanoparticles and reach equilibrium at the end. To correlate the release 
efficiency of fluorescein with the AMF trigger exposure time, the samples were exposed to the 
AMF for longer actuation times of 2, 3, 5, and 10 min. Similar time-dependent release profiles 
were observed in all cases: (i) the burst of release during magnetic heating, (ii) the gradual increase 
in the release at room temperature, and (iii) the plateau reached 80 min post-AMF trigger (Figure 
3.11b-f). Even though the initial rise in release during the burst stage (i) was not obviously 
increased as a function of the longer magnetic heating time, the cumulative release efficiencies of 
fluorescein at plateau were significantly enhanced, reaching 41.9 %, 56.5 %, 65.3 %, and 75.9 % 
with 2, 3, 5, and 10 min of heating time, respectively. This suggested that the number of caps 
removed from the surface of nanoparticles is directly correlated with the AMF trigger time.  
To know whether the removal of the cap is a result of localized internal heating from the 
magnetic core under the AMF or an increase in the ambient temperature, we simultaneously 
monitored the temperature of the solution containing Mag@MSNs-AMA-CD immediately after 1, 
2, 3, 5, and 10 min of AMF actuation. Less than 6 degrees of temperature increase was observed, 
where the temperatures were found to be 24, 24, 26, 27, and 29 °C after 1, 2, 3, 5, and 10 min of 
AMF actuation (Figure 3.11g), respectively. Even the highest temperature of the solution after 
exposing to AMF was below 30 °C, indicating that the release of fluorescein was not triggered by 
 123 
bulk heating from the surrounding solution. Instead, the fairly high local temperature (that can be 
above 65 °C)83 achieved internally from the magnetic core was the main heat source to cleave the 
thermolabile ACVA, which will undergo thermolysis over 60 °C.17,71  
 
 
 
Figure 3.12. TEM images of fluorescein-loaded Mag@MSN-AMA-CD after 10 min exposure of the AMF 
trigger. 
 
To confirm that the mesoporous structure of silica particles can withstand the temperature of 
localized magnetic heating, the structure of Mag@MSNs-AMA-CD after 10 min of the AMF 
actuation was analyzed by TEM. The TEM image (Figure 3.12) shows that the mesoporous silica 
structure was intact without any damage and the diameters of the particles didn’t change after 
exposing to the internal heating from the inner magnetic core. The cleavage of the C-N bonds was 
supported by the change in the zeta potential of the Mag@MSN-ACVA particle from -21.0 mV 
before exposure to -1.8 mV after 10 min of exposure (Figure 3.13). The results confirm that the 
release of fluorescein molecules from Mag@MSNs-AMA-CD is through the removal of the 
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thermal-sensitive gatekeepers on the surface rather than the destruction of the mesoporous 
structure of silica particles. 
 
 
Figure 3.13. (a) The cleavage of C-N bonds caused by 10 min of AMF trigger. (b) Zeta potential values of 
Mag@MSNs-ACVA before and after 10 min of AMF trigger in D.I. water. The concentration of 
Mag@MSNs-ACVA in D.I. water is 0.5 mg/mL. 
 
The second type of release study was performed with multiple sequential exposures of AMF 
to achieve the maximal release of fluorescein. To confirm the tightness of the gatekeeper, the 
release of fluorescein before each trigger was monitored by fluorescence spectroscopy every 10 
min. Only slight leakage (less than 10 %) of fluorescein was observed in the first 30 min at room 
temperature before exposure to the first cycle of AMF actuation. Three cycles of AMF actuation 
for 3 min followed by 70 min of the monitoring at room temperature were carried out. The 
 125 
 
Figure 3.14. Time dependent release profile of fluorescein from Mag@MSNs- through magnetic actuation 
under AMF for 3 min for 3 cycles (N = 3). The temperature of the solution right after each exposure was 
measured to be 26 °C, 3 degrees higher than that before each AMF exposure. 
 
temperature of the solution right after each AMF exposure was measured to be 26 °C, 26 °C, and 
26 °C, respectively, only 3 degrees higher than that before each AMF exposure. The minimal 
temperature increase indicates that the observed release was not triggered by the bulk heating from 
the surrounding solution but by the higher local temperature achieved internally from the magnetic 
core. The release efficiency at plateau where fluorescein molecules achieved equilibrium after the 
first cycle was 60 % (Figure 3.14), which is similar to the release efficiency of fluorescein after 3 
min of AMF actuation shown in Figure 3.11d (56.5 %). Subsequently, the second cycle of AMF 
actuation was applied and the release efficiency increased to approximate 80 % compared to the 
background. The second heating cycle caused an additional 20 % more fluorescein can be released. 
However, when the third cycle of AMF actuation was applied, no increase in the release of 
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fluorescein was observed. This implies two possibilities: (1) part of the caps still block the pore 
openings after the trigger, and/or (2) even after the caps are fully removed, some fluorescein 
molecules adhere to the pores of Mag@MSNs-AMA-CD. Stepwise time-dependent release profile 
triggered by multiple cycles of AMF actuation was observed in three stages which is similar to 
Figure 3.11b-f. Based on this stepwise release profile, we can control the release of desired amount 
of fluorescein in the specific time period. 
3.3.6 Alternating magnetic field-triggered release of Doxorubicin 
 
Figure 3.15. (a) UV-Vis spectra of Mag@MSNs-AMA-CD and DOX-loaded Mag@MSNs-AMA-CD in 
PBS. Inset shows the photograph of tubes containing (1) Mag@MSNs-AMA-CD and (2) DOX-loaded 
Mag@MSNs-AMA-CD in PBS. Time-dependent release profile of DOX from Mag@MSNs- in PBS 
through magnetic actuation under AMF for (b) 2, (c) 5, and (d) 10 min, respectively (N=3). The 
concentration of DOX-loaded Mag@MSNs-AMA-CD in PBS for each release study was 0.5 mg/mL. 
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In preparation for in vitro cancer cell studies, we investigated the loading and AMF release of 
doxorubicin (DOX), a widely used anticancer drug. DOX was loaded in Mag@MSNs-AMA by 
soaking the particles in a 2.6 mM DOX solution for 24 h followed by the capping by β-CD. The 
loading capacity of DOX in Mag@MSNs-AMA-CD was calculated to be 4 % after the DOX-
loaded Mag@MSNs-AMA-CD was thoroughly washed with deionized water and PBS to remove 
the untrapped DOX molecules. The absorption peak at 503 nm of UV-vis spectrum (Figure 3.15a) 
provides spectroscopic evidence that DOX was loaded in Mag@MSNs-AMA-CD. 
To prove that the dosage of released DOX from Mag@MSNs-AMA-CD could be controlled 
after being triggered by different durations of AMF exposure, sample tubes containing DOX-
loaded Mag@MSNs-AMA-CD in PBS were placed in the center of the coil with 2, 5, or 10 min 
of exposure time. Before the AMF exposure, the release of DOX was monitored every 30 min over 
a period of 60 min at room temperature. Only slight leakage (less than 5 %) of DOX was observed 
in the first 60 min at room temperature before the AMF exposure. After the AMF exposure, the 
release of DOX was monitored every 30 min over a period of 3 h followed by every 2 h over a 
period of 6 h. The released DOX gradually increased over time at room temperature until it leveled 
off at 540 min post AMF exposure. The cumulative release efficiencies of DOX reach 35.6 %, 
45.6 %, and 53.1 % with 2, 5, and 10 min of AMF exposure, respectively (Figure 3.15b-d). The 
temperature of the solution after the AMF exposure was measured to be 24, 26, and 28 °C, 
respectively. The minimal temperature increase shows that the release of DOX was not triggered 
by bulk heating from the surrounding solution but by the localized high temperature from the 
magnetic core. The results demonstrated that the release of DOX can be triggered by an AMF and 
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that the dosage of the DOX released from the nanocarriers can be controlled by different lengths 
of the AMF exposure. 
3.3.7 In vitro studies of cytotoxicity and stability of drug delivery system 
In vitro cytotoxicity studies were carried out to evaluate the potential biological 
applications of the drug delivery system. A pancreatic cancer cell line (PANC-1) was used to 
evaluate the cytotoxicity of Mag@MSNs-AMA-CD by a colorimetric cell counting kit-8 (CCK-8) 
assay. The cell viabilities of PANC-1 after 20 h and 70 h incubation at various nanoparticle 
concentrations are shown in Figure 3.16a. No significant decrease in cell viability was detected 
even at a very high particle concentration (200 µg/mL) at both 20 h and 70 h. The Mag@MSNs-
AMA-CD particles we developed are not toxic and are suitable to be used as drug delivery carriers. 
To test the stability of the gatekeepers of Mag@MSNs-AMA-CD in vitro, PANC-1 cells 
were treated with DOX-loaded Mag@MSNs-AMA-CD at various concentrations. The results 
show that no significant cell viability decrease was observed after 4 h incubation (Figure 3.16b). 
The minimal cytotoxicity proves the tightness of the gatekeepers which prevent the leakage of 
DOX from the nanocarriers in a biological environment at 37 °C. In addition, the proliferation of 
PANC-1 (Figure 3.16c) was not hindered in a 12 h growth in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % fetal bovine serum (FBS) after 4 h treatment by DOX-loaded 
Mag@MSNs-AMA-CD. These results demonstrate that the drug delivery system prevents the 
leakage of DOX and thus minimizes the cytotoxicity before activation, and that the proliferation 
of the PANC-1 was not hindered. 
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Figure 3.16. (a) Cytotoxicity of Mag@MSNs-AMA-CD. PANC-1 was incubated with Mag@MSNs-AMA-
CD at various nanoparticle concentrations for 20 and 70 h, and the viability was determined by a CCK-8 
assay and normalized to the control without Mag@MSNs-AMA-CD treatment. Data are means ± SD of 
three independent experiments. (b) Cytotoxicity of DOX-loaded Mag@MSNs-AMA-CD. PANC-1 was 
incubated with DOX-loaded Mag@MSNs-AMA-CD at various concentrations for 4 h. The viability was 
determined by a CCK-8 assay and normalized to the control without DOX-loaded Mag@MSNs-AMA-CD 
nanoparticle treatment. Data are means ± SD of three independent experiments. (c) After the 4 h treatment 
of DOX-loaded Mag@MSNs-AMA-CD, cells were allowed to grow in the regular culture medium for 12 
h, and the viability was determined by a CCK-8 assay and normalized to the control without DOX-loaded 
Mag@MSNs-AMA-CD treatment. Data are means ± SD of three independent experiments.  
 
3.3.8 In vitro cellular killing studies 
In vitro cellular killing by DOX-loaded Mag@MSNs-AMA-CD after AMF exposure was 
studied. PANC-1 cells were treated with DOX-loaded Mag@MSNs-AMA-CD for 4 h followed by 
the AMF exposure for 2, 5, and 10 min. (Figure 3.17a). The cell viabilities of the control groups 
including without the treatment by nanoparticles, and treatment by Mag@MSNs-AMA-CD 
without DOX were also investigated. Figure 3.17b shows that without the treatment by 
Mag@MSNs-AMA-CD, the exposure of the cells to AMF (2, 5, and 10 min) did not kill the PANC-
1 cells. The results corroborated that the magnetic field was harmless to cells and is a safe stimulus 
for the drug delivery. No decrease of PANC-1 cell viability was observed after the 4 h incubation 
with 50 µg/mL Mag@MSNs-AMA-CD followed by exposure to various lengths of AMF (2, 5, 
and 10 min). The results indicate that the localized heating generated from Mag@MSNs-AMA-
CD during the AMF exposure was not harmful to the cells, and was desirable because killing by 
hyperthermia did not occur. 
The effects of the release of DOX from Mag@MSNs-AMA-CD in PANC-1 cells triggered 
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by the AMF were studied. The PANC-1 cells were incubated with 50 µg/mL DOX-loaded 
Mag@MSNs-AMA-CD followed by various lengths of exposure to AMF (2, 5, and 10 min). The 
results show that the viabilities of PANC-1 were 72 %, 63 %, and 47 % after 2, 5, and 10 min of 
AMF exposure, respectively (Figure 3.17b), which demonstrates that the loss of cell viabilities 
was correlated with the lengths of AMF exposure time. As AMF exposure time was increased, the 
dosage of released DOX from the nanocarriers increased and thus killed more PANC-1 cells. The 
results demonstrate that not only the release of DOX from Mag@MSNs-AMA-CD in cellular 
environment can be remotely triggered by an AMF, but also that the dosage of the released DOX 
is controlled by the lengths of AMF exposure and thus different levels of cell killing can be 
achieved. 
Uptake of DOX-loaded Mag@MSNs-AMA-CD by PANC-1 cells and the release of DOX 
from the nanocarriers in PANC-1 cells after the exposure of the AMF were verified by fluorescence 
microscope images. PANC-1 cells were treated with 50 µg/mL DOX-loaded Mag@MSNs-AMA-
CD for 4 h. Before the AMF trigger, the red fluorescence derived from DOX was located around 
the nuclei but not overlapped with blue fluorescence derived from the nucleus stained by Hoechst 
33342 dye ((ii) in Figure 3.17c), compared with that of control group (without the treatment of 
nanoparticles, (i) in Figure 3.17c). The results indicate that before the exposure to AMF, DOX was 
not released from the Mag@MSNs-AMA-CD nanoparticles taken up by the PANC-1 cells. 
However, after the AMF exposure, some of the red fluorescence derived from DOX overlapped 
with the blue fluorescence of the Hoechst-stained nuclei ((iii) in Figure 3.17c). This result 
demonstrates that DOX was released from Mag@MSNs-AMA-CD in PANC-1 cells after the 
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exposure of the AMF, and thus stained the nuclei and caused cell death. 
 
 
Figure 3.17. (a) In vitro cellular killing effect of DOX-loaded Mag@MSNs-AMA-CD after AMF exposure. 
PANC-1 cells were treated with DOX-loaded Mag@MSNs-AMA-CD followed by various lengths of AMF 
exposure. (b) The viability of PANC-1 after treatment by Mag@MSNs-AMA-CD, or DOX-loaded 
Mag@MSNs-AMA-CD. The control is cells without treatment by nanoparticles. The cells were treated for 
4 h at a concentration of 50 µg/mL followed by 2, 5, or 10 min of AMF exposure. The cells were allowed 
to grow in the regular culture medium for 12 h, and the viability was determined by a CCK-8 assay. Data 
are means ± SD of four independent experiments. The viable cells in each sample were determined by the 
absorbance at 450 nm and 650 nm (as a reference). (c) Fluorescence microscope images of PANC-1 cells 
(ii) after 4 h treatment by DOX-loaded Mag@MSNs-AMA-CD, and (iii) after 4 h incubation with DOX-
loaded Mag@MSNs-AMA-CD followed by 10 min of AMF exposure. The control group (i) is cells without 
the treatment by nanoparticles. Panels from left to right: cells of PANC-1 with the blue-emitting nucleus 
stained by Hoechst 33342; red emission from DOX; and the merged images. Scale bar is 20 µm. 
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3.3.9 Significance for potential biomedical applications 
 To reduce the side-effects of drugs, release of therapeutics within a specific time, to a targeted 
location, and with a controlled dosage has always been a goal for drug delivery applications. 
Although many proof-of-concept stimulated release of drugs have been studied, a majority of them 
are responsive to internal stimuli such as pH,3,87 redox,7,8 or enzymes,9 and it is almost impossible 
to precisely control the amount of therapeutics released from the carriers. Even though several 
studies have reported the externally triggered release of drugs via magnetic fields, none of them 
quantified the release efficiency of the cargos, making is hard to estimate the amount of cargo 
released upon trigger, nor did they test the tunable dosage released by changing the trigger duration 
under the magnetic field. In this work, we successfully demonstrated that the release efficiency 
(hence, the release amount) of fluorescein and DOX can be well controlled by manipulating the 
AMF trigger time (Figure 3.11g). Additionally, with the AMF as an external stimulus, the particles 
with therapeutics can be delivered and released to the target site on-demand. For those treatments 
to some disease requiring multiple dosing such as multiple dose insulin injection therapy, the 
common way is to inject therapeutics several times daily. With the drug delivery strategy 
developed in this study, by simply applying multiple sequential exposure of AMF, the therapeutics 
could be released stepwise in situ with the desired amount in the specific time period, and finally 
reach the required amount in its therapeutic window. The designed controllable drug delivery 
provides alternative method to those therapies required multiple injection, and at the same time 
reduces the off-target side effects in chemotherapy. 
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 In addition to chemotherapy, high temperatures (hyperthermia) can also damage and kill 
cancer cells, usually with minimal injury to normal tissues. Although hyperthermia is a promising 
way to kill cancer cells, a number of challenges must be overcome including: (1) increasing 
probability of tumor metastasis,31-35 (2) difficulty in accurate temperature measurement inside a 
tumor, (3) problems of keeping an area at a constant temperature without affecting nearby tissues, 
and (4) body tissue’s heterogeneity in response to heat.31 Even using local hyperthermia for which 
energy (such as microwave, radiofrequency, or ultrasound) must be delivered to a small volume 
(e.g. a tumor) does not solve all the problems stated above. On the other hand, the internal heat 
source generated by applying AMF to magnetic cores only heats up a small local area (within a 
range of magnetic core) as compared to area affected by microwave, radiofrequency, and 
ultrasound. Thus, this magnetic heating method in combination with drug delivery provides an 
alternative approach of cancer treatment that has the potential to overcome the challenges faced 
with traditional chemotherapy and hyperthermia, and is especially beneficial to the case where 
thermal ablation or necrosis is undesired. 
 
3.4 Conclusions 
In summary, monodisperse manganese and cobalt doped iron oxide (MnFe2O4@CoFe2O4) 
nanoparticles with a high magnetization (105 emu/g) and high specific loss power (1510.8 W/g) 
were synthesized. The high magnetization of these superparamagnetic nanoparticles provides 
efficient magnetic heating under an alternating magnetic field (AMF), thus holding great promise 
for magnetic heating triggered drug delivery. To increase the amount of drug over that available 
using the nanoparticles themselves, mesoporous silica shell “containers” are synthesized around 
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the magnetic core, forming a core@shell structure with 55 nm in diameter. The spatial, temporal, 
and dose control of drug release was achieved using a thermal-responsive gatekeeper containing a 
thermal-labile molecule 4,4′-azobis(4-cyanovaleric acid), and a host guest complexation formed 
by adamantylamine and β-cyclodextrin. This gatekeeper was stable at physiological temperature, 
while at the higher temperature (60 or 80 °C) the gatekeeper was cleaved. When the fluorescein 
loaded gatekeeper modified nanoparticles were heated for 10 min in 60 or 80 °C water baths, 39 
% or 55 % respectively of fluorescein was released. However, when the AMF was applied, the 
magnetic core served as a heat source, and the localized heating generated from the core led to 
more efficient fluorescein release (75.9 % of the highest) with the temperature rise of the bulk 
solution no more than 5 degrees. Most importantly, in this study we demonstrated externally-
controlled dosage of fluorescein or doxorubicin (DOX) by controlling the AMF exposure time. 
Multiple sequential exposure of AMF allows cargo release in a stepwise manner. In vitro studies 
show that the drug delivery system is biocompatible. DOX-loaded nanoparticles did not cause a 
decrease in cell viability in the absence of AMF stimulation, but the viabilities of the pancreatic 
cancer cells decreased by 28 %, 37 %, and 53 % as the AMF exposure time increased from 2, 5 to 
10 min. Taken together, the thermal-responsive drug delivery actuated by AMF offers the potential 
of becoming an emerging chemotherapy that non-invasively and precisely control the dosage of 
drugs, and avoiding the risk generated when overheating the bulk solution. 
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Chapter 4 
Shortwave Infrared Imaging with J-aggregates Stabilized in 
Hollow Mesoporous Silica Nanoparticles 
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Abstract 
Tissue is translucent to shortwave infrared (SWIR) light, rendering optical imaging superior 
in this region. However, the widespread use of optical SWIR imaging has been limited, in part, by 
the lack of bright, biocompatible contrast agents that absorb and emit light above 1000 nm. J-
aggregation offers a means to transform stable, near-infrared (NIR) fluorophores into red-shifted 
SWIR contrast agents. Here we demonstrate that J-aggregates of NIR fluorophore IR-140 can be 
prepared inside hollow mesoporous silica nanoparticles (HMSNs) to result in nanomaterials that 
absorb and emit SWIR light. The J-aggregates inside PEGylated HMSNs are stable for multiple 
weeks in buffer and enable high resolution imaging in vivo with 980 nm excitation. 
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4.1 Introduction 
Optical imaging with shortwave infrared (SWIR, 1000–2000 nm) light has emerged as a 
powerful method of fluorescence imaging in animals due to the superior resolution and contrast 
one can achieve with low energy light (Figure 4.1A).1 A primary challenge with SWIR imaging is 
the development of bright, biocompatible, SWIR contrast agents.2 Originally, the advantageous 
qualities of imaging in the SWIR region were showcased with carbon nanotubes,3 quantum dots,4 
and rare earth nanomaterials5. In efforts to set the stage for clinical translation, the past three years 
have seen a focus on the synthesis of non-toxic, SWIR-emissive organic fluorophores.6 This work 
has significantly expanded the suite of fluorophores that emit above 1000 nm; however, challenges 
remain in the stability, delivery, and brightness of SWIR dyes. Consequently, we looked to explore 
an alternative avenue to create SWIR organic materials: J-aggregation.  
J-aggregation is the slip-stacked alignment of chromophores that leads to constructive 
coupling of the excited state transition dipoles (Figure 4.1B).7 The photophysical consequences of 
J-aggregation are bathochromically-shifted absorption and emission spectra, narrow absorption 
and emission bands with small Stokes shifts, enhanced absorbance coefficients (ε), and shortened 
fluorescence lifetimes which can result in enhanced quantum yields (ΦF) and cycling rates. Many 
J-aggregate characteristics are beneficial qualities for in vivo imaging: red-shifted absorption and 
emission spectra will enable significant depth penetration during both the excitation and image 
acquisition,2,8 narrow bands can facilitate multiplexed imaging, and increased ε will result in bright 
materials. Despite the significant photophysical advantages J-aggregates typically have over the 
monomer, there are few reports of employing J-aggregates for in vivo imaging due to the difficulty 
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in obtaining and stabilizing the necessary chromophore alignment in complex settings.9 
 
Figure 4.1. (A) Regions of the electromagnetic spectrum employed for optical imaging. For further details 
on contrast and resolution within regions of the SWIR see references 1bc; 8b-c. (B) J-aggregation and 
characteristic photophysical properties. (C) IR-140. (D) Work reported herein: the stabilization of IR-140 
J aggregates in hollow mesoporous silica nanoparticles (HMSNs) to result in biocompatible SWIR-emissive 
contrast agents. 
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Nanostructures can sequester and protect payloads, rendering nanomaterials a promising 
approach toward stabilizing J-aggregates in vivo. In 2016, Zheng and coworkers performed image-
guided surgery with porphyrin lipids that formed J-aggregates upon self-assembly into 
nanovesicles.10 The following year, Xu and coworkers prepared pyrrolopyrrole cyanine J-
aggregate-containing polymer micelles, which could be visualized after subcutaneous injection.11 
In work recently published, Fan and coworkers reported a squaraine J-aggregate, stabilized in 
polymeric micelles, for SWIR image-guided photothermal therapy.12 Each of these reports utilizes 
self-assembled organic nanomaterials,13 which are prone to disassembly when diluted in the 
presence of hydrophobic biomolecules, leading to destabilization of the J-aggregate.14 Here, we 
employ robust, biocompatible, hollow mesoporous silica nanoparticles to stabilize and protect 
SWIR-emissive J-aggregates of IR-140 for in vivo imaging (Figure 4.1C/D).  
Hollow mesoporous silica nanoparticles (HMSNs) have 2–4 nm pores that open into a large, 
10–200 nm cavity, allowing these nanostructures to carry significant cargo.15 The surfaces of the 
HMSNs can be modified to alter the biodistribution of the nanoparticles.16 Consequently, there are 
numerous reports of HMSNs as the core scaffold of multifunctional materials.15a,16b,17 Included in 
these studies are the loading or conjugation of visible18 and near-infrared15a,19 fluorophores and 
administering the resulting nanomaterials for imaging. However, the controlled assembly of J-
aggregates in HMSNs has yet to be demonstrated. 
To realize SWIR-emissive J-aggregates inside HMSNs, we utilized the heptamethine dye IR-
140 (1). IR-140 is a commercially available NIR fluorophore (λmax,abs=826 nm, λmax, em=875 nm) 
that has been applied as a photopolymerization initiator,20 fluorescent payload,21 component of 
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plasmonic arrays,22 as well as a Raman23 and two-photon24 imaging agent. In 2016, Wang and 
Weiss reported that introduction of IR-140 to glutathione coated quantum dots results in J-
aggregate formation with two aggregates observed: J1 (λmax,abs=965 nm, non-emissive), and J2 
(λmax,abs=1040 nm, λmax,em=1047 nm).25 We envisioned that similar IR-140 J-aggregates could be 
formed on the negatively charged pores and inner surface of HMSNs. Further, once the aggregates 
were assembled inside the particles, the hydrophobic nature of IR-140 would make them unlikely 
to disassemble in aqueous environments, rendering J-aggregates stable in vivo. 
4.2 Experimental Section 
4.2.1 Materials 
IR-140 (95%), cetyltrimethylammonium chloride (CTAC, 25 wt% in water), 
cetyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 98%), (3-
aminopropyl)triethoxysilane (APTS, 99%), ammonium nitrate (NH4NO3, 98+%), triethanolamine 
(TEA, 99+%), 2-(N-morpholino)ethanesulfonic acid hydrate (MES hydrate, 99.5+%), and 
phosphate buffer saline (X10) were purchased from Sigma-Aldrich. Sodium carbonate anhydrous 
(99.5+%) was purchased from EMD Millipore. Alpha-methoxy-omega-carboxylic acid 
poly(ethylene glycol) (MeO-PEG-COOH, Mw = 23,000 Da) was purchased from Iris Biotech 
GmbH. Ethanol (200 proof) was purchased from Decon Laboratories, Inc. 1-Ethyl-3-(-3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC-HCl, 99+%), and N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS, 99+%) were purchased from CovaChem. 
Dimethyl sulfoxide (DMSO, 99.9+%), sodium hydroxide (NaOH, 97+%), and ammonium 
hydroxide (NH4OH) purchased from Fisher Scientific. Dulbecco’s modified Eagle’s medium 
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(DMEM) with high glucose, fetal bovine serum (FBS), antibiotics (10,000 U/mL penicillin, 10,000 
µg/mL streptomycin, and 29.2 mg/mL L-glutamine), trypsin-ethylenediaminetetraacetic acid 
(trypsin-EDTA) (0.05 %), and Dulbecco’s phosphate-buffered saline (DPBS) were purchased from 
Gibco. Cell counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. 
All chemicals were used without further purification. 
4.2.2 Instrumentation 
Bath sonication was performed using a Branson 3800 ultrasonic cleaner or an Elma S15 
Elmasonic. Masses for analytical measurements were taken on a Sartorius MSE6.6S-000-DM or 
MSA6.6S-000-DM Cubis Micro Balance. Absorbance spectra were collected on a JASCO V-770 
UV-Visible/NIR spectrophotometer with a 2000 nm/min scan rate after blanking with the 
appropriate solvent, on a Cary 5000 UV-Vis-NIR spectrophotometer or on a Shimadzu UV-1800 
UV-Visible Scanning Spectrophotometer. Photoluminescence spectra were obtained on a Horiba 
Instruments PTI QuantaMaster Series fluorometer. Quartz cuvettes (10 mm, 3 mm and 2 mm) were 
used for absorbance and photoluminescence measurements. The dynamic light scattering (DLS) 
measurements were performed on a ZETAPALS instrument with a 660 nm red diode laser 
(Brookhaven Instruments Corporation). Zeta potential value was measured on a Malvern Zetasizer 
Nano at room temperature. Nitrogen adsorption/desorption isotherms were acquired at 77 K on a 
Autosorb-iQ, Quantachrome Instruments. Transmission electron microscopy was performed on a 
Tecnai T12 instrument with an operating voltage of 120 kV. Animal imaging was performed on 
custom instrumentation described below. 
4.2.3 Synthesis of Stöber silica spheres 
Stöber silica spheres were synthesized by a sol-gel reaction in basic solution as reported 
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previously. Briefly, NH4OH (1.6 mL) was dissolved in a mixture of ethanol (71.4 mL) and D.I. 
water (10 mL) in a 250 mL flask with vigorous stirring. After stirring for 10 min at room 
temperature, TEOS (2 mL) was rapidly added to the solution which was further stirred for 1 h at 
room temperature for the formation of Stöber silica nanoparticles. Afterwards, the solution 
containing Stöber silica spheres was centrifuged (7830 rpm, 7197 g, 20 min) and washed with 
ethanol and D.I. water twice, respectively. The Stöber silica spheres were finally dispersed in 40 
mL of D.I. water for further use. 
4.2.4 Synthesis of hollow mesoporous silica nanoparticles (HMSNs) 
The synthesis of hollow mesoporous silica nanoparticles (HMSNs) was carried out by using 
Stöber silica spheres as the hard templates which were later removed by selective etching in a basic 
solution. First, CTAC (2 g, 25 wt% in water solution) and TEA (20 mg) were dissolved in D.I. 
water (20 mL) in a 100 mL round-bottom flask with vigorous stirring at 80 °C. The reaction 
mixture was stirred for 5 min followed by the addition of 10 mL of Stöber silica sphere solution 
prepared as described above, and stirred for 20 min. To coat mesoporous silica on the surface of 
Stöber silica spheres, TEOS (150 µL) was added dropwise to the solution with vigorous stirring. 
The nanoparticles were designated as dSiO2@MSNs (Scheme 4.1). After 1 h, the solution was 
cooled to 50 °C and sodium carbonate (1.89 g) dissolved in D.I. water (3 mL) was added to 
selectively etch the Stöber silica sphere template in the mesoporous silica shell. The etching 
process was carried out at 50 °C for 2 h. Afterwards, the solution containing HMSNs were 
centrifuged (7830 rpm, 7197 g, 15 min) and washed with ethanol 3 times (3 x 50 mL) to remove 
the unreacted impurities. To remove the CTAC surfactant templates, HMSNs were dispersed in 50 
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mL of ethanol containing NH4NO3 (1 g). The solution was brought to 60 °C with vigorous stirring. 
After 1 h, the solution was cooled to room temperature, centrifuged (7830 rpm, 7197 g,15 min), 
and washed once with ethanol (50 mL). The surfactant removal process was repeated two more 
times. Finally, surfactant free HMSNs were washed with D.I. water (2 x 50 mL) and ethanol (2 x 
50 mL) twice, respectively and stored in 10 mL of absolute ethanol for further use. 
4.2.5 Synthesis of APTS functionalized HMSNs (HMSNs-APTS) 
APTS functionalized HMSNs (HMSNs-APTS) were synthesized by procedures similar to 
those of HMSNs. First, CTAC (2 g, 25 wt% in water solution) and TEA (20 mg) were dissolved 
in D.I. water (20 mL) in a 100 mL round-bottom flask with vigorous stirring at 80 °C. The reaction 
solution was stirred for 5 min followed by the addition of 10 mL of Stöber silica sphere solution 
prepared as described above. After stirring for 20 min, TEOS (150 µL) was added dropwise to the 
solution with vigorous stirring. After 1 h, a mixture of APTS (40 µL) and ethanol (120 µL) was 
added to the solution followed by stirring for another 1 h at 80 °C to conjugate APTS on the surface 
of HMSNs. The Stöber silica sphere etching and surfactant removal processes were the same as 
described in the synthesis of HMSNs section. The resulting nanoparticles were dispersed in ethanol 
and designated as HMSNs-APTS. 
4.2.6 Synthesis of APTS functionalized Stöber silica Spheres 
The Stöber silica spheres (80 mg) were dispersed in a mixture of ethanol (20 mL) and APTS 
(10 µL). The solution was stirred at room temperature for 5 min and was brought to 78 °C. Then, 
the solution was refluxed for 12 h with vigorous stirring. Subsequently, the solution was cooled to 
room temperature, and APTS functionalized Stöber silica spheres (Stöber silica spheres-APTS) 
were washed twice (2 x 20 mL) with ethanol and stored in 10 mL of absolute ethanol for further 
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use. 
4.2.7 Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs 
HMSNs, HMSNs-APTS, or dSiO2@MSNs (2 mg) dispersed in ethanol were centrifuged 
(14000 rpm, 16873 g, 15 min) and washed with DMSO (3 x 1 mL) before IR-140 loading. HMSNs 
or HMSNs-APTS were then dispersed in 200 µL of a DMSO solution containing 5, 10, or 20 mM 
IR-140 by sonication in a bath sonicator for 10 min. For dSiO2@MSNs, the nanoparticles were 
dispersed in 200 µL of a DMSO solution containing 5, or 20 mM IR-140 by sonication in a bath 
sonicator for 10 min. After stirring the solution for 20 h to make IR-140 diffuse into the pores and 
cavity of HMSNs, HMSNs-APTS, or dSiO2@MSNs, the solution containing the particles was 
centrifuged (14000 rpm, 16873 g, 15 min) and the supernatant was kept for loading capacity 
calculations. Then, IR-140 loaded HMSNs were washed with three different methods: (a) washed 
with PBS (1 mL) using a water bath sonication, (b) gently washed with PBS (1 mL) by using 
plastic transfer pipettes, and (c) washed with water (1 mL) by using plastic transfer pipettes, 
respectively, to remove free DMSO and DMSO loaded in the pores. IR-140 loaded HMSNs-APTS, 
or IR-140 loaded dSiO2@MSNs were washed only by method (b). Afterwards, IR-140 loaded 
nanoparticles were centrifuged (8000 rpm, 5510 g, 3 min) to remove the supernatant. The washing 
steps were repeated 5 times. Finally, IR-140 loaded HMSNs, HMSNs-APTS, or dSiO2@MSNs 
were re-dispersed in PBS (1 mL) solution by sonication. 
4.2.8 PEG conjugation on the surface of IR-140 loaded HMSNs-APTS (HMSNs-PEG 
preparation) 
To increase the colloidal stability, PEG was conjugated on the surface of IR-140 loaded 
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HMSNs-APTS via amide bond formation. After IR-140 was loaded in HMSNs-APTS, the 
nanoparticles were gently washed with PBS (5 x 1 mL), D.I. water (2 x 1 mL), and MES buffer 
solution (pH = 6.0, 10 mM) (1 x 1 mL), respectively. Finally, IR-140 loaded HMSNs-APTS (2 mg) 
were dispersed in MES buffer (1 mL) by sonication. Alpha-methoxy-omega-carboxylic acid 
poly(ethylene glycol) (MeO-PEG-COOH, CAS No. 92450-99-2) (10 mg) was dissolved in MES 
buffer (200 µL) followed by the addition of EDC-HCl (5 mg) and sulfo-NHS (2.5 mg) pre-
dissolved in MES buffer (300 µL). The solution was stirred for 30 min. Then, the MES buffer 
solution containing the activated MeO-PEG-COOH (500 µL) was added to 1 mL of 2 mg/mL IR-
140 loaded HMSNs-APTS MES solution. The solution was further mixed and stirred for 20 h to 
conjugate PEG on the surface of IR-140 loaded HMSNs-APTS. Then, IR-140 loaded HMSNs-
PEG were centrifuged (10000 rpm, 8609 g, 10 min) and washed with D.I. water (2 x 1 mL) and 
PBS (1 x 1 mL) to remove the excess MeO-PEG-COOH, EDC-HCl, sulfo-NHS, and MES buffer 
solution. Finally, IR-140 loaded HMSNs-PEG were dispersed in PBS buffer (1 mL) solution for 
UV-Vis-NIR or photoluminescence measurements. 
4.2.9 Cell culture procedures 
HeLa cells, a cervical cancer cells line, were cultured in T-75 flasks (Corning) with vented 
caps in a high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS), and 1 % antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) 
in a humidity-controlled incubator at 37 °C with 5% CO2. The HeLa culture media were daily 
changed and the cells were harvested by trypsinization with 0.05% trypsin-
ethylenediaminetetraacetic acid (EDTA) for passaging every 2–3 days. 
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4.2.10 Animal procedures  
Animal experiments were conducted in accordance with the approved institutional protocols 
of Helmholtz Zentrum München. Non-invasive whole mouse imaging was performed on two six-
week old female CD-1 nude mice (22.4 g, 19.1 g), purchased from Charles River Laboratories. 
Mice were anesthetized with an i.p. injection of a ketamine/xylazine mixture. Tail vein injections 
were performed with a catheter assembled from a 30 ga needle connected through plastic tubing 
to a second 30 ga needle with syringe prefilled with isotonic saline solution. The bevel of the 
needle was then inserted into the tail vein and secured using tissue adhesive. 
4.2.11 SWIR imaging apparatus  
For whole mouse imaging, we used a custom-built setup. A 35 W 980 nm laser (Lumics 
LU0980D350-D30AN) was coupled in a fiber (600 µm core, Thorlabs BF46LS01) The output 
from the fiber was fixed in an excitation cube and reflected off of a mirror (Thorlabs BBE1-E03), 
and passed through a positive achromat (Thorlabs AC254-050-B), 1000 nm shortpass filter 
(Thorlabs FESH 1000), and an engineered diffuser (Thorlabs ED1-S20-MD) to provide uniform 
illumination over the working area. The excitation flux at the object was adjusted to be close to 
100 mWcm-2 with an error of ± 3% (power density used is defined separately in each experiment). 
The working area was covered by a heating mat coated with blackout fabric (Thorlabs BK5). A 4-
inch square first-surface silver mirror (Edmund Optics, 84448) was used to direct the emitted light 
through a custom filter set (Thorlabs NF980-41, 3x FELH1000, 2x FGL1000) to an Allied Vision 
Goldeye G-032 Cool TEC2 camera at -30 °C, equipped with a C-mount camera lens (Navitar, 
SWIR-35). The assembly was partially enclosed to avoid excess light while enabling manipulation 
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of the field of view during operation. The image acquisition toolbox of MATLAB programming 
environment is used in combination with a custom MATLAB script to preview and collect the 
required image data. The prepared MATLAB script allows users to access basic functionalities of 
the image acquisition device by establishing a packet jitter free data streaming link between the 
desktop computer and the acquisition device. 
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4.3 Results and discussion 
We prepared HMSNs by synthesizing a mesoporous silica coating on a Stöber sphere core 
that was subsequently removed via etching with sodium carbonate (Scheme 4.1, Figure 4.2). The 
HMSNs were treated with varying amounts of IR-140 in different solvents (Figure 4.3A). J-
aggregate formation was assayed by UV/Vis/NIR spectroscopy evaluating loss of monomeric IR-
140 at 826 nm and formation of the J-aggregates at 965 nm (J1) and 1040 nm (J2). Upon 
optimization, we found that SWIR J-aggregates could be obtained when IR-140 dissolved in 
dimethyl sulfoxide (DMSO) was combined with HMSNs and washed. The washing procedure 
proved essential for obtaining the desired J2 aggregate formation (Figure 4.3B, Figure 4.4), with 
gentle PBS washes yielding the largest amount of the desired J2 aggregate (dark blue, Figure 4.3B). 
When these optimized conditions were repeated on Stöber spheres that did not have pores or an 
inner surface for IR-140 to associate with, only a small J-band was observed (Figure 4.3B, gray 
line, Figure 4.5). Similar results were obtained when loading was performed on mesoporous silica 
coated Stöber spheres (Figure 4.4). These control experiment (Figure 4.6) suggests that the 
majority of IR-140 is protected inside the HMSN cavity. Through analysis of IR-140 collected 
after the washing procedures, we calculated the loading of IR-140 to be ~103 molecules/particle 
(Figure 4.7, Note S4.1) 
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Scheme 4.1. Synthesis of hollow mesoporous silica nanoparticles (HMSNs). 
 
 
 
Figure 4.2. TEM images of (A) Stöber silica spheres, (B) dSiO2@MSNs, and (C) HMSNs. The 
nanoparticles were dispersed in ethanol at a concentration of 0.1 mg/mL. TEM images were measured on 
a Tecnai T12 instrument with an operating voltage of 120 kV. 
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Figure 4.3. (A) Schematic of loading IR-140 into HMSNs. (B) Washing conditions facilitate J-aggregation. 
10 mg/mL HMSNs were combined with 10 mM IR-140 in DMSO and washed with PBS with (green) and 
without (dark blue) sonication. Pre-wash spectrum, diluted 1:350 is shown in orange. Loading control for 
solid, non-porous Stöber spheres is shown in gray. (C/D) Transmission electron microscopy images of 
HMSNs with (D) and without (C) IR-140 treatment. 
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Figure 4.4. UV/Vis/NIR spectra of HMSNs or dSiO2@MSNs containing IR-140. The loading 
concentrations of IR-140 were (A) 20 mM and (B) 5 mM; HMSNs or dSiO2@MSNs were loaded at 10 
mg/mL. The HMSNs particles were washed by methods (a, PBS with sonication, teal), (b, PBS, blue), or 
(c, water, gray) (5x, 1 mL), or the dSiO2@MSNs were washed by method (b, PBS, magenta) (see Section 
II, synthetic procedures). The absorbance spectra were measured with 10 mm quartz cuvettes at 0.25 mg 
nanoparticles/mL in PBS. 
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Figure 4.5. Control experiment with Stöber silica spheres. (A) The zeta potential of Stöber silica spheres 
(black), and Stöber silica spheres-APTS (red) in D.I. water at 0.05 mg/mL at room temperature. In the case 
of the APTS-modified Stöber spheres, we believe the surface is saturated with APTS as higher 
concentrations of APTS did not significantly change the zeta potential. (B/C/D) UV/Vis/NIR spectra of 
Stöber silica spheres (black) or Stöber silica spheres-APTS (red) containing IR-140. The loading 
concentrations of IR-140 were (B) 20 mM, (C) 10 mM, or (D) 5 mM; Stöber silica spheres or Stöber silica 
spheres-APTS were loaded at 10 mg/mL. After the loading, the particles were washed with PBS (5x, 1 mL). 
The absorbance spectra were measured with 10 mm quartz cuvettes at 0.25 mg nanoparticles/mL PBS. 
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Figure 4.6. UV/Vis/NIR spectra of IR-140 loaded HMSNs, Stöber silica spheres, Stöber silica spheres-
APTS, or dSiO2@MSNs. The loading concentrations of IR-140 were 10 mM; HMSNs, Stöber silica spheres, 
Stöber silica spheres-APTS, or dSiO2@MSNs were loaded at 10 mg/mL. After the loading, the particles 
were gently washed with PBS (5x, 1 mL). The absorbance spectra were measured with 10 mm quartz 
cuvettes at 0.25 mg nanoparticles/mL in PBS. 
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Figure 4.7. The loading capacity, defined as (grams IR-140/grams HMSNs or HMSNs-APTS) x 
100%, of IR-140 in HMSNs (black) or HMSNs-APTS (red) at different IR-140 loading 
concentrations. The loading concentration of HMSNs or HMSNs-APTS was 10 mg/mL. Error 
represents the standard deviation of three replicates. 
 
The HMSNs were further characterized through transmission electron microscopy (TEM), 
indicating ~85 nm particles with a distinct cavity and pores (Figure 4.3C). The pore size was 
quantified to be 3.2 nm through nitrogen adsorption experiments (Figure 4.8). While the pores are 
clearly visible in the TEM of the empty HMSNs, they are darkened after treatment with IR-140 
(Figure 4.3D), suggesting the presence of IR-140. Control experiments in which HMSNs were 
subjected to PBS washing procedures but no IR-140 show no change in contrast of the pores upon 
TEM analysis (Figure 4.9). 
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Figure 4.8. Nitrogen adsorption (black)/desorption (red) isotherms of (A) HMSNs, (C) HMSNs-APTS, and 
(E) dSiO2@MSNs. The BET surface areas of HMSNs, HMSNs-APTS, and dSiO2@MSNs are 969 m2/g, 
831 m2/g, and 340 m2/g, respectively. The total pore volumes of HMSNs, HMSNs-APTS, and 
dSiO2@MSNs are 1.40 cc/g, 1.01 cc/g, and 0.39 cc/g, respectively. Pore diameter distributions of (B) 
HMSNs, (D) HMSNs-APTS, and (F) dSiO2@MSNs. The average pore diameters are 3.2 nm, 3.1 nm, and 
3.1 nm, respectively. 
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Figure 4.9. TEM images of HMSNs with (C) and without (A) IR-140 treatment. (A) HMSNs were 
dispersed in ethanol at a concentration of 0.1 mg/mL. (C) The loading concentration of IR-140 was 10 mM; 
HMSNs were loaded at 10 mg/mL. After loading, the particles were washed with PBS (5x, 1 mL) and 
dispersed in PBS at a concentration of 0.1 mg/mL. (B) As a control, HMSNs were washed with PBS (5x, 
1mL) but without the loading of IR-140. After washing, HMSNs were dispersed in PBS at a concentration 
of 0.1 mg/mL. (D) Mixture of HMSNs with and without IR-140 treatment. The mixed particles were 
prepared by mixing HMSNs in PBS solution (50 µL, 0.2 mg/mL) with IR-140 loaded HMSNs in PBS 
solution (50 µL, 0.2 mg/mL) at the mass ratio of 1:1. TEM images were measured on a Tecnai T12 
instrument with an operating voltage of 120 kV. 
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After confirming that the HMSNs could facilitate J-aggregation of IR-140, we modified the 
surface with poly(ethylene glycol) (PEG) such that they could be suspended in aqueous media. 
This was accomplished by loading HMSNs that had undergone surface silanization with (3-
aminopropyl)triethoxysilane (APTS) prior to Stöber sphere and surfactant removal (Scheme 4.2). 
This procedure resulted in HMSNs that were positively charged on the outside but still contained 
a negatively charged interior to associate with the cationic IR-140.26 Nitrogen adsorption data 
(Figure 4.8) also suggests that the pores are not modified with APTS.27 The introduction of IR-140 
into the HMSNs-APTS proceeded similarly to the HMSNs, yielding analogous loading of IR-140 
and a higher ratio of J2:J1 (Figure 4.10). Control experiments performed with Stöber spheres 
treated with APTS support that IR-140 is protected on the interior of the HMSNs (Figures 4.5 and 
4.6). After loading, a 23kDa PEG-carboxylate was conjugated to the amines present on the outer 
surface of the HMSNs-APTS using carbodiimide chemistry (Scheme 4.2). Successful PEG 
conjugation was verified by changes in hydrodynamic diameter and zeta potential (Figures 4.11 
and 4.12). 
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Scheme 4.2. Synthesis of IR-140-loaded HMSN-PEG. (A) Overall synthesis starting from Stöber spheres. 
(B) Detailed schematic of conjugation of PEG to the surface of HMSN-APTS. Note that we believe the 
APTS modification is only on the outer surface due to the Stöber silica sphere blocking the inner surface 
and the CTAC surfactant blocking the pores. 
 169 
 
Figure 4.10. UV/Vis/NIR spectra of HMSNs-APTS containing IR-140 for dye loading concentrations of 
20 mM (black), 10 mM (red), or 5 mM (blue) in PBS, after washing the particles with PBS (5 x 1 mL). The 
loading concentration of HMSNs-APTS was 10 mg/mL. The absorbance spectra were measured with 10 
mm quartz cuvettes at 0.25 mg nanoparticles/mL. 
 
Figure 4.11. The dynamic light scattering size distribution of HMSNs-APTS (black), HMSNs-APTS 
containing IR-140 (red), and HMSNs-PEG containing IR-140 in PBS (blue) measured at 0.05 mg/mL at 
room temperature in PBS. Note that the HMSNs-APTS are not soluble in water and significant aggregation 
is observed in the DLS until after conjugation of PEG. 
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Figure 4.12. The zeta potential of HMSNs (black), HMSNs-APTS (red), HMSNs-APTS containing IR-140 
(blue), and HMSNs-PEG containing IR-140 (pink) in D.I. water at 0.05 mg/mL at room temperature.  
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We evaluated the photophysical properties of the PEGylated HMSNs (HMSNs-PEG) 
containing IR-140 in comparison to IR-140 in solution as the monomer and J-aggregate (Figure 
4.13A). Monomeric IR-140 has been well-characterized;28 however, the solution J-aggregate of 
IR-140 had previously not been reported.29 After screening numerous conditions (Figure 4.14), we 
found that 35% DMSO/0.9% NaCl in water afforded formation of the desired SWIR J-aggregate 
with a lmax,abs=1042 nm, lmax,em=1043 nm, e=3.9 x 105 M-1cm-1, and FF =0.01% (Table 4.1, Notes 
S4.2 and S4.3). The IR-140-containing HMSNs-PEG had similar spectral properties with a 
lmax,abs=1038 nm, lmax,em=1047 nm, although the absorbance was considerably broader, which we 
attribute to the presence of other non-emissive aggregate states. When solutions of IR-140 in 
DMSO, IR-140 in 35% DMSO/0.9% NaCl in water, and IR-140 loaded HMSNs-PEG in PBS were 
excited with a 980 nm laser, the wavelength to be used for in vivo imaging experiments, the IR-
140 J-aggregate in solution and in the particles were similarly emissive, while the monomer was 
not excited by 980 nm light (Figures 4.13B and 4.15).30 Thus, J-aggregation is essential for SWIR 
imaging with low energy excitation. 
 
Table 4.1. Photophysical characterization of 1 (IR-140) 
Species λmax,abs (nm) ε (M-1cm-1) λmax,em (nm) Φ (%) 
1 monomer a 826 1.7 ± 0.1 x 105 875 20[6] 
1 J-aggregate b 1042 3.9 ± 0.4 x 105 1043 0.012 ± 0.007 
a in DMSO 
b in 35% DMSO/0.9% NaCl in water 
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Figure 4.13. (A) Normalized absorption and emission of IR-140 J-aggregate in HMSNs-PEG (blue), J-
aggregate in solution (red), and monomer (yellow). (B) Emission (1000–1700 nm) of IR-140 monomer 
(left), J-aggregate in solution (middle) and J-aggregate in HMSNs-PEG (right) upon 980 nm excitation. (C) 
Normalized relative absorption of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water (red) and in 
HMSNs-PEG in PBS (blue) on day zero (solid) and day 1 or 14 (dotted). (D) Photostability under laser 
irradiation (97 mW/cm2) at 980 nm for IR-140 J-aggregate in HMSNs-PEG (blue) and IR-140 J-aggregate 
in 35% DMSO/0.9% NaCl in water (red), and at 785 nm for monomer in DMSO (yellow). 
 
 
Figure 4.14. UV-Vis-NIR characterization of IR-140 J-aggregate formation in solution at 0.01 mg/mL in 
(A) DMSO/water, (B) DMSO/1xPBS, and (C) DMSO/0.9% NaCl in water. 
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Figure 4.15. Emission of monomer and J-aggregate states of IR-140 under 980 nm excitation. (A) 
Absorbance traces of samples (10 mm path length) used in vial images in B and in Figure 4.13B, baseline 
corrected to 521 nm. (B) Images of IR-140 monomer in DMSO (left), IR-140 J-aggregate in solution (center) 
and J-aggregate in HMSNs-PEG (right) under 980 nm irradiation (99 ± 3 mWcm-1). All Eppendorf tubes 
are placed in the same location, such that laser intensity across all samples is identical. See Figure 4.13B 
experimental procedure for sample preparation and acquisition settings. Displayed images were background 
subtracted, averaged over 10 frames and the contrast was set to identical values for comparison. 
 
 
Next, we analyzed the role of the HMSNs in stabilizing IR-140 J-aggregates. Over two weeks 
in PBS at room temperature, we observed only a ~10% decrease in absorbance from the IR-140 
loaded HMSNs-PEG and no evidence that the packing of the IR-140 within the nanoparticles was 
changing (Figures 4.13C, blue; Figure 4.16). Comparatively, only ~8% of the J-aggregate in 
solution remained after 1 day (Figure 4.13C, red; Figure 4.16). Not only do the HMSNs stabilize 
the assembly of the J-aggregate, but they also enhance the photostability. The fluorescence of 
solutions containing IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water and HMSNs-PEG 
containing IR-140 J-aggregate in PBS were continually irradiated with a 980 nm laser (97 mW/cm2) 
and the fluorescence intensity was measured with an InGaAs camera. The photostability of 
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monomeric IR-140 in DMSO was also evaluated via excitation at 785 nm (97 mW/cm2). As shown 
in Figure 4.13D, the J-aggregates within the HMSNs-PEG are 4-fold more stable than the J-
aggregates in solution and ~60-fold more stable than the monomer (Table 4.2, Note S4.4). This 
result is consistent with the use of silica shells to overcome the poor photostability that is 
characteristic of J-aggregates by limiting the amount of reactive oxygen species that can access 
the aggregate.31 Photobleaching experiments in deoxygenated solvents support that the HMSNs 
protect the IR-140 J-aggregate from reactive oxygen species (Figure 4.17). Taken together, our 
data show that the HMSNs are critical for stabilizing J-aggregates to light and solution. 
 
Figure 4.16. Stability of J-aggregates over time, displayed as the normalized, relative absorbance remaining 
for IR-140 in HMSNs-PEG after 14 days, and IR-140 in solution after 1 day. IR-140 loaded HMSNs-PEG 
were dispersed in PBS (0.25 mg/mL), and IR-140 J-aggregate was composed of 0.01 mg/mL IR-140 in 
35% DMSO/0.9% NaCl in water. Error represents the standard deviation of three replicates. 
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Table 4.2. Photobleaching rates of IR-140 (1). 
Species 𝜆ex (nm) kraw (s-1) x 103 krel (s-1) x 103 Relative stability 
1 monomer 785 19.54 ± 0.04 19 ± 1 1 
1 J-aggregate 980 1.276 ± 0.008 1.28 ± 0.05 15 ± 1 
1 in HMSNs-PEG 980 0.317 ± 0.002 0.32 ± 0.01 62 ± 5 
 
 
  
Figure 4.17. Photostability of J-aggregates in the presence and absence of oxygen. (A) Raw data of IR-140 
J-aggregate in 35 % DMSO/0.9% NaCl at 0.01 mg/mL under 980 nm irradiation with 79 mWcm-2 power 
density. The relative rates of oxygenated to deoxygenated photobleaching is 7.1 to 1. (B) Raw data of 
HMSNs-PEG loaded with IR-140 at 1.0 mg/mL in 1x PBS under 980 nm irradiation with 101 mWcm-2 
power density. The relative rates of oxygenated to deoxygenated photobleaching is 1.9 to 1. Error bars 
represent the standard deviation of three replicate experiments in (A) and (B) oxygenated and two replicate 
experiments in (B) deoxygenated. Deoxygenated samples were prepared by purging with N2 for 30-60 min; 
oxygenated samples were not purged with N2. Note: The photobleaching rate of the solution IR-140 
aggregate is substantially attenuated by the removal of oxygen, (~7x) while the photobleaching of the 
HMSNs IR-140 is improved by only ~2x. These data indicate that the IR-140 loaded inside the HMSNs are 
less affected by the presence of oxygen, which may be due to a shielding of reactive oxygen species by the 
dense silica shells.   
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Finally, with bright SWIR-emissive nanoparticles prepared and characterized, we evaluated 
their biocompatibility and in vivo imaging performance. In vitro studies showed no cytotoxicity of 
the IR-140 loaded HMSNs-PEG over 6 h at concentrations up to 200 µg/mL (Figure 4.18). These 
data are consistent with other studies regarding mesoporous silica, which is generally considered 
non-toxic to animals.26,32 We performed in vivo imaging experiments using the IR-140 loaded 
HMSNs-PEG with excitation at 980 nm and collection from 1000–1700 nm. The SWIR-emissive 
HMSNs-PEG were intravenously injected into nude mice and the mice were immediately imaged 
(Figure 4.19). The HMSNs-PEG rapidly clear from the blood stream and intense signal can be 
seen in the lungs, liver, and spleen. Fifty minutes after injection, the signal intensity within these 
organs remained constant (Figure 4.20). 
 
Figure 4.18. Cytotoxicity study of IR-140 loaded HMSNs-PEG examined by a CCK-8 assay. HeLa cells 
were incubated in 200 µL fresh DMEM containing 0, 2, 5, 10, 15, 20, and 40 µg of IR-140 loaded HMSNs-
PEG (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) for 3 (black) or 6 (red) hours at 37 °C. The viable cells in 
each condition was determined by the absorbance at 450 nm and 650 nm (as a reference). The DMEM (100 
µL) mixed with CCK-8 reagent (10 µL) served as a background. Error bars represent the standard deviation 
of three replicate experiments. 
 178 
 
Figure 4.19. Whole-mouse imaging at 16 fps (980 nm, 91 mW/cm2 excitation; 1000–1700 nm collection) 
upon i.v. delivery of IR-140 HMSNs-PEG. Background subtracted stills were averaged over 5 frames at 3 
s (A), 8 s (B), 25 s (C), and 120 s (D) post injection. Scale bar represents 1 cm. Data are representative of 
two replicate experiments. 
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Figure 4.20. Images from the front (A/C) and left side (B/D) of a nude mouse directly after vascular 
clearance (>2 m post injection) (A/B), and after 50 minutes (C/D), showing uptake of IR-140 loaded 
HMSNs-PEG in the liver and spleen. Images were acquired with 60 ms exposure time at 16.65 fps with 
980 nm ex. (91 ± 3 mW/cm2) and 1000–1700 nm detection (see general experimental procedures, section 
I, for details of optical set up). Displayed images were background subtracted, averaged over 5 frames, 
outliers were removed, and the contrast was set to identical values for comparison. Regions of interest were 
defined and applied to quantify the intensity in the liver (A/C) and spleen (B/D) over time. Scale bar 
represents 1 cm. (E) Quantification of signal for liver and spleen showing no significant change in signal 
over 50 minutes. Error bars represent the standard deviation over the regions of interest. Data are 
representative of two replicate experiments. 
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4.4 Conclusions 
In summary, we have presented J-aggregation as an approach to prepare biocompatible, 
SWIR contrast agents and demonstrated this concept by stabilizing J-aggregates of the NIR 
fluorophore IR-140 inside HMSNs. The bathochromically-shifted absorption and emission and 
small Stokes shifts of the IR-140 J-aggregate allow imaging with 980 nm excitation and 1000–
1700 nm acquisition, providing high resolution in vivo images. The modularity of the HMSNs will 
enable facile exchange of the imaging agent as well as the addition of targeting agents and/or 
therapeutics, poising these materials to become SWIR theranostics.33 While we did not observe an 
enhanced ΦF with the IR-140 J-aggregate, likely due to disorder or intermolecular vibrations,34 
work is ongoing to access a SWIR J-aggregate that exhibits the superradience phenomena 
predicted by Kasha.35 Collectively, the use of J-aggregates stabilized in HMSNs as SWIR imaging 
agents has the potential to overcome the stability, toxicity, and brightness challenges of contrast 
agents for this compelling region of the electromagnetic spectrum. 
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4.5 Experimental procedures of the figures 
Figure 4.2 
Stöber silica spheres, dSiO2@MSNs, or HMSNs were dispersed in ethanol at a concentration 
of 0.1 mg/mL. The suspension (5 µL) of the nanoparticles was dropped onto the carbon-coated 
copper grid and dried at room temperature. Transmission electron microscopy was measured on a 
Tecnai T12 instrument with an operating voltage of 120 kV. 
Figure 4.3 B 
Refer to Section II “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 10 
mM IR-140 was used as the loading solution. Then, IR-140 loaded HMSNs were washed by 
methods (a), (b), or (c) to compare the extent of IR-140 aggregate by using the above washing 
methods. The washing steps were repeated 5 times and finally IR-140 loaded HMSNs were re-
dispersed in 1 mL of PBS solution by sonication. 
Stöber silica spheres dispersed in ethanol were centrifuged (14000 rpm, 15 min) and washed 
with DMSO 3 times before IR-140 loading. Afterwards, Stöber silica spheres were dispersed in 
200 µL of DMSO solution containing 10 mM IR-140 by sonication in a bath sonicator for 10 min. 
Then, the solution was stirred for 20 h After the IR-140 loading, the solution containing the 
particles was centrifuged (14000 rpm, 15 min) to get IR-140 loaded Stöber silica spheres. Then, 
IR-140 loaded Stöber silica spheres were washed with 1 mL of PBS by gently washing with plastic 
transfer pipettes to remove free DMSO. After each washing step, IR-140-loaded Stöber silica 
spheres were centrifuged (8000 rpm, 3 min) to remove the supernatant. The washing steps were 
repeated for 5 times and finally IR-140-loaded Stöber silica spheres were re-dispersed in PBS 
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solution (1 mL) by sonication. The absorbance spectra of IR-140 loaded HMSNs or IR-140 loaded 
Stöber silica spheres were measured with 10 mm quartz cuvettes at a concentration of 0.25 mg 
nanoparticles/mL PBS on a Cary 5000 UV-Vis-NIR spectrophotometer at room temperature. 
Absorbance traces were corrected for the non-linearity between gratings. Absorbance traces were 
corrected for the non-linearity between gratings. 
For the prewash spectrum: after the IR-140 (10 mM) loading, the particles solution (10 
mg/mL) was diluted 1:350 with DMSO for measurement. The absorbance spectrum of the prewash 
sample was measured with 3 mm quartz cuvettes on a JASCO V-770 UV-Vis-NIR 
spectrophotometer at room temperature. 
Figure 4.3 C/D 
HMSNs and IR-140 loaded HMSNs were dispersed in ethanol and D.I. water, respectively at 
a concentration of 0.1 mg/mL. The suspension (5 µL) of the nanoparticles was dropped onto the 
carbon-coated copper grid and dried at room temperature. Transmission electron microscopy was 
measured on a Tecnai T12 instrument with an operating voltage of 120 kV. 
Figure 4.4 
Refer to Section II “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 5 or 
20 mM IR-140 was used as the loading solution. Then, IR-140 loaded HMSNs were washed by 
methods (a), (b), or (c). In addition, IR-140 loaded dSiO2@MSNs were washed by method (b). 
The washing steps were repeated 5 times and finally IR-140 loaded HMSNs or IR-140 loaded 
dSiO2@MSNs were re-dispersed in 1 mL of PBS solution by sonication. The absorbance spectra 
of IR-140 loaded HMSNs or IR-140 loaded dSiO2@MSNs were measured with 10 mm quartz 
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cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a Cary 5000 UV-Vis-NIR 
spectrophotometer at room temperature. Absorbance traces were corrected for the non-linearity 
between gratings. 
Figure 4.5 
Stöber silica spheres or Stöber silica spheres-APTS were prepared and described in synthetic 
procedures. Stöber silica spheres or Stöber silica spheres-APTS (2 mg for each) dispersed in 
ethanol were centrifuged (14000 rpm, 16873 g, 15 min) and washed with DMSO 3 times before 
IR-140 loading. Afterwards, Stöber silica spheres or Stöber silica spheres-APTS were dispersed in 
200 µL of DMSO solution containing 20, 10, or 5 mM IR-140 by sonication in a bath sonicator 
for 10 min. Then, the solution was stirred for 20 h After the IR-140 loading, the solution containing 
the particles was centrifuged (14000 rpm, 16873 g, 15 min) to get IR-140 loaded Stöber silica 
spheres or Stöber silica spheres-APTS. Then, IR-140 loaded Stöber silica spheres or Stöber silica 
spheres-APTS were washed with 1 mL of PBS by gently washing with plastic transfer pipettes to 
remove free DMSO and DMSO loaded in the pores. After each washing step, IR-140 loaded Stöber 
silica spheres or Stöber silica spheres-APTS were centrifuged (8000 rpm, 5510 g, 3 min) to remove 
the supernatant. The washing steps were repeated for 5 times and finally IR-140 loaded Stöber 
silica spheres or Stöber silica spheres-APTS were re-dispersed in PBS solution (1 mL) by 
sonication. The absorbance spectra of Stöber silica spheres or Stöber silica spheres-APTS were 
measured with 10 mm quartz cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a 
Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. Absorbance traces were 
corrected for the non-linearity between gratings. 
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For zeta potential measurement, Stöber silica spheres or Stöber silica spheres-APTS were 
dispersed in D.I. water (2 mL) at a concentration of 50 µg/mL. The measurement was performed 
on a Malvern Zetasizer Nano at room temperature. 
Figure 4.6 
 HMSNs, Stöber silica spheres, Stöber silica spheres-APTS, or dSiO2@MSNs (2 mg for each) 
dispersed in ethanol were centrifuged (14000 rpm, 16873 g, 15 min) and washed with DMSO 3 
times before IR-140 loading. Afterwards, HMSNs, Stöber silica spheres, Stöber silica spheres-
APTS, or dSiO2@MSNs were dispersed in 200 µL of DMSO solution containing 10 mM IR-140 
by sonication in a bath sonicator for 10 min. Then, the solution was stirred for 20 h. After the IR-
140 loading, the solution containing the particles was centrifuged (14000 rpm, 16873 g, 15 min) 
to get IR-140 loaded nanoparticles. Then, IR-140 loaded nanoparticles were washed with 1 mL of 
PBS by gently washing with plastic transfer pipettes to remove free DMSO and DMSO loaded in 
the pores. After each washing step, IR-140 loaded nanoparticles were centrifuged (8000 rpm, 5510 
g, 3 min) to remove the supernatant. The washing steps were repeated for 5 times and finally IR-
140 loaded nanoparticles were re-dispersed in PBS solution (1 mL) by sonication. The absorbance 
spectra of IR-140 loaded HMSNs, Stöber silica spheres, Stöber silica spheres-APTS, or 
dSiO2@MSNs were measured with 10 mm quartz cuvettes at a concentration of 0.25 mg 
nanoparticles/mL PBS on a Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. 
Absorbance traces were corrected for the non-linearity between gratings. 
Figure 4.7 
The loading capacity of IR-140 in HMSNs or HMSNs-APTS was calculated based on the 
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absorbance difference between the IR-140 DMSO solution before and after loading. After loading 
with IR-140 for 20 h, HMSNs or HMSNs-APTS were centrifuged (14000 rpm, 16873 g, 15 min) 
and the supernatant was collected for absorbance measurements. The loading capacity of IR-140 
was calculated using the difference of maximum absorbance at 831 nm and the following definition 
of loading capacity (%): (mass of loaded IR-140/mass of particles) x 100. 
Figure 4.8 
HMSNs (A/B) and HMSNs-APTS (C/D), and dSiO2@MSNs (E/F) were prepared as 
described in the synthetic procedures and degassed at 120 °C under vacuum for 16 h before the 
measurement. The surface area and pore diameter distribution of HMSNs, HMSNs-APTS, and 
dSiO2@MSNs were determined by Brunauer-Emmett-Teller (BET) and Barrett-Joyner-Halenda 
(BJH) methods, respectively. 
Figure 4.9 
(A) HMSNs were dispersed in ethanol at a concentration of 0.1 mg/mL. (B) The control 
HMSNs were subjected to washing by method (b) in the Section II “Loading of IR-140 in HMSNs, 
HMSNs-APTS, or dSiO2@MSNs” but without the loading of IR-140. The particles were dispersed 
in PBS at a concentration of 0.1 mg/mL. (C) Refer to Section II “Loading of IR-140 in HMSNs, 
HMSNs-APTS, or dSiO2@MSNs”. 10 mM IR-140 was used as the loading solution. IR-140 
loaded HMSNs were dispersed in PBS at a concentration of 0.1 mg/mL. (D) The mixed samples 
were prepared by mixing 50 µL of HMSNs in PBS solution (0.2 mg/mL) and 50 µL of IR-140 
loaded HMSNs in PBS solution (0.2 mg/mL) and were sonicated in a water bath sonicator for 20 
s. The suspension (5 µL) of each of the nanoparticles was dropped onto the carbon-coated copper 
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grid and dried at room temperature. Transmission electron microscopy was measured on a Tecnai 
T12 instrument with an operating voltage of 120 kV. 
Figure 4.10 
HMSNs-APTS (2 mg) dispersed in ethanol were centrifuged (14000 rpm, 16873 g, 15 min) 
and washed with DMSO (3 x 1 mL) before IR-140 loading. Afterwards, HMSNs-APTS was 
dispersed in 200 µL of DMSO solution containing 5, 10, or 20 mM IR-140 by sonication in a bath 
sonicator for 10 min. Then, the solution was stirred for 20 h to let IR-140 diffuse into the pores 
and cavity of HMSNs-APTS. After the IR-140 loading, the solution containing the particles was 
centrifuged (14000 rpm, 16873 g, 15 min) to get IR-140 loaded HMSNs-APTS. Then, IR-140 
loaded HMSNs-APTS were washed with PBS (1 mL) by gently washing with plastic transfer 
pipettes to remove free DMSO and DMSO loaded in the pores. After each washing step, IR-140 
loaded HMSNs-APTS were centrifuged (8000 rpm, 5510 g, 3 min) to remove the supernatant. The 
washing steps were repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed 
PBS (1 mL) by sonication. The absorbance spectra of IR-140 loaded HMSNs-APTS were 
measured with 10 mm quartz cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a 
Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. Absorbance traces were 
corrected for the non-linearity between gratings. 
Figure 4.11 
Refer to Section II “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 20 
mM IR-140 was used as the loading solution. The loading concentration of HMSNs-APTS was 10 
mg/mL. Then, IR-140 loaded HMSNs-APTS were washed by method (b). The washing steps were 
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repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed in PBS (1 mL) by 
sonication. The synthetic procedures of PEGylation of IR-140 loaded HMSNs-APTS can be 
referred to Section II “PEG conjugation on the surface of IR-140 loaded HMSNs-APTS”. For 
dynamic light scattering size measurement, HMSNs-APTS, HMSNs-APTS containing IR-140, 
and HMSNs-PEG containing IR-140 were dispersed in PBS (2 mL) at a concentration of 50 µg/mL. 
The measurement was performed on a ZETAPALS instrument with a 660 nm red diode laser at 
room temperature. 
Figure 4.12 
Refer to Section II “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 20 
mM IR-140 was used as the loading solution. The loading concentration of HMSNs-APTS was 10 
mg/mL. Then, IR-140 loaded HMSNs-APTS were washed by method (b). The washing steps were 
repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed in 1 mL of PBS 
solution by sonication. The synthetic procedures of PEGylation of IR-140 loaded HMSNs-APTS 
can be referred to Section II “PEG conjugation on the surface of IR-140 loaded HMSNs-APTS”. 
For zeta potential measurement, HMSNs, HMSNs-APTS, HMSNs-APTS containing IR-140, and 
HMSNs-PEG containing IR-140 were dispersed in D.I. water (2 mL) at a concentration of 50 
µg/mL. The measurement was performed on a Malvern Zetasizer Nano at room temperature. 
Figure 4.13A 
All absorbance and emission traces were baseline corrected and normalized. Absorbance 
traces were acquired on a JASCO V-770 UV-Visible/NIR spectrophotometer. The slit widths used 
in fluorescence spectra were 5.76 mm for excitation and 11.52 mm for emission. The step size was 
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1.0 nm, integration time 0.1 s, and traces were acquired after an automatic detector background 
subtraction. 
IR-140 monomer was dissolved in DMSO and diluted to an O.D. of ~ 0.7 for absorbance and 
less than 0.1 for fluorescence spectroscopy (ex. 785 nm) in a 1 cm path length cuvette. The 
monomer absorption trace was corrected for the non-linearity between gratings before baseline 
subtraction and normalization. 
The IR-140 J-aggregate in 35% DMSO/0.9% NaCl was prepared by dissolving 0.02 mg of 
IR-140 in 350 µL DMSO, vortexing briefly, adding 650 µL 0.9% aqueous NaCl, and shaking 
briskly. The solution becomes warm and immediately loses the blue color. Absorbance and 
emission traces of the J-aggregate in solution were obtained with a 2 mm path length cuvette. For 
the fluorescence trace, a 10 mm path length was used on the excitation side and a 2 mm path length 
on the emission side. A reabsorption correction was performed on the emission trace analogous to 
that described in Note S4.2.  
The IR-140 loaded HMSNs-PEG were prepared as described in the synthetic procedures, 
section VI. The absorbance was collected without dilution in a 10 mm cuvette. The fluorescence 
spectrum was obtained by diluting the sample to an O.D. of less than 0.1 in a 3 mm path length 
square quartz cuvette, and exciting at 885 nm with a shortpass filter (Thorlabs, FES0900).  
Figure 4.13B 
Samples consisted of IR-140 monomer: 0.01 mg/mL IR-140 in DMSO (left); IR-140 J-
aggregate in solution: 0.01 mg/mL IR-140 in 35% DMSO/0.9% NaCl in water (center); IR-140 
HSMNs-PEG: 1 mg/mL in PBS (right). Vials were excited with 980 nm light (with Thorlabs 
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FESH1000) with an average power density of 99 ± 3 mWcm-2. Power densities over the three 
samples were not identical due to varying distance from the excitation cube. See Figure 4.15 for 
images with consistent distances from the excitation cube. Collection was from 1000–1700 nm 
(1000 nm LP, Edmund Optics 84-776). The custom lens system consists of a 4f configuration with 
a f=750.0mm lens (Thorlabs LB1247-C) and two f=200.0mm lenses (Thorlabs LB1199-C). For 
ergonomic reasons a 2’’ protected silver-coated elliptical mirror (PFE20-P01) mounted to a 
kinematic mount (Thorlabs KCB2EC/M) was used. Images were acquired at 35 ms exposure time, 
16.65 fps. Displayed image was background subtracted and averaged over 6 frames.  
Figure 4.13C 
Stability of IR-140 in HMSNs-PEG over time. IR-140 loaded HMSNs-PEG were dispersed 
in PBS at 0.25 mg/mL. The absorbance spectra were taken in a 3 mm path length cuvette 
immediately (day 0) and after 14 days (day 14) on a JASCO V-770 UV-Visible/NIR 
spectrophotometer. The absorbance was normalized, relative to spectrum (1). Results of the 
triplicate experiment are presented in Figure 4.16. 
Stability of IR-140 in solution over time. IR-140 J-aggregate was prepared in DMSO as 
described in Figure 4.11A. The aggregate absorbance in a 2 mm path length cuvette was obtained 
immediately (day 0) and after 17 h storage in the dark (day 1) on a JASCO V-770 UV-Visible/NIR 
spectrophotometer. The absorbance was normalized, relative to spectrum at day 0. Results are 
reproduced in triplicate in Figure 4.16.  
Figure 4.13D 
Three solutions were prepared: (a) 1 mg/mL solution of HMSNs-PEG containing IR-140 (b) 
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0.01 mg/mL IR-140 in 35% DMSO/0.9% NaCl solution, and (c) 0.01 mg/mL IR-140 in DMSO. 
Each solution (400 µL) was irradiated with 97 ± 3 mWcm-2 of 980 nm (a and b) and 785 nm (c) 
light and their emission was monitored by a SWIR camera. Acquisition settings were 2 fps and (a) 
25 ms, (b) 15 ms, and (c) 0.3 ms. Excitation and emission settings were identical to Figure 4.13B. 
Error represents the standard deviation of three measurements.  
Figure 4.14 
Samples were prepared as by dissolving 0.02 mg IR-140 in DMSO, and then adding to the 
appropriate aqueous phase (either MilliQ water, 1x PBS, or 0.9% NaCl in water) and shaking 
vigorously. The appropriate volumes of DMSO and aqueous phase were used to sum to 2.0 mL for 
each listed percentage. For the 0% DMSO traces, IR-140 is at its solubility limit, after sonicating 
0.02 mg IR-140 in 1.0 mL of the appropriate solvent for 4 hours. Absorbance traces were measured 
in a 3.0 mm cuvette with blanking to the appropriate solvent mixture on a JASCO V-770 UV-
Visible/NIR spectrophotometer. 
Figure 4.15 
Samples were prepared and excitation and acquisition was performed as described in Figure 
4.13B. Absorbance traces were acquired on a Shimadzu UV-1800 UV-Visible Scanning 
Spectrophotometer. 
Figure 4.16 
IR-140 loaded HMSNs-PEG, obtained as described in the experimental procedures II “PEG 
conjugation on the surface of IR-140 loaded HMSNs-APTS,” were dispersed in PBS (0.25 mg/mL). 
The absorbance spectra were taken in a 3 mm path length cuvette immediately (day 0) and after 
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14 days storage in the dark. IR-140 J-aggregate in solution was prepared by dissolving 0.02 mg 
IR-140 in 700 µL DMSO, and subsequently adding 1.3 mL 0.9% NaCl and briskly shaking. The 
aggregate absorbance in a 2 mm path length cuvette was obtained immediately and after 24 h 
storage in the dark. 
Figure 4.17A 
Deoxygenated IR-140 solution J-aggregates were prepared by adding 1.4 mL DMSO to 0.04 
mg IR-140 in a purged dram vial, followed by 2.6 mL 0.9% NaCl solution in water and shaking. 
Solvents were deoxygenated by purging with N2 for at least one hour. Oxygenated IR-140 solution 
J-aggregates were prepared analogously, but with solvents which had been exposed to air. 
Solutions (4 mL), sealed with septa, were irradiated for 20 min. The optical parameters for 
experiment in (A) consisted of the following: a 4-inch square first-surface silver mirror (Edmund 
Optics, 84448) was used to direct the emitted light through a custom filter set (Edmund optics #84-
776, TL) to an Allied Vision Goldeye G-032 Cool TEC2 camera at -20 °C, equipped with a C-
mount camera lens (Navitar, SWIR-35). Excitation light was passed through a positive achromat 
(Thorlabs AC254-050-B), 1000 nm shortpass filter (Thorlabs FESH 1100), and an engineered 
diffuser (Thorlabs ED1-S20-MD) to provide uniform illumination over the working area. 
Exposure time used was 100 ms, with 2 fps. 
Figure 4.17B 
IR-140 containing HMSNs-PEG were prepared according to experimental procedures II, 
sections “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs” and “PEG 
conjugation on the surface of IR-140 loaded HMSNs-APTS”. Deoxygenated solutions were 
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purged with N2 for at least 30 min, while oxygenated were left open to air. Both sample types (1 
mg/L, 0.40 mL), sealed with septa, were irradiated for 20 minutes. The optical parameters for 
experiment in (B) consisted of the following: a 4-inch square first-surface silver mirror (Edmund 
Optics, 84448) was used to direct the emitted light through a custom filter set (Edmund optics #84-
776, 3x FELH1000,) to an Allied Vision Goldeye G-032 Cool TEC2 camera at -20 °C, equipped 
with a C-mount camera lens (Navitar, SWIR-35). Excitation light was passed through a positive 
achromat (Thorlabs AC254-050-B), 1000 nm shortpass filter (Thorlabs FESH 1000), and an 
engineered diffuser (Thorlabs ED1-S20-MD) to provide uniform illumination over the working 
area. Exposure time used was 200 ms, with 2 fps.  
Data were analyzed analogous to that discussed in Note S4.4, however only the relative rates 
between oxygenated and deoxygenated experiments were calculated and evaluated. 
Figure 4.18 
The viabilities of HeLa cells after the treatment of IR-140 loaded HMSNs-PEG were 
examined by using a cell counting kit-8 (CCK-8) assay. The cells were seeded in 96-well plates at 
a density of 5 x 103 cells per well in 200 µL DMEM supplemented with 10% FBS and 1% 
antibiotics in a humidity-controlled incubator at 37 °C for 24 h attachment. After the attachment, 
the medium was removed and the cells were incubated in 200 µL fresh DMEM containing 0, 2, 5, 
10, 15, 20, and 40 µg of IR-140 loaded HMSNs-PEG (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) 
for 3 or 6 h in an incubator at 37 °C. After incubation, the medium was removed and the treated 
cells were washed with DPBS 1 time (200 µL). To measure the cell viability, 100 µL of DMEM 
and 10 µL of CCK-8 cellular cytotoxicity reagent were added to each well. Then, the plates were 
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put in the incubator for 2 h at 37 °C. To measure the number of the viable cells in each condition, 
a plate reader (Tecan M1000) was used to measure the absorbance at 450 nm and 650 nm (as a 
reference). The DMEM (100 µL) mixed with CCK-8 reagent (10 µL) served as a background 
control. 
Figure 4.19 
The IR-140 HMSNs-PEG in PBS were sonicated (Elma S15 Elmasonic) for 30 mins prior to 
injection and filtered through a 40 µm nylon filter. 200 µL of the IR-140 HMSNs-PEG in PBS 
were injected via the tail vein and immediately imaged. The excitation flux (980 nm) had an 
average power density of 91 ± 3 mWcm-2 over the field of view. Images were acquired at 60 ms 
exposure time and 16.65 fps, in 8-bit format. Displayed images were background subtracted with 
an average of 10-frames from the pre-injection time points, outliers were removed, and the stills 
were averaged over 5 frames. 
Figure 4.20 
Refer to Figure 4.17 experimental procedures. 
  
 194 
4.6 Supplementary notes 
Note S4.1: Estimation of the amount of dye molecules in a single HMSN and HMSN-PEG 
In order to calculate how many IR-140 molecules loaded in a single HMSN or HMSN-APTS, 
we need to estimate the mass of a single HMSN or HMSN-APTS using the equation: 
mamorphous silica  = 𝑉()*+,-*./	/0102(	 ×	𝜌()*+,-*./	/0102(          (1) 
Amorphous silica is defined as the silica in HMSNs shell excluding mesopores. The density 
(ρ) of amorphous silica is known to be 2.5 (g/cm3 amorphous silica). There are several ways to 
estimate the volume of a single MSNs, as we have published previously.[7] Here, we started to 
determine the shell volume of a single HMSN (𝑉/-511) from the equation below:  
𝑉/-511 	= 789 ×	"𝑅;9 −	𝑅=9# = 𝑉)5/*,*+5 + 𝑉()*+,-*./	/0102(     (2) 
 
 
Figure S4.1. HMSN or HMSN-APTS used in this work. 𝑅; and 𝑅=	are the outer radius and inner radius 
of HMSN or HMSN-APTS, respectively. 𝑉/-511 is the shell volume of a single HMSN. 𝑉)5/*,*+5  is the 
volume of the mesopores in the shell. 𝑉()*+,-*./	/0102(  is the volume of silica in the shell excluding 
mesopores. 
 𝑉/-511 	of the HMSNs used here (Figure S4.1) was calculated to be 141961 nm3 based on equation 
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(2). 𝑉)5/*,*+5  was determined to be 0.94 (cm3/g amorphous silica) from N2 adsorption-
desorption isotherm analysis.  
Although we cannot directly calculate  𝑉()*+,-*./	/0102(  from the equation (2) at this point 
because 𝑉)5/*,*+5  is a function of the mass of amorphous silica, we can first determine the ratio 
( 𝑎 ) between 𝑉)5/*,*+5  and 𝑉()*+,-*./	/0102(  which would facilitate determination of 𝑉()*+,-*./	/0102( .  
𝑉	)5/*,*+5 	÷ 𝑉	()*+,-*./	/0102( 	= 	𝑎            (3) 
From the density of amorphous silica, 1 g of amorphous silica has a volume of 0.4 cm3, and 
thus 𝑎 = 2.35, which is derived from 𝑉	)5/*,*+5/𝑉	()*+,-*./	/0102( 	=	 0.94 cm3/0.4 cm3. Now, 
plug the ratio in equation (2): 
𝑉/-511 = 	𝑉	)5/*,*+5 	+ 𝑉	()*+,-*./	/0102( = 2.35	𝑉	()*+,-*./	/0102( + 𝑉	()*+,-*./	/0102(	 																																																																							= 3.35	𝑉	()*+,-*./	/0102(          (4) 
From above, we determine that the percentage (𝑏) of 𝑉	()*+,-*./	/0102( occupying 𝑉/-511  is: 
(𝑉	()*+,-*./	/0102( 	÷ 	𝑉/-511) 	× 	100	% = 𝑏       (5) 𝑏  was calculated to be 30%. Since we already calculated 𝑉/-511  to be 141961 nm3, 𝑉	()*+,-*./	/0102( was then determined to be 42446 nm3 from (5). The mass of a single HMSN 
(mamorphous silica) was then calculated by plugging in 𝑉	()*+,-*./	/0102( in the equation (1), which 
was determined to be 1.06	× 	10J;K (g). 
To estimate the amount of dye molecules in a single HMSN, the average loading capacities 
of IR-140 in HMSNs (5.9	± 1.2 %, 8.9 ± 1.1 %, and 22.9 ± 2.8 % with 5 mM, 10 mM, and 20 
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mM IR-140 as the loading solution, respectively) were used to determine the mass of IR-140 
loaded in a single HMSN. Then, the number of IR-140 molecules loaded in a single HMSN could 
be calculated as: 
number of IR-140 molecules loaded in a single HMSN = [(the loading capacity of IR-140 in 
HMSNs)	× mamorphous silica  ÷ molecular weight of IR-140] ×	𝑁N                  (6) 
where 𝑁N is the Avogadro’s constant. For example, using equation (6), with 5 mM IR-140, the 
number of IR-140 molecules loaded in a single HMSN was then determined to be 4.87 × 109 ± 
0.99 × 109 molecules. The number of IR-140 molecules loaded in a single HMSN with 10 and 
20 mM IR-140 were 7.35 × 109 ± 0.91 × 109 and 1.89 × 107 ± 0.23 × 107, respectively. 
By applying the above calculation to HMSNs-APTS, we can also estimate how many IR-140 
molecules were loaded in a single HMSN-APTS. Given that 𝑉	)5/*,*+5	of HMSNs-APTS is 0.73 
cm3/g, the mass of a single HMSN-APTS is calculated to be 1.26 × 10J;K g. 
Given that the loading capacity of IR-140 in HMSN-APTS is 6.6 ± 2.5 %, 10.2 ± 1.8 %, 
and 21.6	± 1.5 % with 5, 10, and 20 mM IR-140, respectively, the number of IR-140 molecules 
loaded in a single HMSN-APTS were estimated to be 6.43 × 103	± 2.44 × 109, 9.94 × 103 ± 1.76 × 109, and 2.10 × 104 ± 0.15 × 107, respectively. 
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Note S4.2: absorption coefficients 
Absorption coefficients were calculated according to the Lambert - Beer-Lambert law,  
𝐴 = 	𝜀𝑙𝑐  (7) 
where A represents absorbance (unitless), 𝜀  the absorption coefficient (M-1cm-1), 𝑙  the path 
length (cm), and c the concentration (M). Masses were determined on a microbalance and diluted 
using Hamilton microsyringes to concentrations within the linear range of the UV-Vis-NIR 
spectrophotometer. Four concentrations were obtained for each experiment and the reported error 
represents the standard deviation of three measurements.  
The monomer absorption coefficient was straightforward as only one species is present in 
solution. These data were collected using a 10 mm quartz cuvette in DMSO. The raw data was 
corrected for non-linearity between gratings, and baseline corrected to 478 nm. The absorption 
coefficient at all relevant wavelengths is displayed below in Figure S4.2. The absorption 
coefficient at λmax,abs = 826 nm was 1.7 ± 0.1 x 105 M-1cm-1.  
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Figure S4.2. Absorption coefficient of IR-140 monomer in DMSO.  
 
The J-aggregate absorption coefficient is more complex due to the requirement of high 
concentrations for selective formation of the J-aggregate over the monomer. As a result, to use 
higher concentrations, yet stay in the linear range of the spectrometer, these data were collected 
using a 3 mm cuvette. The raw data were baseline corrected to 449 nm and are included below in 
Figure S4.3. The uncorrected absorption coefficient (εraw) at λmax,abs = 1043 nm was 3.3 ± 0.3 x 105 
M-1cm-1.  
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Figure S4.3. Uncorrected absorption coefficient of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water.  
 
Despite the higher concentrations, some monomer remained in solution. The uncorrected data 
can be corrected for the remaining monomer in solution using the absorption coefficient of the 
monomer at its λmax,abs and making the assumption that the absorption coefficient of the monomer 
does not change significantly between 100% DMSO and 35% DMSO/0.9% NaCl in water. We 
used the equation: 
𝛼) + 𝑎T = 1  (8) 
where αm represents the mole fraction of monomer and αj the mole fraction of J-aggregate. The 
value αm for each absorbance trace was obtained using the Beer-Lambert law from the absorption 
coefficient of the monomer and the known concentration of total dye. The value 𝑎T was then used 
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coefficient was then recalculated with the corrected concentration values. The corrected absorption 
coefficient at λmax,abs = 1043 nm was 3.9 ± 0.4 x 105 M-1cm-1. Error was taken as the standard 
deviation of the three replicates. The corrected absorption coefficient is displayed below in Figure 
S4.4.  
 
 
 
Figure S4.4. Corrected absorption coefficient of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water.  
  
Wavelength(nm)
Ab
so
rp
tio
n
co
ef
ﬁc
ie
nt
(M
-1
cm
-1
)
0.0
5.0 x104
1.0 x105
1.5 x 105
2.0 x105
2.5 x 105
3.0 x105
3.5 x105
4.0 x105
4.5 x105
400 500 600 700 800 900 1000 1100 1200
 201 
Note S4.3: Quantum yield 
The photoluminescence quantum yield (ΦV)	of a molecule or material is defined as follows, ΦV = WX	WY   (9) 
where PE and PA are the number of photons absorbed and emitted, respectively. To determine the 
quantum yield, we either use a relative method with a known standard in the same region of the 
electromagnetic spectrum, or an absolute method, in which the number of photons absorbed and 
emitted are measured independently. Here, due to the limits of our petite integrating sphere (Horiba 
KSPHERE-Petite with InGaAs detector Horiba Edison DSS IGA 020L), we use a relative method, 
with IR-26 as the known standard.  
The quantum yield was measured at three different excitation wavelengths, 885 nm, 900 nm, 
and 915 nm and the results were averaged to obtain the value reported.  
To compare an unknown to a reference with a known quantum yield, the following 
relationship was used:  ΦV,[ = 	ΦV,+(𝑚[ 𝑚]⁄ )(𝜂[= 𝜂+=⁄ )  (10) 
Where m represents the slope of the line (y = mx + b) obtained from graphing integrated 
fluorescence intensity versus optical density across a series of samples, 𝜂 is the refractive index 
of the solvent, and the subscripts x and r represent values of the unknown and reference, 
respectively. 
The (ΦV,+) of IR-26 was taken to be 0.05 ± 0.03%, as we have previously measured[8], and 
which agrees with several recent measurements.[6,9]   
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To obtain a plot of integrated fluorescence intensity versus absorbance for the reference and 
unknown, five solutions and a solvent blank were prepared and their absorbance and emission 
spectra were acquired. IR-26 was diluted in dichloroethane to concentrations with optical densities 
less than 0.1 to minimize effects of reabsorption. The baseline corrected (to 1500 nm) fluorescence 
traces were integrated from 950 – 1500 nm, and the raw integrals were corrected by subtracting 
the integral over an identical range from fluorescence traces of the blank solvent (Figure S4.5A). 
The methods employed here were validated with comparison of IR-26 to IR-1061, giving a ΦV value of 0.3 ± 0.2 %, which is in agreement with our prior absolute quantum yield 
measurement,[8] but with lower precision due to the uncertainty in IR-26 absolute ΦV . 
 
 
Figure S4.5. Solvent corrected integrated fluorescence intensity versus absorbance plots for (A) IR-26 and 
(B) IR-140 J-aggregate, also corrected for reabsorption.  
 
The IR-140 J-aggregate was prepared as described in Figure 4.11A, in 35% DMSO/0.9% 
NaCl in water. Due to the necessity of using concentrated samples for IR-140 to remain in the J2 
R² = 0.96
R² = 0.97
R² = 0.98
0
20
40
60
80
100
0 0.01 0.02 0.03
In
te
gr
at
ed
flu
or
es
ce
nc
e
in
te
ns
ity
(c
ou
nt
s)
Absorbance at λex
IR-26
885 nm
900 nm
915 nm
R² = 0.98
R² = 0.98
R² = 0.98
0
20
40
60
80
100
120
140
160
180
0 0.05 0.1 0.15 0.2
C
or
re
ct
ed
In
te
gr
at
ed
flu
or
es
ce
nc
e
in
te
ns
ity
(c
ou
nt
s)
Absorbance at λex
IR-140 J aggregate
885 nm
900 nm
915 nm
A. B.
 203 
aggregate state, high concentrations of IR-140 J-aggregate were used for quantum yield 
measurements (the OD with a 2 mm path length at the relevant excitation wavelengths ranged from 
0.07 – 0.16). The baseline corrected (to 1400 nm) fluorescence traces of the optically dense IR-
140 J-aggregate samples were corrected for reabsorption by the relationship,  
𝐼(𝜆) = 𝐼*(𝜆)[−ln	(10Jde(f)) (1 − 10Jde(f))⁄ ]  (11) 
where 𝐼(𝜆)  and 𝐼*(𝜆)  are the corrected and experimental fluorescence intensities at each 
wavelength, and 𝑂𝐷(𝜆) is the optical density of the sample at the corresponding wavelength. The 
corrected fluorescence traces were then integrated from 965 nm – 1400 nm, and the raw integrals 
were corrected by subtracting the integral over an identical range from fluorescence traces of the 
blank solvent.  
The integrated fluorescence intensities were then plotted against the baseline corrected 
absorbance values at the relevant wavelength, and the slope and error in slope were obtained (R2 
> 0.95 for all traces) (Figure S4.5B)   
The refractive index for DCE was taken as 1.440[10], while that of the 35% DMSO/0.9% NaCl 
solution in water was approximated as a binary mixture of 35% DMSO in water and taken to be 
1.383.[11] Both values were designated to have a precision to ± 0.001. 
The average quantum yield value (over 885 nm, 900 nm, and 915 nm excitations) was 
calculated to be 0.012 ± 0.007. Errors were propagated from the error in IR-26 ΦV	(± 0.03)[8], 
slope of the integrated fluorescence intensity versus optical density plot (unique for each trace, but 
ranged from 7-10% of the slope value), and refractive indices (± 0.001).  
For quantum yield measurements, fluorescence traces were acquired with ex. 885 nm, 900 
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nm, and 915 nm with a 950 nm shortpass filter (Thorlabs FESH0950) and collection from 950–
1400 nm for IR-140 J-aggregate and 950–1500 for IR-26. The slits were 5.76 mm for excitation 
and 11.52 mm for emission. The step size used was 1.0 nm, integration time 0.1 s, and traces were 
acquired after an automatic detector background subtraction, and with the default excitation 
correction. All absorbance and fluorescence traces were taken in a 10 mm x 2 mm path length 
cuvette. For absorbance traces, the 2 mm path length was used, while emission traces were 
acquired with 10 mm at the excitation side and 2 mm on the emission side, with emission detection 
occurring at 90° from excitation. 
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Note S4.4: Photobleaching rates 
All photobleaching data were fit to a mono-exponential decay and the rate constants were 
obtained from the first order reaction equation:  
ln[𝐴] = 	−𝑘𝑡 + ln	[𝐴]*	  (12) 
where A and Ao represent the emission collected at time t and the initial emission collected, 
respectively. All R2 values were > 0.96. Error bars represent the standard deviation of three 
measurements. If a change in slope occurred in the ln[A] values (i.e. in the IR-140 J-aggregate 
bleaching in 35% DMSO/0.9% NaCl in water solution), the rate was taken as the initial rate and 
the lines were fit only to the linear region (Figure S4.6). This analysis conservatively estimates the 
photobleaching rate of the solution phase aggregate as slower than it appeared in subsequent time 
points (see Figure 4.11D).  
 
Figure S4.6. Photobleaching data plotted as the ln[A] vs time and the corresponding linear fits.   
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corrections for (1) the difference in photon energy between the two wavelengths, and (2) the 
difference in photons absorbed by the two samples. 
To account for photons of different energy, we go back to the common unit of number of 
photons per second per surface unit Np, (cm-2s-1). This value can be obtained by first calculating 
energy of a photon Ep, (J) at the wavelength of irradiation: 
𝐸, = -2f   (13) 
where h is Planck’s constant, and c the speed of light. The Np can then be found from the irradiance 
I (Wcm-2) and Ep by the following equation:  
𝑁, = mno  (14) 
The Np for 980 nm and 785 nm light is 4.8 x 1017 and 3.8 x 1017 cm-2s-1, respectively.  
To account for the difference in photons absorbed, we use the absorption coefficients at the 
wavelength of irradiation, 𝜆ex. For the IR-140 J-aggregate, the corrected absorption value was 
used. The absorption coefficient of IR-140 in HMSNs-PEG was taken to be that of the J-aggregate 
in solution. The relative values of 𝑁,	 × 	𝜀	can then be compared to obtain a ratio, X for each 
wavelength,   
Xqrs = (𝑁,,qrs 	×	ε)) (𝑁,,urv 	×	εT⁄ )  (15) 
Xurv = (𝑁,,urv 	×	εT) (𝑁,,urv 	×	εT⁄ )  (16) 
where ε)  and εT  represent the aborbance coefficient of the monomer and J-aggregate, 
respectively, at their appropriate excitation wavelength, 𝜆ex. The ratio X785 was calculated to be 
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0.998, providing a correction factor for the relative number of photons absorbed per second in the 
785 nm experiment compared to the 980 nm experiments, while the ratio X980 is 1.000. These 
values can be related to the relative rate, krel by the equation:  
𝑘+51 = wxyz{   (17) 
The relative rates with intermediate values used in the calculations are listed below in Table S4.1.  
Table S4.1. Photobleaching rates and values used in calculations and corrections.  
Sample 𝝀ex (nm) Fluence 
(mWcm-2) 
kraw (s-1) x 103 
ε at λi (M-1cm-1) 
x 10-5 
Np 
krel (s-1) x 
103 
Relative 
stability 
1 monomer 785 97 ± 3 19.54 ± .04 1.18 ± 0.07  3.83 x1017 19 ± 1 1 
1 J-aggregate 980 97 ± 3 1.276 ± 0.008 0.95 ± 0.04 4.79 x 1017 1.28 ± 0.05 15 ± 1 
1 in HMSNs-
PEG 
980 97 ± 3 0.317 ± 0.002 0.95 ± 0.04 4.79 x 1017 0.32 ±0.01 62 ± 5 
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Chapter 5 
Analyte-Responsive Gated Hollow Mesoporous Silica 
Nanoparticles Exhibiting Inverse Functionality and an AND 
Logic Response 
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Abstract 
A multifunctional nanoparticle with designed selectivity was made using hollow mesporous 
silica, ship-in-a-bottle synthesis of a crystalline solid-state detector, and protection of the crystal 
by acid-responsive nanogates. The system demonstrates the inverse application of the usual 
trapping of contents by the gate followed by their release. Instead, the gate protects the contents 
followed by selective exposure. Crystallization of [Pt(tpy)Cl](PF6) (tpy = 2,2':6',2"-terpyridine) 
inside the cavity of hollow mesoporous silica created the unique core/shell nanoparticle. The 
crystalline core becomes fluorsecent in the presence of perchlorate. By condensing an acid-
sensitive gate onto the particle, access to the pores is blocked and the crystal protected. The new 
nanomaterial obeys Boolean AND logic; only the presence of both the analyte (ClO4-) and acid 
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results in the optical response. 
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5.1 Introduction 
 Core/shell nanoparticles have attracted much attention in recent years1-14 due to their 
adaptability to many different fields and applications such as electronics,5,15,16 biomedical,11,17-19 
pharmaceutical,20 optics,21-23 and catalysis.24,25 Hollow mesoporous silica nanoparticles (MSNs) 
are of particular interest because the presence of the hollow cavity can act as a reservoir which can 
be controllably filled with another material yielding a core/shell nanoparticle.8,26,27 Chemical 
modification of pore entrances at the surface produces gated MSNs that are gaining wide 
acceptance as useful drug delivery vehicles by carrying cargo molecules such as therapeutic drugs 
to a desired target and releasing them in response to a specific predetermined stimulus. Many 
imaginative methods of trapping cargo in pores and releasing it in response to external signals or 
intracellular biological molecules have been developed, including nanogates such as those used in 
this work. 
 The inverse function, namely protecting an entity inside the particle until it is desirable and 
useful to expose it to an outside influence, has not been widely utilized. Many possible scenarios 
can be imagined where it would be desirable to carry a cargo unexposed and unharmed through an 
intermediary environment to a site and then expose it at a location where its output can be used. 
For example, this capability is attractive for maintaining cargo functionality and performance over 
multiple cycles, preventing contamination of the environment due to cargo leaching, and realizing 
high levels of cargo recovery. A recent example from our laboratories is a nanovalve-based 
chemical amplifier involving an enzyme sequestered in a pore. Opening the pore allows substrate 
molecules to enter resulting in a catalytic production of fluorescent molecules.28 In the example in 
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this work, nanocrystals sensitive to an aqueous analyte are grown in the interior of a hollow MSN 
where they are subsequently protected by closed gates. When the gates are opened the crystals are 
exposed and give an optical response. 
Even more selectivity can be introduced if the nanocarrier possesses a second function made 
possible by the nanogate: Boolean AND logic. In Boolean logic, which is fundamental to modern 
computing, values are either True or False. For a so-called AND gate, an event is only triggered if 
two specific values are True. MSNs have been designed to have pore valves that respond to dual 
stimuli and release trapped molecules in response;29-35 two examples have been reported to release 
molecules with true AND logic.29,36 In this work, we selected an ionic molecular crystal as 
representative of a solid state optical indicator that is responsive to dissolved molecules or ions 
that enter the porous particle. The resulting porous nanoparticle with accessibility controlled by 
gates was designed to have a selective response following AND logic. 
5.2 Experimental Section 
5.2.1 Materials and characterizations 
All reagents including tetraethyl orthosilicate, dodecyltrimethylammonium bromide (DTAB), 
sodium hydroxide, hydrogen chloride, sodium bicarbonate, N-phenylaminomethyltriethoxysilane 
(PhAMTES), sodium 1-allyloxy-2-hydroxypropane sulfonate, aerosol MA-80-1, α-cyclodextrin, 
triethylamine, ammonium persulfate, divinyl benzene, styrene, are commercially available and 
were used without further purification. The structure of hollow mesoporous silica nanoparticles 
was confirmed by powder X-ray diffraction (XRD) experiments in Bragg-Brentano geometry (θ-
2θ) on a Philips X'Pert Powder Diffractometer operated at 40 kV, 40 mA using CuKα radiation 
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(λ=1.54 Å). To confirm the presence of the hollow core, shell thickness, and confirmation that 
1PF6 crystalized inside the hollow core, transmission electron microscopy (TEM) was done. The 
particles were dispersed in ethanol and then deposited and dried on a carbon film-coated Cu grid. 
Images were taken on a JEM1200-EX (JEOL) electron microscope operating at 50 kV. Fourier 
transform infrared (FT-IR) spectroscopy measurements were acquired on a Jasco Model 420 
spectrometer to confirm the attachment of PhAMTES. For monitoring the emission of 1PF6, the 
samples were illuminated using the 514 nm line of a Coherent I306C argon ion laser (40 mW). 
The photoluminescence spectra of the samples were collected using an Acton 2300i 
monochromator and a Princeton Instruments CCD. A 550 nm cut-off filter was placed in front of 
the CCD to block stray laser light. 
5.2.2 Synthesis of polystyrene beads 
Polystyrene beads were made using a previously published procedure. In a reaction vessel, 
0.171 g of sodium bicarbonate was added to 138 mL of water under nitrogen. The water solution 
was then deoxygenated by bubbling nitrogen through the solution for 40 minutes. Afterwards, 2.5 
g of Aerosol MA-80-1 was dissolved in 10 mL of water and then added to the solution. The solution 
was brought to 50 °C and 2.33 g of divinyl benzene and 60 mL of styrene was slowly added. 
Sodium 1-allyloxy-2-hydroxypropane sulfonate was dissolved in 10 mL of water and was 
immediately injected into the solution 5 minutes after the addition of divinyl benzene and styrene. 
The temperature was then brought to 70 °C at which point a solution of 0.75 g of ammonium 
persulfate in 5 mL of water was injected. The reaction continued for 4 hours. The particles were 
washed through dialysis for 3 days changing the water twice a day. They were then centrifuged 
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with water twice and then with methanol two more times. They were then left to dry under vacuum. 
The size of the particles was confirmed by taking a TEM image of the particles. 
5.2.3 Synthesis of Hollow Mesoporous Silica Nanoparticles 
 Hollow mesoporous silica nanoparticles were synthesized by adding 0.5 g of DTAB and 0.25 
g of the polystyrene beads into 20 mL of water. The solution was sonicated for 20 minutes and 
then allowed to rest for 30 minutes to allow any large aggregates of the polystyrene beads to settle. 
The solution was then carefully poured into 100 mL of water and 450 µL of 2 M NaOH was added. 
After 30 minutes, 500 µL of TEOS was added and the reaction was left at room temperature for 
24 hours. The particles were washed thoroughly with water and methanol and then calcined at 500 
°C to remove the surfactant and the polystyrene beads. N2 adsorption-desorption isotherms and 
XRD were used to measure the pore size of hollow mesoporous silica nanoparticles and TEM 
images were taken to confirm the presence of the hollow cavity. 
5.2.4 Surface modification of the hollow mesoporous silica nanoparticles 
 50 mg of the hollow mesoporous silica nanoparticles and 50 µL of PhAMTES were placed in 
3 mL of toluene and the reaction was left overnight stirring at room temperature. The particles 
were then washed with methanol and then with water and then dried in a vacuum. An FT-IR 
spectrum of the particles was taken to confirm the presence of PhAMTES on the hollow 
mesoporous silica nanoparticles. 
5.2.5 Crystalizing 1PF6 inside the hollow core 
 A highly concentrated solution of 1PF6 was made by taking 10 mg of the crystal and 
dissolving it in 300 µL of dimethyl sulfoxide. 20 mg of the particles were added to the solution 
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and it was left stirring for 24 hours. The solution was then allowed to slowly evaporate until the 
particles were dry. 
5.2.6 Blocking the pore openings with α-cyclodextrin 
 The particles were washed twice with dimethyl sulfoxide and then twice with water to remove 
any 1PF6 from the surface of the hollow particles. The particles were then left in 1.5 mL of water 
and 50 mg of α-cyclodextrin was added. The particles were then left stirring overnight.  
5.2.7 Controlled Activation of the System 
 The operation of the system was monitored using fluorescence spectroscopy. 10 mg of the 
particles were placed in an NMR tube. Enough water was added to just wet the particles and the 
NMR tube was placed in front of a CCD. The emission of 1PF6 was measured as a function of 
time at 1-second intervals by using a 514 nm excitation beam (40 mW). The activation profile of 
the system was obtained by plotting luminescence intensities of 1PF6 at the emission maximum 
(670 nm) as a function of time. 40 µL of a 30 mM solution of NaClO4 was added to the sample 
followed by addition of 40 µL of an acid solution to bring the pH to 3 in order to activate the 
system. 
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5.3 Results and discussion 
A schematic diagram of the system is shown in Figure 5.1. The nanogate initially selected for 
this study is composed of a N-phenylaminomethyltriethoxysilane (PhAMTES) stalk and a α-
cyclodextrin cap (αCD).26 The αCD has a pH dependent supramolecular interaction with the 
aniline-based stalk that blocks the pore openings at neutral pH. Protonation of the stalk under 
acidic conditions reduces the binding constant and αCD dissociates. In prior applications of this 
system, physical blockage of the pore opening by αCD caused the gating. Surprisingly in the case 
of perchlorate anion, the stalk itself provided the gating as described below. The ionic crystal is 
the perchlorate ion-responsive [Pt(tpy)Cl](PF6) (tpy = 2,2':6',2"-terpyridine) (1PF6), which is a 
yellow solid that is practically insoluble in water.37 Solid platinum(II) terpyridyl salts of this type 
have attracted considerable attention because of their promising vapor38-46 and ion sensing 
properties.37 Specifically, 1PF6 which rapidly changes from yellow to red and becomes intensely 
luminescent upon exposure to aqueous ClO4-,37 an important groundwater contaminant.47,48 The 
response is extraordinarily selective, and it is a consequence of anion exchange at the surface of 
solid [Pt(tpy)Cl](PF6). The resulting 1ClO4H2O is deep red and intensely luminescent. Strong 
intermolecular metal–metal interactions (Pt…Pt: 3.3031(5), 3.3692(5) Å) (Figure 5.2) account for 
the low-lying metal-metal-to-ligand charge-transfer MMLCT[dσ*(Pt)-π*(tpy)]) band near 525 nm, 
where the dσ* arises from the interaction of the dz2(Pt) orbitals of adjacent complexes. Green light 
selectively excites this material resulting in intense MMLCT emission near 690 nm.37 
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Figure 5.1. The stalks on the nanoparticles (left) protect the 1PF6 crystal in the hollow interior from 
perchlorate until pH 3 is reached. After acidification, perchlorate is able to access the nanoparticle, reach 
the crystal and produce brightly luminescent 1ClO4.H2O (middle). Particles capped with αCD (right) 
function similarly. 
 
 
Figure 5.2.  1PF6 converting to 1ClO4·H2O after the addition of ClO4- anion. 
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The core-shell MSNs used in this work consist of spherical particles about 130 nm in diameter 
with a hollow core and a ~35 nm thick shell. These were synthesized using the sol-gel method, 
where polystyrene spheres and dodecyltrimethylammonium bromide (DTAB) were used as the 
templates for the hollow core and the mesopores, respectively. First, highly charged 
monodispersed polystyrene beads were made by emulsion polymerization.49,50 The polystyrene 
beads (~90 nm in diameter Figure 5.3) were then placed in an aqueous solution of DTAB and 
NaOH. TEOS was then added to the solution and the reaction was allowed to continue for 24 hours. 
The resulting white particles were washed and calcined at 500 °C to remove surfactant and 
polystyrene. A TEM image of the resulting particles (Figure 5.4) show that the shell thickness was 
about 35 nm. N2 adsorption-desorption isotherms show that the Brunauer-Emmett-Teller (BET) 
surface area, total pore volume, and average pore diameter are 1143 m2/g, 0.75 cm3/g, and 2.5 nm 
respectively (Figure 5.5). In addition, the high surface area and pore volume of hollow MSNs – 
the desired properties of MSNs – suggest that cargos such as [Pt(tpy)Cl](PF6) can be loaded inside 
the pores and cavity of hollow MSNs, allowing those loaded cargos to be efficient sensor to detect 
the presence of ClO4- in the water solution. 
 The stalk was attached to the particles’ surfaces by stirring PhAMTES and the particles in 
toluene at room temperature overnight. The particles were washed several times in ethanol 
followed by water, using centrifugation. After the final washing, the particles were dried at room 
temperature under vacuum. Successful attachment of the stalk was confirmed by Fourier transform 
infrared (FT-IR) spectroscopy (Figure 5.6). 
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Figure 5.3. TEM images of the polystyrene beads. 
 
 
Figure 5.4. TEM images of template free hollow mesoporous silica nanoparticles. 
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Figure 5.5. (a) N2 adsorption/desorption isotherms of hollow mesoporous silica nanoparticles. The BET 
surface area and pore volume are 1143 m2/g, and 0.75 cm3/g, respectively. (b) Pore size distribution of 
hollow mesoporous silica nanoparticles. The pore size is 2.5 nm. 
 
 
Wavenumber (cm-1) 
Figure 5.6. FT-IR spectra of hollow particles and hollow particles after PhAMTES modification. The band 
at 2900 cm-1 is assigned to C-H streches and that at 1475 cm-1 is from aromatic C=C streches. 
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In order to crystallize the metal salt inside the hollow cavity, the particles were added to a 
saturated solution of 1PF6 in DMSO/H2O followed by slow evaporation of the solvent at room 
temperature. The resulting material was washed twice with DMSO to remove residual 1PF6 from 
the surface and ensure that the surface phenyl groups on the silanes were accessible to αCD. 
Treatment with αCD in water completed the assembly of the 1PF6-loaded mechanized core shell 
particles. 
 
 
Figure 5.7. Powder XRD of (a) crystalline 1PF6, (b) bare hollow MSNs showing a peak around 2.3° from 
the ordered mesopores, and (c) hollow MSNs containing the crystallized 1PF6. 
 
To establish that the hollow MSNs contained the crystalline form of the 1PF6, powder X-ray 
diffraction (pXRD) data were collected. Figure 5.7a shows a pXRD of the 1PF6 crystal displaying 
the expected diffraction peaks.37 A pXRD of the bare hollow MSNs showed a very broad 2θ peak 
near 2.3° (Figure 5.7b), which gives a d spacing of 37 Å, consistent with a pore diameter around 
1.7 nm. The pXRD of the hollow MSNs with 1PF6 crystallized inside (Figure 5.7c) showed the 
peaks corresponding to the diffraction pattern of 1PF6 crystal. Slight peak shifting in the pXRD 
is attributed to the use of a different pXRD sample holder for the hollow MSNs containing 1PF6. 
These pXRD patterns provide evidence of the presence of crystalline 1PF6 inside the hollow 
cavity of the MSNs. 
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The response of the particles to perchlorate ions and changes in the pH in the aqueous 
environment was monitored by emission spectroscopy. 10 mg of the particles were placed in an 
NMR tube and a sufficient amount of water was added to just wet the particles (Figure 5.8). The 
emission spectra were excited at 448 nm and 514 nm. The wet sample of particles showed very 
weak emission as expected for crystals of the 1PF6 salt. As shown in Figure 5.9ab, the emission 
signal at 690 nm remained essentially unchanged. After the addition of 40 µL of 0.03 M NaClO4, 
no change in intensity was observed. The absence of luminescence confirms that 1PF6 inside the 
hollow particles is not accessible to perchlorate ion in the surrounding medium. It also proves that 
1PF6 is not on the surface of the particles. Then the pH was lowered to 3 by addition of 40 µL of 
an HCl solution to protonate the stalk. The emission intensity began to increase immediately and 
then began to level off to constant intensity after about 3 hours (Figure 5.10). This indicates that 
protonation of the anilinoalkane group allowed the ClO4- to enter inside the particles, converting 
1PF6 to 1ClO4H2O. Since 1PF6 is practically insoluble in water, the luminescence also indicates 
that the reaction happens inside the particle where the crystal is located and does not arise from 
1·PF6 being released from the particles. In order to ensure that the increase in intensity was caused 
by the perchlorate and not just the pH change, the same experiment was conducted without 
perchlorate (Figure 5.9c), and no change in the intensity was observed. This indicates that the acid 
alone has no effect on the emission intensity. Perchlorate was not blocked at all pH from particles 
without stalks (Figure 5.11). 
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Figure 5.8. Experimental set up for sequential fluorescence spectra measurements. 
 
 
 
 
Figure 5.9. Luminescence spectra of the 1PF6 crystal-loaded hollow mesoporous nanoparticles with 
aniline stalks as a function of time (a) without the addition, (b) after the addition of ClO4-, and (c) after the 
addition of HCl when αCD is not used as a cap. 
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Figure 5.10. Luminescence spectra of nanoparticles gated by the PhAMTES stalk as a function of time 
after the addition of acid and perchlorate. A similar response occurs with particles capped with αCD. 
 
Figure 5.11. Luminescence spectra of the 1PF6 crystal-loaded hollow mesoporous nanoparticles without 
aniline stalks as a function of time (a) without the addition, (b) after the addition of the HCl, (c) after the 
addition of ClO4-, and (d) after the addition of HCl and ClO4-. 
 231 
The same series of experiments discussed above was repeated with particles capped by the 
bulky αCD, and the same results were obtained (Figure 5.12 and Figure 5.13). Thus, although the 
bulky neutral αCD may play a role, it is not necessary for gating the perchlorate anion. The 
combination of electrostatic repulsion of perchlorate from the negatively charged silanol groups 
on the particles and the presence of the hydrophobic anilinoalkane stalks prevents entrance of 
perchlorate. Upon protonation, the cationic stalk attracts perchlorate to the pores. However, in 
applications where the analytes are neutral or cationic molecules, the physical pore-blocking 
capability of αCD may be required. 
 Selectivity based on “AND” logic requires two inputs. In this case, the inputs are chemical 
stimuli that both must be present in order to trigger a response. A handful of nanoparticles 
responsive to dual stimuli have been reported, all involving cargo release. The stimuli include pH 
and light, pH and redox, pH and temperature, pH and ATP. But in each of these cases, the responses 
involve “OR” logic because either one or the other of the inputs opens the valve and releases the 
cargo. The system described here exhibits true “AND” logic where both chemical stimuli, namely 
pH and perchlorate analyte, are required to form the luminescent crystal inside the particle. The 
Boolean ‘truth table” is shown in Figure 5.14. This additional level of control is proof of concept 
of a nanomaterial designed to operate only under specific, predefined conditions (in this case an 
aquatic location containing acidic perchlorate). The active element is protected and can travel to 
the target site before it is activated by the specific condition. 
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Figure 5.12. Luminescence spectra of nanoparticles gated by the PhAMTES stalk and αCD as a function 
of time after the addition of acid and perchlorate. 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. (a) Emission intensity at 690 nm as a function of time. At ~45 minutes NaClO4- was added 
and after 2.5 hours the system was brought to a pH of 3. Inset shows close up of NaClO4- addition and pH 
lowering. (b) Emission intensity at 690 nm as a function of time. At ~55 minutes the system was brought 
to a pH of 3 and no change in the intensity was observed. 
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Figure 5.14. Truth table of the AND gate. Input 1 is acidification to pH 3, and input 2 is the perchlorate ion. 
The numbers 1 and 0 in the figure represent “True” and “False”, respectively. The output is the 
luminescence of 1ClO4H2O inside the hollow nanoparticles. Nanoparticles with only the stalk (left of 
dashed line) and those capped by αCD (right) function similarly. 
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5.4 Conclusions 
In summary, a gated nanoparticle with designed selectivity was synthesized using hollow 
mesoporous silica, ship-in-a-bottle synthesis of the molecular crystalline solid state detector, and 
protection of the crystal by the pores’ gates. In contrast to the usual nanovalves where gating is 
caused by steric blockage by a cyclodextrin (CD) cap, gating of perchlorate is governed by the 
stalk. The system demonstrates the inverse application of the gate – protection of the contents 
followed by selective exposure rather than trapping of contents followed by their release. This 
concept may find future applications in environmental sensing and in biomedical diagnostics. 
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